#### Oxamide IMPDH Inhibitors

## Background of the Invention

The present invention relates to novel oxamide derivatives, a process for their manufacture, pharmaceutical preparations containing these derivatives, and the use of these derivatives as medicaments. In particular, the present invention relates to novel oxamide derivatives which are inhibitors of inosine monophosphate dehydrogenase (IMPDH).

Inosine monophosphate dehydrogenase (IMPDH) is an enzyme involved in the de novo synthesis of guanine nucleotides. The enzyme catalyses the NAD-dependent oxidation of inosine-5'-monophosphate (IMP) to xanthosine-5'-monophosphate which is the rate limiting step in the synthesis of guanine nucleotides. As a result of the key role of the enzyme in guanine nucleotide biosynthesis, the enzyme represents an important target for the development of inhibitors which would have utility as therapeutic agents in the treatment of IMPDH related processes.

The de novo synthesis of guanine nucleotides is particularly important in B- and T-

lymphocytes to provide sufficient levels of nucleotides to support a proliferative response to mitogen or antigen [Wu, J.C., Persp. in Drug Discovery and Design., 2, 185-204, (1994)].

IMPDH inhibition is thus an attractive target for selectively inhibiting the immune system. Inhibitors of IMPDH are known [Pankiewicz, K.W., Exp. Opin. Ther. Patents., 9, 55-65, (1999)], and the uncompetitive inhibitor mycophenolic acid (MPA) has been demonstrated to inhibit the response of B-and T-cells to mitogen or antigen [Allison, A.C. and Eugui, E.M., Transplant. Proc., 25, 8-18, (1993)]. MPA has therefore been utilised as an

25 immunosuppressant.

It is also recognised that IMPDH plays a role in other rapidly proliferating cells such as tumour cell lines, indicating that IMPDH inhibition is a target for anti-cancer chemotherapy [ Nagai, M. et al., 51, 3886-3890, (1990)].

30

10

15

20

IMPDH inhibition has also been shown to play a role in viral replication in some cell lines which support virus replication [Pankiewicz, K.W., Exp. Opin. Ther. Patents., 9, 55-65, (1999)]. Ribavirin, for example, is a broad spectrum antiviral agent which has been approved by the U.S. Food and Drug Administration for use as an aerosol for infants with serious

respiratory infections due to respiratory syncytial virus and is also in use as an agent for the treatment of patients infected with Hepatitis C virus when used in combination with interferon [ Patterson, J.L. and Fernandez-Larsson, R., Rev. Infect. Dis., 12, 1139-1146, (1990); McHutchison, J.G. et al., New. Engl. J.Med., 339, 1549-1550, (1998)]. Ribavirin is converted in cells to ribavirin 5' monophosphate which is an inhibitor of IMPDH.

Additionally, the IMPDH inhibitors ribavirin and MPA have been shown to inhibit the replication of yellow fever virus (a RNA virus) whilst MPA has been demonstrated to inhibit Hepatitis B virus replication (a DNA virus) in vitro supporting the broad range antiviral activity of these inhibitors [Neyts, J. et al., Antiviral Res., 30, 125-132, (1996); Gong, Z.J. et al., J. Viral Hepatitis., 6, 229-236, (1999)]. Furthermore, MPA has also been shown to potentiate the antiviral effects of nucleoside analogues both in vitro and in animal models [Neyts, J. and De Clercq, E., Inter. Antiviral News., 7, 134-136, (1999)]. Together these observations indicate that IMPDH inhibitors have utility as broad spectrum antiviral agents.

IMPDH inhibitors would therefore have therapeutic potential as immunosuppressants, anticancer agents and anti-viral agents. Specifically, such compounds may be used in the treatment of transplant rejection, the treatment of cancer and as antiviral agents in the treatment of viral diseases such as retroviral infections and hepatitis C virus infections (either alone or in combination with other antiviral agents such as interferon or derivatives thereof, such as conjugates with polyethylene glycol).

#### Summary of the Invention

10

15

25

The novel oxamide derivatives provided by the present invention are compounds of the general formula (I):

#### wherein

15

20

25

30

- 5 R<sup>1</sup> represents heterocyclyl;
  - R<sup>2</sup> represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, hydroxy or cyano;
  - R<sup>3</sup> represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
  - R<sup>4</sup> represents hydrogen, or unsubstituted lower alkyl;
- 10 R<sup>5</sup> represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
  - R<sup>6</sup> represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
  - R<sup>7</sup> represents hydrogen, or unsubstituted lower alkyl;
  - $R^8$  represents hydrogen, lower alkyl, lower cycloalkyl, aryl, or heterocyclyl; or  $R^4$  and  $R^8$  together with the nitrogen atom to which they are attached represent heterocyclyl;

and pharmaceutically acceptable salts thereof.

The oxamide derivatives provided by the present invention are inhibitors of the enzyme inosine monophosphate dehydrogenase (IMPDH). They can be used as medicaments, especially for treating immune mediated conditions or diseases, viral diseases, bacterial diseases, parasitic diseases, inflammation, inflammatory diseases, hyperproliferative vascular diseases, tumours, and cancer. They can be used alone, or in combination with other therapeutically active agents, for example, an immunosuppressant, a chemotherapeutic agent, an anti-viral agent, an anti-barasitic agent, an anti-inflammatory agent, an anti-fungal agent and/or an anti-vascular hyperproliferation agent.

In particular, compounds of the present invention and compositions containing the same are useful as chemotherapeutic agents, inhibitors of viral replication and modulators of the immune system, and can be used for the treatment of viral diseases such as retroviral infections and hepatitis C virus infections (either alone or in combination with other antiviral agents such as interferon or derivatives thereof, such as conjugates with polyethylene glycol), inflammatory diseases such as osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma, and adult respiratory distress syndrome, hyperproliferative vascular diseases such as restenosis,

stenosis and artherosclerosis, cancer, for example lymphoma and leukaemia, and as immunosupressants in the treatment of autoimmune diseases, graft versus host diseases and transplant rejection

5 Compounds of the present invention which have antiviral effects and/or immuno-supressive properties are particularly useful for treating HCV infection.

## Detailed Description of the Invention

If not otherwise specified, an unmodified term includes both substituted and unsubstited forms if that term has been defined as substituted or unsubstituted. For example" lower alkyl" includes substituted and unsubstituted lower alkyl. Similarly, "optionally substituted" includes substituted or unsubstituted. The term "saturated" applied to ring structures includes fully and partially saturated rings.

- As used herein, the term "lower alkyl", means a straight-chain or branched-chain alkyl group containing up to 10 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to 6 carbon atoms, e.g.methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.butyl, tert-butyl, n-pentyl, n-hexyl and 1,1-dimethylethyl; and which is unsubstituted or substituted by e.g. one or more of cyano, halo, carboxyl, hydroxyl, lower alkoxy, lower cyclo alkoxy, aryloxy,
- heterocyclyloxy, heterocyclyl -(lower alkoxy)-aryl-amino-oxalyl-oxy, lower alkoxy-carbonyl, aryl, aryl-carbonyl-amino-aryl, lower alkyl-carbonyl-amino-aryl, heterocyclyl, lower alkyl-heterocyclyl,

lower cycloalkyl, lower alkenyl, lower alkynyl,

- amino, mono- or di-(lower alkyl) amino, lower cycloalkyl amino, aryl amino, heterocyclylamino, lower alkyl-aryl-lower alkyl-amino, lower alkoxy-carbonyl-amino, lower alkenylcarbonyl-amino, lower alkyl-carbonyl-amino, di-(aryl)-lower alkyl-carbonyl-amino, lower
  alkyl-sulphonyl-lower alkyl-carbonyl-amino, lower cycloalkyl-lower alkyl-carbonyl-amino,
  heterocyclyl-lower alkyl-carbonyl-amino, lower alkoxy-lower alkyl-carbonyl-amino, di-aryllower alkyl-carbonyl-amino, aryl-carbonyl-amino, lower alkyl-aryl-carbonyl-amino, tri-(lower
  - alkyl)-aryl-carbonyl-amino, mono- or di-(lower alkoxy)-aryl-carbonyl-amino, di-(lower alkyl)-amino-aryl-carbonyl-amino, lower alkyl-carbonyl-amino-aryl-carbonyl-amino, heterocyclyl-aryl-carbonyl-amino, lower cycloalkyl-carbonyl-amino, mono- or tetra-(lower

alkyl)-lower cycloalkyl-carbonyl-amino, heterocyclyl-carbonyl-amino, mono- or di-(lower alkyl)-heterocyclyl-carbonyl-amino, tri-(lower alkyl)-aryl-oxalyl-amino, lower alkyl-carbamoyl, or aryl-carbamoyl,

thio, lower alkyl thio, lower cycloalkyl thio, aryl thio, heterocyclyl thio, lower alkyl sulphonyl, lower cycloalkyl sulphonyl, aryl sulphonyl, heterocyclyl sulphonyl.

Where there is more than one substituent, each substituent may be the same or different, for example tri-fluoromethyl, triphenylmethyl, 1-[1-methyl-1-[methylformyl]-2-phenyl] ethyl, or 2-[1-hydroxyl-3-cyclohexyl].

The term "unsubstituted lower alkyl" means an alkyl group as defined above where no substituents are present.

The term "lower alkenyl" means an alkenyl group containing from 2 to 7 carbon atoms, e.g. allyl, vinyl and butenyl.

The term "lower alkynyl" means an alkynyl group containing from 2 to 7 carbon atoms, e.g. propargyl or butynyl.

The term "lower cycloalkyl", alone or in combination as in "lower cycloalkyl-lower alkyl", means a cycloalkyl group containing 3 to 10 carbon atoms, preferably 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and adamantyl, and which may be unsubstituted or substituted by e.g. one or more of lower alkyl, carboxyl, hydroxyl or aryl or optionally be benz-fused e.g. to aryl. Where there is more than one substituent, each substituent may be the same or different. Cyclopropylmethyl, 2-cyclobutyl-ethyl and 3-cyclohexyl-propyl are examples of lower cycloalkyl-lower alkyl groups.

The term "halo" denotes fluorine, chlorine, bromine or iodine.

15

20

25

The term "lower alkoxy" denotes an unsubstituted or substituted lower alkyl group as defined hereinbefore, which is bonded via an oxygen atom, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert.-butoxy and the like. Suitable substituents are those applicable for "lower alkyl".

The term "aryl", alone or in combination as in "aryl-lower alkyl", means phenyl or naphthyl, optionally benz-fused, for example benz-fused to a lower cycloalkyl ring. "Aryl" denotes unsubstituted or substituted by e.g. one or more of halo, cyano, carboxyl,

- lower alkyl-thio, nitro,
  oxo, hydroxyl, lower alkoxy, lower cycloalkyloxy, aryloxy, heterocyclyl oxy
  lower alkyl-heterocyclyl, heterocyclyl,
  lower alkoxy-carbonyl, lower alkyl-carbonyl, heterocyclyl-carbonyl, lower alkyl-heterocyclyl-carbonyl,
- sulphamoyl, lower alkyl- sulphamoyl,
  thio, lower alkyl thio, lower cycloalkyl thio, aryl thio, heterocyclyl thio,
  lower alkyl-sulphonyl, lower cycloalkyl sulphonyl, aryl sulphonyl, heterocyclyl-sulphonyl,
  amino, mono- or di-(lower alkyl) amino, lower alkyl-sulphonyl-amino, di-(lower alkyl)heterocyclyl-amino, lower alkyl-carbonyl-amino, (lower alkyl-carbonyl)(lower alkyl)-amino,
  lower alkoxy-carbonyl-amino, aryl-carbonyl-amino,
  - mono- or di-(lower alkyl)-carbamoyl, aryl-carbamoyl, lower alkyl, aryl-lower alkyl, amino-lower alkyl, heterocyclyl-lower alkyl, lower alkoxy-carbonyl-lower alkyl, lower alkyl-sulphamoyl-lower alkyl, aryl-sulphonyl-amino-lower alkyl, lower alkyl, lower alkyl, aryl-sulphonyl-amino-lower alkyl, lower alkyl, aryl-sulphonyl-amino-lower alkyl, lower alkoxy-carbonyl-amino-lower alkyl,
- heterocyclyl-oxy-carbonyl-amino-lower alkyl, aryloxy-carbonyl-amino-lower alkyl, lower alkyl-carbonyl-amino-lower alkyl, lower alkyl-aryl-carbonyl-amino-lower alkyl, aryl-carbamoyl-lower alkyl, lower cycloalkyl-carbonyl-amino-lower alkyl, heterocyclyl-carbonyl-amino-lower alkyl, or aryl-carbonyl-amino-lower alkyl. Where there is more than one substituent, each substituent may be the same or different, for example 1-(3-methoxy-4-oxazolyl)phenyl, 1-(3-chloro-4-methoxy)phenyl, 1-(3-chloro-4-methyl) phenyl and 1-(3-fluoro-4-methyl)phenyl.

The same substituents as listed above apply for all terms containing the phrase "phenyl" i.e. substituted or unsubstituted) phenyl.

The term "aryloxy" denotes an aryl group as defined hereinbefore, which is bonded via an oxygen atom, e.g. phenoxy, and the like.

As used herein, the term "heterocyclyl", alone or in combination as in "heterocyclyl-lower alkyl", means a saturated, unsaturated or partially saturated monocyclic or bicyclic ring system which contains one or more hetero atoms selected from nitrogen, sulphur and oxygen; and which is attached to the rest of the molecule via a carbon atom (C-linked), or a nitrogen atom (N-linked) in the ring system, and which is unsubstituted or substituted in the same manner as the aryl group defined hereinbefore and/or by oxido. Where there is more than one substituent, each substituent may be the same or different.

Examples of heterocyclyl groups are oxazolyl, isoxazolyl, furyl, tetrahydrofuryl, 1,3-dioxolanyl, dihydropyranyl, thienyl, pyrazinyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, quinolinyl, dihydrooxazolyl, pyrimidinyl, benzofuranyl, tetrazolyl, pyrrolidinonyl, (N-oxide)-pyridinyl, pyrrolyl, triazolyl e.g. 1,2,4-triazolyl, pyrazolyl, benzotriazolyl, piperidinyl, morpholinyl, thiazolyl, pyridinyl, dihydrothiazolyl, imidazolidinyl, pyrazolinyl, benzothienyl, piperazinyl, imidazolyl, thiadiazolyl e.g. 1,2,3-thiadiazolyl, and benzothiazolyl.

15

20

25

30

10

Any functional (i.e. reactive) group present in a side-chain may be protected, with the protecting group being a group which is known per se, for example, as described in "Protective Groups in Organic Synthesis", 2nd Ed., T.W. Greene and P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991. For example, an amino group can be protected by a tert-butoxycarbonyl, formyl, trityl, benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (Fmoc), trifluoroacetyl, 2-(biphenylyl)isopropoxy-carbonyl or isobornyloxycarbonyl group or in the form of a phthalimido group; or a hydroxyl group can be protected by a tert-butyldimethylsilyl, tetrahydropyranyl, 4-methoxybenzyl, or benzyl; or a carboxyl group can be protected in the form of an ester, for example as a methyl or tert.butyl ester. The protecting group may be retained in the final compound or optionally removed by techniques known in the art.

The compounds of this invention may contain one or more asymmetric carbon atoms and may therefore occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Furthermore, where a compound of the invention contains an olefinic double bond, this can have the (E) or (Z) configuration. Also, each chiral centre may be of the R or S configuration. All such isomeric forms of these compounds are embraced by the present invention.

# Examples of compounds of formula (I) are shown below in Table 1a and 1b:

Table 1a

	<u>Table 1a</u>	
	H	
	H,C N C N C N N O N N O N N O N N O N N O N N O N N O N N O N N O N	
HI CH CH	N Chra	
	H,C H, C N O	NO-OH,
HICK TO THE TOTAL		H,C N N N N N N N N N N N N N N N N N N N
	N OH	
	H.C. I J. N. D. OH,	NO.
A 7.00	N CH, CH, CH,	
F F F	on on on	QH, NH, COH, COH, COH, COH, COH, COH, COH, CO

THIC OH,	H: N OH,	NO CONT.
H CH <sub>3</sub>	HIS ONLY ONLY ONLY ONLY ONLY ONLY ONLY ONLY	OH OH OH
	N ON ON	No.
N S S S S S S S S S S S S S S S S S S S		
H. 1 1 N 1 N N N N N N N N N N N N N N N	His Andrews An	
HI N N N N N N N N N N N N N N N N N N N	HC N N	
C 34,04	NA OFF	
	H,C TH T N	
N# C' J N		

	0 0 N N N N N N N N N N N N N N N N N N	
	0, 2, 5	C
Xoin Ongin	0 N	0 N N N N N N N N N N N N N N N N N N N
N N N N N N N N N N N N N N N N N N N		O. N.
S-11 N N N N N N N N N N N N N N N N N N		

N-11 N N N N N N N N N N N N N N N N N N	O N N N N N N N N N N N N N N N N N N N	
	N N N N N N N N N N N N N N N N N N N	0 0 0 0 0 0 0 0 0
	O N CI	0 N N N N N N N N N N N N N N N N N N N
	IN.	
		0
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		0 N N N N
N N N N N N N N N N N N N N N N N N N	O N N F F F	

"	N N N N N N N N N N N N N N N N N N N	, N, N, S
	0,2	
		0. 1 1 2 n 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
		0.

C		
C	O N N N N N N N N N N N N N N N N	0 N
o		
N		
0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
	of the state of th	
N N N N N N N N N N N N N N N N N N N		0 N N N N N N N N N N N N N N N N N N N
0 N N N N N N N N N N N N N N N N N N N		

3 N N N N N N N N N N N N N N N N N N N		
		0
0		O. N. I. V. N.
O N F F		
0 N N N N N N N N N N N N N N N N N N N		
	P F F F F F F F F F F F F F F F F F F F	0 N 0 0 N
		o N 1 N 7 0
		O N O N O N O N O N O N O N O N O N O N

0 N		
0		
0 N 1 N 10		
0 5 N		
0 N T N T	N. J	
0 N	N <sup>-</sup>	
0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.		
, N-1		0 N N N N N N N N N N N N N N N N N N N
N N N N N N N N N N N N N N N N N N N		O. N. I.N. S.O.

C N N N N N N N N N N N N N N N N N N N		
0 N		0
	OT NOT NOT NOT NOT NOT NOT NOT NOT NOT N	
		N-D
		O THE STATE OF THE
		0 N 0 0 0
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		
O N N N N N N N N N N N N N N N N N N N		

0, , , , , , , , , , , , , , , , , , ,		
0 1 1 1 N 1 F		
0 1 1 N 1 1 N 1 1 N 1 1 N 1 1 N 1 1 N		
0 N	0	
ŀ		
	0 N N	
0 N T N C C		
0 N		O
N O S		
0	0 N	
	0 N N N N N	

Compounds of formula (I), and formula (IX) below where R<sup>2</sup> is methoxy, R<sup>4</sup>, R<sup>7</sup>, and R<sup>8</sup> are as in formula (I) or formula (IX), and R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>9</sup>, and R<sup>10</sup> are hydrogen are shown in table 1b below.

table 1b

Name	Structure	MS(ES) $(M+H)^+$	Ex No
Benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]a mino]-2-methylpropyl}-1-piperidinecarboxylate		535	421
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	426	422
N-[2-(1-Acetyl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	The second secon	443	423
N-(2-Cyclohexyl-1,1- dimethylethyl)-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N 0 0 249	400	424

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino)ethyl]oxalamide	N	423	425
N-[2-(1,2,3,4-Tetrahydro-1-quinolyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		449	426
N-[2-(4-Hydroxyphenylthio)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		442	427
N-[3-(4-Hydroxyphenyl)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	N N N N N N N N N N N N N N N N N N N	424	598
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[(1-oxido-4-pyridyl)carboxamido] ethyl]oxalamide		454	599
N-[2-(4-Acetylbenzamido)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CM OHE CH	479.1	600
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-[(4- methylbenzamido)methyl]pheny l]oxalamide		485.1	601
N-[3-[(2-Methoxybenzamido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH. CH. CH. CH.	501.1	602
N-[3-[(4-Chlorobenzmido) methyl]phenyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	C1	505.1	603
N-[3-[[(1,3-Benzodioxol-5-yl)carboxamido]methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		515.2	604
N-[2-(2,3-Dihydro-1-indolyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	o N N N N	435	605

N-[2-(3,4-Dihydro-6-methyl- 2H-quinol-1-yl)-1,1- dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 +	463	606
N-[1-(3-Benzofuranyl)-1- methylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	и , <sub>,</sub> н, с с ,	420	607
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- phenoxypiperidino)propyl]oxala mide	N	507	608
N-[2-(1-Butyryl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		471	609
N-[2-[1-(Methanesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	50 50 60 1	479	610
N-[2-[1-(Benzenesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	K	541	611
N-[2-(1-Isobutyryl-4- piperidinyl)-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	And the state of t	471	612
tert-Butyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino] oxalyl] amino]-3-methylbutyl]-1-piperidinecarboxylate	34, 34, 34, 36, 48	515	613
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- piperidinyl)propyl]oxalamide	CH, C CH <sub>3</sub> O N T N CH <sub>3</sub> N O O O O O O O O O O O O O O O O O O	415	614

Preferred compounds of formula (I) and any of the compounds of formula (I) described below are those where at least one of  $R^2$ ,  $R^3$ ,  $R^5$  and  $R^6$  is not hydrogen especially where  $R^2$  represents lower alkoxy, preferably methoxy.

In preferred compounds of formula (I) and any of the compounds of formula (I) described below, R<sup>1</sup> represents a five-membered heterocycle with one to three heteroatoms selected from nitrogen, oxygen, and sulfur. Furthermore, preferred compounds of formula (I) are those where R<sup>1</sup> represents an unsubstituted or substituted oxazole ring or triazole ring. When substituted, the preferred substituents are methyl, ethyl, or benzyl.

Also preferred are compounds of formula (I) and any of the compounds of formula (I) described below as follows: where  $R^4$  represents hydrogen or branched lower alkyl, and where  $R^3$ ,  $R^6$ , and  $R^7$  represent hydrogen. Most preferably, $R^1$  represents oxazolyl (especially unsubstituted),  $R^2$  represents lower alkoxy (especially methoxy) and  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$  represent hydrogen.

Also preferred are compounds of formula (I) and any of the compounds of formula (I) described below where R<sup>8</sup> represents branched lower alkyl, aryl, a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur. These compounds may be substituted or unsubstituted as defined above. It is additionally preferred for these compounds that R<sup>1</sup> represents oxazolyl (especially unsubstituted), R<sup>2</sup> represents lower alkoxy (especially methoxy) and R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup> and R<sup>7</sup> represent hydrogen.

In formula (I) and any of the compounds of formula (I) described below, R<sup>8</sup> may be branched lower alkyl, aryl, and/or cycloalkyl,and/ or a heterocyclic ring as defined immediately above.

In particular, preferred compounds of formula (I) are those of the general formula:

wherein

10

15

20

25

 $R^2$  to  $R^8$  are defined as above; and,

 $R^{4}$  is hydrogen, lower alkyl, aryl-lower alkyl;  $R^{10}$  is hydrogen.

In some compounds of formula (IX), R<sup>9</sup> represents methyl, ethyl, or benzyl, and R<sup>10</sup> preferably is hydrogen. In others, R<sup>9</sup> and R<sup>10</sup> both represent hydrogen. It is preferred that R<sup>8</sup> represents branched lower alkyl, aryl, a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, and in addition is preferred that R<sup>2</sup> represent lower alkoxy, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, and R<sup>7</sup> represent hydrogen.

10

More particularly, preferred compounds of formula (I) are those of the general formula (IX), wherein  $R^2$  is methoxy or chloro;  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^9$ , and  $R^{10}$  are hydrogen, and  $R^8$  is heterocyclyl, aryl, or branched chain lower alkyl;

## 15 Examples of such compounds are:

	tert-Butyl[3-[[[3-methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]benzyl]carbamate
H. S. N. J. M. S. N. S.	N-tert-Butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide
Chrai	[3-[[[3-Methoxy-4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamic acid tetrahydro-3(S)-furyl ester
	N-[3-(Benzamidomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide
	Isopropyl [3-[[[3-methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]benzyl]carbamate
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- (1-methyl-1-phenylethyl)oxalamide
H,C H,C OH,	N-(1,1-Dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

HC'HC CH' I N CH'	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- (1,1,3,3-tetramethyl-butyl)oxalamide
N N N N N N N N N N N N N N N N N N N	N-(1,1-Dimethylpropargyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide
	N-(2-Hydroxy-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide
	N-(1,1-Dimethyl-2-phenylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide
	Phenyl [3-[[[4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamate
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [3-[(phenylcarbamoyl)methyl] phenyl]oxalamide
21.	tert-Butyl [2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]carbamate
14 H <sub>2</sub> C - H	N-(2-Amino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-(4-nitrophenyl) ethyl]oxalamide
See The second s	N-[3-(Aminomethyl)phenyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)
	Methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]car bamate
N O OH	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- (3-pyridyl)oxalamide
	N-[3- [(Benzenesulfonamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide

CIH CH3	N-(2-Dimethylamino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide hydrochloride (1:1)
H <sub>1</sub> C N O OH <sub>3</sub>	N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1-methyl-1- (methylcarbamoyl)ethyl]oxalamide
H,C CI	N-tert-Butyl-N'-[3-chloro-4-(5-oxazolyl)phenyl]oxalamide
CH <sub>3</sub> O CH <sub>3</sub>	N-tert-Butyl-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide

or their pharmaceutically acceptable salts.

In particular, preferred compounds of formula (I) and (IX) are also those of the general formulas:

$$R^{10}$$
 $R^{10}$ 
 $R^{10}$ 

$$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{10}$ 
 $R^{10}$ 

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> are defined as above

 $R^{11}$  and  $R^{13}$  is H or lower alkyl, m=1 to 5 and

5

10

 $R^{12}$  is heterocyclyl, or aryl (substituted or unsubstited) other than 4-fluorophenyl.

Particularly preferred compounds of formula (XIa or XIb) are those wherein

R<sup>2</sup> is methoxy, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>9</sup>, R<sup>10</sup>,R<sup>11</sup> and R<sup>13</sup> are hydrogen and wherein R<sup>12</sup> is (unsubstituted or substituted) phenyl other than 4-fluorophenyl and (unsubstituted or substituted heteroaryl). Also preferred are those compounds where R<sup>12</sup> represents a 5 or 6 membered monocyclic or a 9 or 10 membered bicyclic saturated or unsaturated heteroaromatic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

## 10 Examples of such compounds are listed in table 1c

table 1c

	table ic	·	
Name	Structure	MS(ES) $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-methylphenyl)ethyl]oxalamide	N 10 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	408	302
N-[1,1-Dimethyl-2-(2- methylphenyl)ethyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	N C C C C C C C C C C C C C C C C C C C	408	303
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-pyridyl)ethyl]oxalamide	N D O CH, N N N N N N N N N N N N N N N N N N N	395	304
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methylphenyl)ethyl]oxalamide	N C C CH2	408	305
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2-thienyl)ethyl]oxalamide	N	400	306
N-[2-(4-Benzyloxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N	500	307
N-[2-(4-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N OHC OH	410	308
N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide	A CHECK SA	424	309

N-[2-(2-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N O OH	410	310
N-(1,1-Dimethyl-2-phenyl- propyl)-N'-(3-methoxy-4-oxazol- 5-yl-phenyl)-oxalamide	N 2	408	311
N-[2-(3-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N	410	312
N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(3-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide		424	313
N-[2-[4-(Cyanomethoxy)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N 2 3 4 1	449	314
2-[4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	N	468	315
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid		468	438
2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid		468	439
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1,1-dimethyl- 2-(1-oxido-4- pyridyl)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	411	440
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1,1-dimethyl- 2-(1-oxido-3- pyridyl)ethyl]oxalamide	N 2	411	441
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-2-pyridyl)ethyl]oxalamide	N 2 O	411	442
2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)]amino]-2-methylpropyl]phenoxy]acetic acid	N ONE ON	468	443
	<b>.</b>	•	

N-[2-(2-Benzofuranyl)-1,1- dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	N OH,C CH,	434	444
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methyl-2-benzofuranyl)ethyl]oxalamide	0HC	448	445
N-[2-(7-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	464	446
N-[2-(5-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	NO. 1	464	447
N-[2-(6-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	THE STATE OF THE S	464	448
Benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	N T N T N T N T N T N T N T N T N T N T	528	449
4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	N Harrison	438	450
Benzyl 3-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	The second secon	528	451
3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	M. THE OH CO	438	452
N-[2-(3-Benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	No. on one of the one	434	453
Benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate	N LAC ON C	568	454
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid	No. 185	477.9	455

N-[3-Methoxy-4-(5-oxazolylphenyl]-N'-[1-[(4-pyridyl)methyl]-1-cyclopentyl]oxalamide	N	421	456
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1-[(1-oxido-4-pyridyl)methyl]-1-cyclopentyl]oxalamide	N O SCH	437	457
N-[2-(4-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N dic as 1	464	458
N'-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[2-(2,6-dimethyl-4- pyridyl)-1,1-dimethylethyl] oxalamide	ALC CH	423.22	653
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2,6-dimethyl-1-oxido-4-pyridyl)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	439.3	654
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclopropyl]oxalamide		393	655
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclopropyl]oxalamide		409	656
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclobutyl]oxalamide		407	657
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1-cyclobutyl] oxalamide		421	658
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(4-pyridyl)methyl]- 1-cyclohexyl]oxalamide		435	659
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclohexyl]oxalamide	N N N N N N N N N N N N N N N N N N N	451	660

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2- methyl-4-pyridyl)ethyl]oxalamide		409	661
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-methyl-1-oxido-4- pyridyl)ethyl]oxalamide		425	662
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzothiophenecarboxylic acid	N N N S OH	494	663

Particularly preferred compounds of formula (I) and (IX) are also those of the general formula

$$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{14}$ 
 $R^{15}$ 
 $R^{18}$ 
 $R^{18}$ 
 $R^{16}$ 
 $R^{16}$ 
 $R^{10}$ 
 $R^{$ 

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> are defined as above, R<sup>11</sup>, R<sup>13</sup>,R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are H or lower alkyl and R<sup>19</sup> is alkyl, cycloalkylalkyl, heterocyclyl alkyl or aryl alkyl.

Particularly preferred compounds of formula (XII) are those wherein R<sup>2</sup> is methoxy and R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>13</sup> are hydrogen. Also preferred are compounds wherein R<sup>19</sup> represents arylalkyl, branched lower alkyl, a 3 to 7 membered cycloalkyl alkyl, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclyl alkyl with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1d below

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- pyridinyl)methylamino]phenyl]ethyl]oxala	CH O HC OH ( )	500.1	316
mide	N-		

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(3- pyridyl)methylamino]phenyl]ethyl]oxalam ide	OL O	500.1	317
N-[2-[4-(2-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	0m	489.1	318
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-Dimethyl-2-[4-(2-thenylamino)phenyl]ethyl]oxalamide	\$ 5 %	505.1	319
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-(2,2-dimethylpropylamino)phenyl]ethyl]oxalam ide	in Jacob A Ton On	479.2	320
N-[2-[4-[(1H-Imidazol-2-yl)methylamino]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	on the second se	489.1	321
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(4- pyridyl)methylamino]phenyl]ethyl]oxalam ide	0. H. H. H. O.	500.1	322
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- thiazolyl)methylamino]phenyl]ethyl]oxala mide	ON THE STATE OF TH	506.1	323
N-[2-[4-(3-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	on the second se	489.1	324
N-[2-[4-[5-(Hydroxymethyl)-2- furfurylamino]phenyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		519.1	325
N-[2-(4-Benzylaminophenyl)-1,1- dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	O. T. N. T.	499.1	326
N-[2-[4-(2-Hydroxybenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	GH, H GH CH	515.1	327
N-[2-[4-(3-Cyanobenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		524.1	328

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[4-(3- pyridyl)benzylamino]phenyl]ethyl]oxalami de		576.2	329
N-[2-[4-(2-Fluorobenzylamino)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	PHY OR PASSES	517.1	33()

Particularly preferred compounds of formula (I) and (IX) are also those of general formula

$$R^{10}$$
 $R^{10}$ 
 $R$ 

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> are defined as above, R<sup>11</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are H or lower alkyl and R<sup>20</sup> is alkyl, cycloalkyl, aryl, heterocyclyl.

Particularly preferred compounds of formula (XIII) are those wherein R<sup>2</sup> is methoxy and R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>9</sup>, R<sup>10</sup>,R<sup>11</sup> and R<sup>13</sup> are hydrogen. Also preferred are compounds where R<sup>20</sup> represents aryl, branched lower alkyl, a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1e below

10

Table 1e

Name	Structure	MS(ES) (M+H)	Ex No
N-[2-[4- (Cyclopropylcarboxamido)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	CH OHO OH	477.1	331
N-[2-[4-(Cyclobutylcarboxamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl oxalamide	CH OHC OH,	491.1	332
N-{3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-(4- pivalamidophenyl)-1,1- dimethylethyl]oxalamide	CH OHC OH	493.1	333

	· · · · · · · · · · · · · · · · · · ·		,
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	N .		
-N'-[1,1-dimethyl-2-[4-[(1H-pyrrol-	CH CHE CHE CHE	502.1	334
2-yl)carboxamido]phenyl]ethyl]	, o. ) . ~ N		-
oxalamide	N <sup></sup>		i
N-[2-[4-[(2-Furyl)			
carboxamido]phenyl]-1,1-		503.1	335
dimethylethyl]-N'-[3-methoxy-4-(5-	1		
oxazolyl)phenyl]oxalamide	N-		
N-[2-[4-[(3-Furyl)			
carboxamido]phenyl]-1,1-	o. h. h.	503.1	336
dimethylethyl]-N'-[3-methoxy-4-(5-		505.1	330
oxazolyl)phenyl]oxalamide	No.		
N-[2-[4-[(1H-Imidazol-4-yl)	N. N.	<b>500.1</b>	
carboxamido]phenyl]-1,1-	one one one one of the	503.1	337
dimethylethyl]-N'-[3-methoxy-4-(5-	.0., .		
oxazolyl)phenyl]oxalamide	N-		
N-[2-[4-[(Tetrahydro-2(RS)-furyl)			
carboxamido]phenyl]-1,1-	N	507.2	338
dimethylethyl]-N'-[3-methoxy-4-(5-	on the state of th		
oxazolyl)phenyl]oxalamide	N		
N-[3-Methoxy-4-(5-oxazolyl)			
phenyl]-N'-[1,1-dimethyl-2-[4-[(2-	н но н х х х х х х х х х х х х х х х х х	514.1	339
pyridyl)carboxamido]phenyl]ethyl]ox	0.		!
alamide	N-		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(4-pyridyl)	" - " HC - " - " - " - " - " - " - " - " - " -	514.1	340
carboxamido]phenyl]ethyl]oxalamide	0,, N,, C		
carooxamidojpiiciiyijetiiyijoxalamide	N		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	5>		
-N'-[1,1-dimethyl-2-[4-[(2-thienyl)	N. J. H. J. H.	519.1	341
carboxamido]phenyl]ethyl]oxalamide			
	N-		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N-[1,1-dimethyl-2-[4-[(3-thienyl)	THE SHEET STATE OF THE STATE OF	519.1	342
carboxamido]phenyl]ethyl]oxalamide			
	N-		
N-[2-[4-(2-Cyclopentylacetamido)	. п. т. н. с. н. с		1
phenyl]-1,1-dimethylethyl]-N'-[3-	N N	519.2	343
methoxy-4-(5-oxazolyl)phenyl]	N-		
oxalamide			
N-[3-Methoxy-4-(5-oxazolyl) phenyl]			
-N'-[1,1-dimethyl-2-[4-(2-	n	527.2	344
methylbenzamido)phenyl]ethyl]oxala	, N, - N C OI	_	
mide	N =		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	.√CH		<u> </u>
-N'-[1,1-dimethyl-2-[4-(4-	H Hq. H	527.2	345
methylbenzamido)phenyl]ethyl]oxala	,0,1	٠.١.٠	343
,			
mide			

N-[2-[4-(Cycloheptylcarboxamido)		<b>5</b> 25 -	
phenyl]-1,1-dimethylethyl]-N'-[3-	ON THE ONE OF THE ONE	533.2	346
methoxy-4-(5-oxazolyl)phenyl]			İ
oxalamide	N -		
N-[2-[4-[(5-Isoxazolyl) carboxamido]			
phenyl]-1,1-dimethylethyl]-N'-[3-		504.1	347
methoxy-4-(5-oxazolyl)phenyl]	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
oxalamide	N-		
N-[2-[4-(Cyclopentylcarboxamido)	C 4 2 MS 24 2 C		
phenyl]-1,1-dimethylethyl]-N'-[3-	G-4 2 HC 2H, 2	505.2	348
methoxy-4-(5-oxazolyl)phenyl]	1 0		
oxalamide	\		
N-[2-{4-[(Tetrahydro-3(RS)-furyl)	-0,		
carboxamido phenyl]-1,1-	CH. THE M.	507.1	349
dimethylethyl]-N'-[3-methoxy-4-(5-	Cm. (mp. 3n, )	- · · · ·	
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(1-methyl-	CH. OHE H NOT OH.	516.1	350
1H-pyrrol-2-yl)carboxamido]phenyl]	C. T. N ~ N. T. T. A. S. CH.	510.1	330
ethyl]oxalamide	27.		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	0 1 1 N N N N N N N N N N N N N N N N N		
-N'-(1,1-dimethyl-2-[4-[(1,2,3-	0+ ) HC H, N- 5	521.1	351
	C, TN - N	521.1	331
thiadiazol-4-yl)carboxamido]phenyl]	0 /		
ethyl]oxalamide			
N-[2-[4-(3-Fluorobenzamido)phenyl]	77 S		
-1,1-dimethylethyl]-N'-[3-methoxy-	or HE	531.1	352
4-(5-oxazolyl)phenyl]oxalamide	of the state of th	231.1	332
r (5 Oxazoryr)phenyrjoxadamae	N		
N-[2-[4-(4-Fluorobenzamido)phenyl]			
-1,1-dimethylethyl]-N'-[3-methoxy-	Sur THE LATE OF THE STATE OF TH	531.1	353
4-(5-oxazolyl)phenyl]oxalamide	0		
· · ·	n-"		
N-[2-[4-(2-			
Methoxybenzamido)phenyl]-1,1-	Ot 14,0 51 / N	543.2	354
dimethylethyl]-N'-[3-methoxy-4-(5-	· ·		
oxazolyl)phenyl]oxalamide	N		
N-[2-[4-(2-Chlorobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	On His A	547.1	355
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	N-4		
N-[2-[4-(3-Chlorobenzamido)	7 8		
phenyl]-1,1-dimethylethyl]-N'-[3-	on HCH O	547.1	356
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	N-		
N-[2-[4-(4-Chlorobenzamido)	. ~0		
phenyl -1,1-dimethylethyl -N'-[3-	0n 1 nc 1 nc 1 nc 1	547.1	357
methoxy-4-(5-oxazolyl)phenyl]	0	<u>.</u>	
oxalamide	N-		
Ozarannuc	<u> </u>		<u> </u>

N-[2-[4-[(1H-Indol-2-yl)			
carboxamido]phenyl]-1,1-	35 S S S S S S S S S S S S S S S S S S S	552.1	358
dimethylethyl]-N'-[3-methoxy-4-(5-	3		
oxazolyl)phenyl]oxalamide	N-		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[4-		556.1	359
(dimethylamino)benzamido]phenyl]e		550.1	3,3.,
thyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	n. (n. h. ~ 100)	<b>-</b> 07.1	2.70
-N'-[1,1-dimethyl-2-[4-(3,3-	O. C.	507.1	360
dimethylbutyramido)]phenyl]ethyl]o	N		
xalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	0, 1, 0		
-N'-[1,1-dimethyl-2-[4-[2-(1-	0 N	519.1	361
tetrazolyl)acetamido]phenyl]ethyl]ox	N-		
alamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	Chiral		
-N'-[1,1-dimethyl-2-[4-[(5-oxo-2(S)-	040 + 040	520.1	362
pyrrolidinyl)carboxamido]phenyl]eth		<u> </u>	
yl]oxalamide	i l		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	Chral		
$-N'-(1,1-dimethyl-2-\{4-[(5-oxo-2(R)-1)]\}$	(m)	520.1	363
		320.1	303
pyrrolidinyl)carboxamido]phenyl]eth	'w-/		
yl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	N X.		
-N'-[1,1-dimethyl-2-[4-[(2-		563.1	364
naphthyl)carboxamido]phenyl]ethyl]	,0., · · · · · ·		
oxalamide			
N-[2-{4-[(6-Cyano-3-pyridyl)	^ <i>i</i>		
carboxamido]phenyl}-1,1-	ra ra, ra	580.1	365
dimethylethyl]-N'-[3-methoxy-4-(5-		(M+H+	
oxazolyl)phenyl]oxalamide		ACN)	
N-[2-[4-(3-Methoxybenzamido)			
phenyl -1,1-dimethylethyl -N'-[3-	CE CHILD MY COSH	543.1	366
methoxy-4-(5-oxazolyl)phenyl]		J 10.11	2.777
oxalamide	'\'		
N-[2-[4-(3,5-Difluorobenzamido)			
		549.1	367
phenyl]-1,1-dimethylethyl]-N'-[3-		J47.1	207
methoxy-4-(5-oxazolyl)phenyl]	J. Harris		
oxalamide	N		
N-[2-[4-[(1H-Indol-5-yl)	, n. · 🏹		
carboxamido]phenyl]-1,1-	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	552.1	368
dimethylethyl]-N'-[3-methoxy-4-(5-	,o. · . · · ·		
oxazolyl)phenyl]oxalamide	N		
(E)-N-[2-[4-(2-Butenamido)phenyl]-	. M. CHE 21, 10 19 20 20 20 20 20 20 20 20 20 20 20 20 20		
1,1-dimethylethyl]-N'-[3-methoxy-4-	0	477.1	369
(5-oxazolyl)phenyl]oxalamide	N.		
	·		<del></del>

N-[2-[4-(2-Methoxyacetamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	OF CHECK	481.2	370
N-[3-methoxy-4-(5-oxazolyl)phenyl]- N'-[1,1-dimethyl-2-[4-[(2-methyl-3- furyl)carboxamido]phenyl]ethyl]oxal amide	on one in the second	517.1	371
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(5-methyl-4-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide	9 HE 3 O OI,	518.1	372
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(3-methyl-4-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	373
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(5-methyl-3-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	374
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[1,1-dimethyl-2-[4-[(1-oxido-3-pyridyl)carboxamido]phenyl]ethyl]ox alamide	6	530.1	375
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(1-oxido-4-pyridyl)carboxamido]phenyl]ethyl]ox alamide		530.1	376
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4,5-dimethyl-2-furyl)carboxamido] phenyl]ethyl]oxalamide	on of the second	531.1	377
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(2,5-dimethyl-2H-pyrazol-3-yl) carboxamido]phenyl]-1,1- dimethylethyl]oxalamide		531.1	378
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(3-methyl-2-thienyl)carboxamido]phenyl]ethyl]ox alamide		533.1	379
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[2-(3-thienyl)acetamido]phenyl]ethyl]oxala mide	(n	533.1	380

N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-2-thienyl)carboxamido]phenyl]ethyl]ox alamide		533.1	381
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-1,2,3-thiadiazol-5-yl)carboxamido]phenyl]ethyl]oxalamide		535	382
N-[2-[4-(4-Acetamidobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		570.1	383
N-[2-[4-(3,4-Dimethoxybenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		573.1	384
N-[2-[4-(4-Chloro-2-methoxybenzamido)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	THE TOTAL OF THE TOTAL OF THE	578.2	385
N-[2-[4-(2,6-Dichlorobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	OF THE PROPERTY OF STATE OF ST	581	386
N-[2-[4-[(Bicyclo[4.2.0]octa-1(6),2,4-triene-7(RS)-yl)carboxamido] phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	or the north of th	539.1	387
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-(2-oxo-2-phenylacetamido)phenyl]ethyl]oxala mide		541.1	388
N-[2-{4-[2-(2-Fluorophenyl) acetamido]phenyl}-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	OR OR OR	545	389
N-[2-{4-[2-(4-Fluorophenyl) acetamido]phenyl}-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		545	390
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[2-{4-[(4-methoxy-3-thienyl) carboxamido]phenyl}-1,1- dimethylethyl]oxalamide	ON CHICAGO	549	391

N-[2-[4-(4-Acetylbenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-		555.1	392
methoxy-4-(5-oxazolyl)phenyl]			
oxalamide	~		
N-[2-[4-[(1,3-Benzodioxol-5-yl)	#7-F		
carboxamido]phenyl]-1,1-		557.1	393
dimethylethyl]-N'-[3-methoxy-4-(5-	\$ 1.10°		
oxazolyl)phenyl]oxalamide	\(\tilde{\chi}\)		
N-[2-[4-[2-(2-Chlorophenyl)			
acetamido]phenyl]-1,1-	OHE SHOW	561.1	394
dimethylethyl]-N'-[3-methoxy-4-(5-	,0, , , , , , ,		
oxazolyl)phenyl]oxalamide	N		
N-[2-[4-[2-(4-Chlorophenyl)			
acetamido]phenyl]-1,1-		561.1	395
dimethylethyl]-N'-[3-methoxy-4-(5-	`x = 1		
oxazolyl)phenyl]oxalamide			
tert-Butyl 4-[[4-[2-[[[3-methoxy-4-			
(5-oxazolyl)anilino]oxalyl]amino]-2-		613	596
methylpropyl]phenyl]carbamoyl)benz	# \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
oate			
4-[[4-[2-[[[3-Methoxy-4-(5-oxazolyl)	.он		
anilino]oxalyl]amino]-2-	CH CHANGE	557	597
methylpropyl]phenyl]carbamoyl]benz	1 2 x 94		
oic acid	N-S		

Particularly preferred compounds of formula (I) and formula (IX) are also those of general formula

$$R^{10} \xrightarrow{N} R^{9} R^{2} \times XVIII$$

$$R^{10} \xrightarrow{N} R^{10} \times $

5

10

wherein  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^9$  and  $R^{10}$  are defined as above,  $R^{11}$  and  $R^{13}$  are H or lower alkyl, n=0 or 1,  $R^a$ ,  $R^b$  are lower alkyl or  $R^a$  and  $R^b$  taken together with the carbon atom to which they are attached form a 3 to 7 member carbocycle, and  $R^{12}$  is heterocyclyl, aryl or lower cycloalkyl and Z is O, S or  $NR^{28}$ , wherein  $R^{28}$  is H or lower alkyl.

Further preferred compounds of formula XVIII are those of general formulas:

$$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{10}$ 
 $$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{10}$ 
 $R^{1$ 

wherein  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^9$  and  $R^{10}$  are defined as above;  $R^{11}$  and  $R^{13}$  is H or lower alkyl, n=0 or 1, m=1 to 5 and,  $R^{12}$  is heterocyclyl, aryl or lower cycloalkyl.

Particularly preferred compounds of formulae (XVIII), and (XIVa and XIVb) are those wherein R<sup>2</sup> is methoxy and R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>13</sup> are hydrogen.

Also preferred are compounds of formulae (XVIII), and (XIVa and XIVb) where R<sup>12</sup> represents aryl, , a 3 to 7 membered cycloalkyl ring, or a 5 or 6 membered monocyclic or 9 or 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Examples of such compounds are listed in table 1f<sup>1</sup> below

table 1f<sup>l</sup>

	tubic II		
Name	Structure	MS(ES)	Ex No
		$(M+H)^{+}$	
N-[3-(4-Hydroxy-phenoxy)-1,1-	<b>№</b> 0 0 сн,		
dimethyl-propyl]-N'-(3-methoxy-	O CH <sub>1</sub>	440	396
4-oxazol-5-yl-phenyl)-oxalamide	О СН,		

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(4- methoxyphenoxy)-1,1- dimethylpropyl]oxalamide	0 OH	454	397
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- nitrophenoxy)propyl]oxalamide	0 CH	469	398
N-[3-(2-Hydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N O CH,	440	399
N-[3-(4-Amino-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	439	400
N-[3-(4-Acetylamino-phenoxy)- 1,1-dimethyl-propyl]-N'-(3- methoxy-4-oxazol-5-yl-phenyl)- oxalamide	N. CH.	481	401
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3- pyridyloxy)propyl]oxalamide	N O O N O O O O O O O O O O O O O O O O	425	402
N-[3-(3-Hydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		440	403
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(3- methoxyphenoxy)-1,1- dimethylpropyl]oxalamide	NZ COCOC	454	404
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3- nitrophenoxy)propyl]oxalamide		469	405
N-[3-(3-Aminophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		439	406
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		468	433
2-[3-[{[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		468	434

3-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		468	435
2-[4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenoxy]acetic acid	# 1	498	436
2-[2-[3-[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenoxy]acetic acid		498	437
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(1,1-dimethyl-3-phenoxypropyl)oxalamide	N TO O CHY  THE STATE OF T	424	542
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1-oxido-3-pyridyloxy)propyl] oxalamide		441	543
N-[3-(3,4-Dihydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N TO WEN	456	544
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4- (methylcarbamoyl)phenoxy]propyl ]oxalamide	1 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	481	545
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(3,4-dimethoxyphenoxy)-1,1-dimethylpropyl]oxalamide	M	484	546
N-[3-[4-[(2-Hydroxyethyl) carbamoyl]phenoxy]-1,1-dimethyl-propyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		511	547
N-[3-(3-Chlorophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N CH O CH	458	548
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3- pyridyloxy)propyl]oxalamide		425	549
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyridyloxy)propyl]oxalamide	N O O'H,	425	55()

2-[4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]acetic acid	11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	482	551
2-[3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]acetic acid	N	482	552
4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropoxy]benzoic acid	01. 0 0H, 0. 10 0H, 0. 10 0H,	454	553
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-methylbenzoic acid	N 1 2 34 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	482	554
3-[3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]propionic acid	1	496	555
3-[4-[3-[[[3-Methoxy-4- (5oxazolyl)anilino]oxalyl]amino]- 3-methylbutoxy]phenyl]propionic acid		496	556
3-[2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenyl]propionic acid	n on on	496	557
2-[3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]phenoxy]acetic acid	N : To the second secon	498	558
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-3-methylbenzoic acid	N COLUMN TO THE STATE OF THE ST	482	559
N-[3-(4-Cyano-2- methoxyphenoxy)-1,1- dimethylpropyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	CH CHICOH.	479	560
N-[3-(3-Cyanophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	04 3 40 0.	449.6	561
N-[3-[4-(4-Acetyl-1-piperazinyl) phenoxy]-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	J. 7. 3. 1. 3.	550.4	562

N [2 Mathony 1 (5			
N-[3-Methoxy-4-(5-	one on	531.4	563
oxazolyl)phenyl]-N'-[1,1-dimethyl-	_a_ > 0	1	202
3-(2-morpholinophenoxy)propyl]	N	(M + Na)'	
oxalamide		<u> </u>	
N-[3-Methoxy-4-(5-oxazolyl)	on oncon	100 3	<b>-</b> 4
phenyl]-N'-[1,1-dimethyl-3-[3-	! 0-J	489.6	564
(dimethylamino)phenoxy]	Ne	$(M + Na)^{\dagger}$	
propyl]oxalamide			
N-[3-(1,3-Benzodioxol-5-yloxy)-	0 HC CH,		
1,1-dimethylpropyl]-N'-[3-		468.4	565
methoxy-4-(5-oxazolyl)phenyl]	N-1		
oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	. "		
phenyl]-N'-[3-(3,4,5-	III. SHE CHI	514.4	566
trimethoxyphenoxy)-1,1-	OF CH		
dimethylpropyl]oxalamide	N-1		
N-[3-Methoxy-4-(5-oxazolyl)			
phenyl]-N'-[3-(3,5-	н, не зне зак	506	567
dimethoxyphenoxy)-1,1-	H. HE ONLY O'LL GOH	$(M + Na)^{\dagger}$	
dimethylpropyl]oxalamide	· · · ·		
N-[3-(5,6,7,8-Tetrahydro-5-oxo-2-	С		
naphthyloxy)-1,1-dimethylpropyl]-	on a lagor (1)	492.4	568
N'-[3-methoxy-4-(5-		1,21,1	2.70
oxazolyl)phenyl]oxalamide	N-		
N-[3-(2-Acetamido-5-	э,		
methylphenoxy)-1,1-	on one one of	517.6	569
dimethylpropyl]-N'-[3-methoxy-4-	A Committee of the Comm	$(M + Na)^{\dagger}$	507
(5-oxazolyl)phenyl]oxalamide	N- Ö	(141 + 144)	
N-[3-(3-Acetamidophenoxy)-1,1-			
dimethylpropyl]-N'-[3-methoxy-4-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	503.6	570
	V***	$(M + Na)^{+}$	370
(5-oxazolyl)phenyl]oxalamide	<b>N-</b>	(NI + Na)	
N-[3-(1H-Indol-4-yloxy)-1,1-		+	
dimethylpropyl]-N'-[3-methoxy-4-	ON OHUSH	485.2	571
dimethylpropylj-iN -[3-methoxy-4-   (5-oxazolyl)phenyl]oxalamide	, D	$(M + Na)^{\dagger}$	3/1
(5-0xazoryr/phenyrjoxarannue	he :	(NI T Na)	
N-[3-(2-Fluoro-6-		+	
methoxyphenoxy)-1,1-	Оц. Оно он. (6.5) Э. Ум. Съде С. (8.5)	472.2	572
	p-1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4/2.2	312
dimethylpropyl]-N'-[3-methoxy-4-	N- #		
(5-oxazolyl)phenyl]oxalamide		+	
N-[3-Methoxy-4-(5-oxazolyl)	3	102.1	572
phenyl]-N'-[1,1-dimethyl-3-(2-	2,7	492.4	573
oxo-2H-1-benzopyran-7-	Ň-		
yloxy)propyl]oxalamide			
N-[3-(4-Acetyl-3-methylphenoxy)-	C4 CHC 12 ~~~	100	
1,1-dimethylpropyl]-N'-[3-	GHG 3H	480.2	574
methoxy-4-(5-oxazolyl)phenyl] oxalamide	0		

(E)-N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4-(3-oxo-1-butenyl)phenoxy]propyl] oxalamide		492.4	575
N-[3-(3-Acetylphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	on one on	466.4	576
N-[3-(4-Acetylphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	OH : HO > 000 O	466.2	577
N-[3-(4-Acetamido-2-chlorophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	Ch, "NC 14 NO 14	515.6	578
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-pyridyloxy)propyl]oxalamide		425	579
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1- oxido-4-pyridyloxy)propyl] oxalamide		441	580
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6- dimethyl-4-pyridyloxy)propyl] oxalamide	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	453	581
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2,6- dimethyl-1-oxido-4-pyridyloxy) propyl]oxalamide	NST OF SHIP OF	469	582
N-[2-(4-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	G	435	583
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(2-methoxy-4- pyridyloxy)-1,1-dimethylpropyl] oxalamide	N 20 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	455	584
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4- (1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide	Cn	478	585
N-[3-(4-Cyanophenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	586

N-[2-(3-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	0H 0 0H	476	587
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[3- (1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide	2 C CH N N N N N N N N N N N N N N N N N	478	588
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-[4- (1H-tetrazol-5-yl)phenoxy]propyl] oxalamide	Mark Service Control of No. 1	492	589
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclobutyl]ethoxy]benzoate	The state of the s	570.2	590
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoate		584.3	591
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoate	The state of the s	598.3	592
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoic acid		494.2	593
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoic acid	M. S. N. J. N. J.	508.2	594
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)amino]-1-cyclobutyl]ethoxy]benzoic acid	0x 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	480.2	595
Benzyl 2-methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate	1	588	635
3-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	A CH	502	636
2-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 2 C	498	637

3-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	NO OF H	498	638
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopropyl]ethoxy]benzoic acid	C T C C C C C C C C C C C C C C C C C C	466	639
2-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N → 0 → 0 → 0 → 0 → 0 → 0 → 0 → 0 → 0 →	502	640
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid		519	641
(cis/trans)-4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-1-cyclohexanecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	474	642
(cis/trans)-4-[2-[[[3-Methoxy-4- (5-oxazolyl)anilino]oxalyl]amino]- 2-methylpropoxy]-1- cyclohexanecarboxylic acid	O T N T N O O O O O O O O O O O O O O O	460	643
3-Fluoro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	NEO O' NE NE O E OH	486	644
3-Acetamido-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N O N N O HN O HN	525	645
3-(Methanesulfonamido)-4-[3- [[[3-methoxy-4-(5- oxazolyl)anilino]oxalyl]amino]-3- methylbutoxy]benzoic acid	N N N N N N N N N N N N N N N N N N N	561	646
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-3,5-dimethylbenzoic acid	N O O O O O O O O O O O O O O O O O O O	496	647
3-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-pyridinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	469	648
8-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	519	649

5-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-indolecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	507	650	
--	---	-----	-----	--

Further preferred compounds of formula XVIII are those of general formula

$$R^{10}$$
 $R^{10}$ 
 $R$ 

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> are defined as above, R<sup>11</sup> and R<sup>13</sup> are H or lower alkyl, n= 0 or 1, R<sup>a</sup>, R<sup>b</sup> are lower alkyl or R<sup>a</sup> and R<sup>b</sup> taken together with the carbon atom to which they are attached form a 3 to 7 member carbocycle, and R<sup>12</sup> is heterocyclyl, aryl or lower cycloalkyl, especially aryl, a 3 to 7 membered cycloalkyl ring, or a 5 to 6 membered monocyclic or 9 to 10 membered bicyclic saturated or unsaturated heterocyclic ring with 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

Particularly preferred compounds of formula (XIX) are those wherein  $R^2$  is methoxy and  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{13}$  are hydrogen.

Examples of such compounds are listed in table 1f2 below:

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	0 cH,	426	615
N-[2-(4-Hydroxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		442	616
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	440	617
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-pyridylthio)ethyl]oxalamide	о о о о му о му о му о му о му о му о м	427	618

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyridylthio)propyl]oxalamide	N 0 2 2 N 0	441	619
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- thienylthio)propyl]oxalamide	н эн	446	620
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- pyrimidylthio)propyl]oxalamide	N O O OH, OH, OH, OH, OH, OH, OH, OH, OH,	442	621
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- pyridylthio)propyl]oxalamide	N - 1 - 9 - N - OH - S - N - OH - S N	441	622
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(2- thiazolylthio)propyl]oxalamide	N 0 0 0H	447	623
N-[3-(4-Hydroxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N 0 0 00.	456	624
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(5- methyl-1,3,4-thiadiazol-2-ylthio) propyl]oxalamide	N	462	625
N-[3-(2-Benzooxazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	HE CH SUN	481	626
N-[3-(2-Benzothiazolylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	No. 1 September 1997	497	627
Methyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoate	ON THE CONTRACTOR OF THE CONTR	484	628
tert-Butyl 6-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylate	N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	541	629
6-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	N A STATE OF	485	630
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]benzoic acid	N N N N N N N N N N N N N N N N N N N	484	631

	T		7
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N°OO'N N'N S-OOO	532	664
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	NºO O'NONTO	546	665
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-5-benzoxazolecarboxylic acid	N OHO OH	525	666
N-[3-(1H-Imidazol-2-ylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		430	667
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	F O O O O O O O O O O O O O O O O O O O	485	668
4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoic acid	N Z J N X N X	470	669
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-6-benzoxazolecarboxylic acid		525	670

Further preferred compounds of formula (XVIII) are those of general formula

$$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{10}$ 
 wherein  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^9$  and  $R^{10}$  are defined as above,  $R^{11}$ ,  $R^{13}$  and  $R^{28}$  are H or lower alkyl, n=0 or 1,  $R^a$ ,  $R^b$  are lower alkyl or  $R^a$  and  $R^b$  taken together with the carbon atom to which they are attached form a 3 to 7 number carbocycle, and  $R^{12}$  is heterocyclyl, aryl or lower cycloalkyl preferably aryl such as phenyl.

Particularly preferred compounds of formula (XX) are those wherein  $R^2$  is methoxy and  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{13}$  are hydrogen and  $R^{28}$  is hydrogen or methyl.

Examples of such compounds are listed in table 1f3 below.

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino) ethyl] oxalamide	0 0 0 HC 0 N	423	632
N-(3-Anilino-1,1-dimethylpropyl)- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide hydrochloride (1:1)	N C O CH,  O CH <sub>2</sub> O	423	633
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylamino]benzoic acid	ont chi	467	634

5 Particularly preferred compounds of formula (I) or formula (IX) are also those of general formula

$$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{10}$ 
 $R^{1$ 

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> are defined as above, R<sup>11</sup> and R<sup>13</sup> is H or lower alkyl, n = 0 or 1; R<sup>21</sup> is alkyl, cycloalkyl, phenyl, heterocyclyl, cycloalkyl alkyl, phenyl alkyl or heterocyclyl alkyl, alkyl carbonyl, cycloalkyl carbonyl, phenyl carbonyl, heterocyclyl carbonyl, alkyl sulphonyl, cycloalkyl sulphonyl, phenyl sulphonyl, heterocyclyl sulphonyl. Preferably R<sup>21</sup> is phenyl, phenyl alkyl, phenyl carbonyl, or phenyl sulfonyl.

Particularly preferred compounds of formula (XV) are also those wherein  $R^2$  is methoxy,  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{13}$  are hydrogen.

Examples of such compounds are listed in table 1g below

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide		478	407
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	408
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	409
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1,1-dimethyl-3- (4-phenyl-1- piperazinyl)propyl]oxalamide		492	410
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2-methoxy-phenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	411
N-[2-(4-Benzyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		492	412
N-[2-[4-(Benzenesulfonyl)-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		452	413
N-[2-(4-Benzoyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		506	414
N-[2-[4-[4- (Trifluoromethyl)phenyl]-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CH C	546	459
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]oxalamide		492	460
N-[2-[4-(2-Fluorophenyl)-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		496	461

N 12 14 (4 Flyonophoryl) 1			T1
N-[2-[4-(4-Fluorophenyl)-1-	он он N	496	462
piperazinyl]-1,1-dimethylethyl]-N'-	- 1. ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	490	402
[3-methoxy-4-(5-	M		
oxazolyl)phenyl]oxalamide	35		
N-[3-Methoxy-4-(5-	×	500	
oxazolyl)phenyl]-N'-[2-[4-(2-	0. 04 / N /	508	463
methoxyphenyl)-1-piperazinyl]-1,1-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
dimethylethyl]oxalamide	» N		
N-[3-Methoxy-4-(5-	0 H0 OH 0		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	C+ 2 HC 2H 1	548	464
[4-(2-thiophenesulfonyl)-1-			
piperazinyl]ethyl]oxalamide	ł		
N-[3-Methoxy-4-(5-	4, );		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	\$11 - N	584.1	465
[4-(2,4,6-trimethylbenzenesulfonyl)-	0, 1.		
1-piperazinyl]ethyl]oxalamide	N-1		
N-[2-[4-(4-Fluorobenzenesulfonyl)-	7		
1-piperazinyl]-1,1-dimethylethyl]-N'-	O N N N N	560.1	466
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N=1		
N-[2-[4-(Trifluoromethanesulfonyl)-			
1-piperazinyl]-1,1-dimethylethyl]-N'-	CH DH SHI N	534	467
[3-methoxy-4-(5-			
oxazolyl)phenyl)]oxalamide	N-		
N-[2-[4-(Isopropylsulfonyl)-1-	M. CHy (FR) (M. 2)		
piperazinyl]-1,1-dimethylethyl]-N'-	м. сы, ты м <sub>гэ</sub>	508.1	468
[3-methoxy-4-(5-	o		
oxazolyl)phenyl)]oxalamide	N-3		
(E)-N-[3-Methoxy-4-(5-	.~	·	
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		568.1	469
[4-(styrylsulfonyl)-1-	c 1 N 1 4	200.1	105
piperazinyl]ethyl]oxalamide			
N-[2-[4-(Ethanesulfonyl)-1-	3		<del>                                     </del>
piperazinyl]-1,1-dimethylethyl]-N'-	CH. Share H. Soon	494.1	470
[3-methoxy-4-(5-		<b>コノて.1</b>	470
oxazolyl)phenyl]oxalamide	, o		
N-[3-Methoxy-4-(5-	Э , сн		<del>                                     </del>
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Co. N. A.	508.1	471
[4-(propanesulfonyl)-1-	Open C	500.1	7/1
piperazinyl]ethyl]oxalamide			
			<del> </del>
N-[2-[4-(3-Chloropropanesulfonyl)-	CH GHS H C N S	542.1	172
1-piperazinyl]-1,1-dimethylethyl]-N'-	(N	542.1	472
[3-methoxy-4-(5-	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
oxazolyl)phenyl]oxalamide			<del> </del>
N-[3-Methoxy-4-(5-	, ~ °s · ~	55/ 1	172
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	0H .Hs. Hs No chs	556.1	473
[4-(o-toluenesulfonyl)-1-	٥ - ٠ - ٥		
piperazinyl]ethyl]oxalamide	N-		L

N. (2 [4 (2 Fl 1 16 1)			<del>,                                      </del>
N-[2-[4-(2-Fluorobenzenesulfonyl)-	5.	<b>5</b> : 0 1	
1-piperazinyl]-1,1-dimethylethyl]-N'-	SH, SHIC OK N	560.1	474
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Cyanobenzenesulfonyl)-			
1-piperazinyl]-1,1-dimethylethyl]-N'-	CH SHE ON N 1	567.1	475
[3-methoxy-4-(5-	0_ 0_ 0		1
oxazolyl)phenyl]oxalamide	N-J		
N-[3-Methoxy-4-(5-	OHC OK NO DE		
oxazolyl)phenyl]-N'-[2-[4-(3,5-	O- 2 HC OH N 3 30	561.1	476
dimethyl-4-isoxazolylsulfonyl)-1-	0.7		
piperazinyl]-1,1-dimethyl-	الب		
ethyl]oxalamide			
N-[2-[4-(5-Fluoro-2-	6.5		
methylbenzenesulfonyl)-1-		574.1	477
piperazinyl]-1,1-dimethylethyl]-N'-			
[3-methoxy-4-(5-	\		1
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2,5-	2.5		
Difluorobenzenesulfonyl)-1-		578.1	478
piperazinyl]-1,1-dimethylethyl]-N'-			
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	cu.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH. SHELLING CONTRACTOR	546.1	479
[4-(1-methyl-1H-imidazole-4-			
sulfonyl)-1-	N-I		
piperazinyl]ethyl]oxalamide			
N-[2-[4-(2,6-	10.70		
Difluorobenzenesulfonyl)-1-	DE SHE H	578.1	480
piperazinyl]-1,1-dimethylethyl]-N'-	S. Aylan N.	3,0.1	100
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3,4-			
Difluorobenzenesulfonyl)-1-	on che in the latest t	578.1	481
piperazinyl]-1,1-dimethylethyl]-N'-		5,0.1	101
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-	9		<del>   </del>
(Cyclohexylmethanesulfonyl)-1-	2. (N 2N (N N)(N N)	562.2	482
piperazinyl]-1,1-dimethylethyl]-N'-		502.2	102
[3-methoxy-4-(5-	w.º		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-			<del>                                     </del>
		570.1	483
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		370.1	403
[4-(2-phenylethanesulfonyl)-1-			
piperazinyl]ethyl]oxalamide	*		

N. [2 N. d. 4 / 5	30		
N-[3-Methoxy-4-(5-		520	404
oxazolyl)phenyl]-N'-[2-[4-(2,4-	ON I HE OF THE	538	484
dimethoxyphenyl)-1-piperazinyl]-	) ON (		
1,1-dimethylethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		492	485
[4-(4-methylphenyl)-1-	(a)		
piperazinyl]ethyl]oxalamide	<u></u>		
N-[3-Methoxy-4-(5-	. ∼.α,		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		506	486
[4-(2,4-dimethylphenyl)-1-	0 N O		
piperazinyl]ethyl]oxalamide	<u>*</u> ε.·		
N-[3-Methoxy-4-(5-	~ ~		
oxazolyl)phenyl]-N'-[2-[4-(3,4-	1 25 XX	538	487
dimethoxyphenyl)-1-piperazinyl]-	**************************************		
1,1-dimethylethyl]oxalamide	Σ-		
N-[2-(4-Cyclohexyl-1-piperazinyl)-	/\		
1,1-dimethylethyl]-N'-[3-methoxy-4-	g <sub>h,C</sub> .×, h,	484.4	488
(5-oxazolyl)phenyl]oxalamide	N N		
(*************************************	N:		
N-[2-[4-(Cyclohexylmethyl)-1-	-, < )		
piperazinyl]-1,1-dimethylethyl]-N'-	No. No. No.	498.2	489
[3-methoxy-4-(5-	0		
oxazolyl)phenyl]oxalamide	No. 1		
N-[2-[4-(2-Methoxybenzyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	490
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Hydroxybenzyl)-1-	1		
piperazinyl]-1,1-dimethylethyl]-N'-		508.1	491
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	1 2 2 2 2 2 2	506.1	492
[4-(2-methylbenzyl)-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	-,~()		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H <sub>1</sub> 5 H <sub>2</sub> C3-5	498.1	493
[4-(2-thenyl)-1-	N - N - N - N - N - N - N - N - N - N -		1
piperazinyl]ethyl]oxalamide	N-		
N-[3-Methoxy-4-(5-	e <sup>5</sup> <b>\</b>		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		520.2	494
[4-(2(RS)-phenylpropyl)-1-	45	J_L()	3/3
piperazinyl]ethyl]oxalamide	<u>^</u>		
N-[3-methoxy-4-(5-	5 N.		+
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	- me 21 011	486.1	495
		400.1	493
(4-pivaloyl-1-			
piperazinyl)ethyl]oxalamide	`		<u> </u>

		·	
N-[2-[4-(2-Furoyl)-1-piperazinyl]-	2.4		
1,1-dimethylethyl]-N'-[3-methoxy-4-	HO SHOOM W	496.1	496
(5-oxazolyl)phenyl]oxalamide		i I	
	° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° °		
N-[3-Methoxy-4-(5-	2.2		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Ms: CHCON N.	512.1	497
[4-(2-thenoyl)-1-			
piperazinyl]ethyl]oxalamide	ST .		
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	M; OHCOM,	512	498
[4-(3-thenoyl)-1-			
piperazinyl]ethyl]oxalamide	~T		
N-[2-[4-(2-Cyclopentylacetyl)-1-			
piperazinyl]-1,1-dimethyl-ethyl]-N'-		512.1	499
[3-methoxy-4-(5-		512.1	17.
oxazolyl)phenyl)]oxalamide			
N-[2-[4-(Cyclohexylcarbonyl)-1-		-	
		512.1	500
piperazinyl]-1,1-dimethylethyl]-N'-	Ha N N N N N N N N N N N N N N N N N N N	512.1	500
[3-methoxy-4-(5-	i Çırî		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-		500.	-0.
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	41, 1, 2, 2, 2, 3	520.1	501
[4-(2-methylbenzoyl)-1-			
piperazinyl]ethyl]oxalamide	7-1		
N-[3-Methoxy-4-(5-	-: 47		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Hr. O HCOH,	520.1	502
[4-(4-methylbenzoyl)-1-	Ç		,
piperazinyl]ethyl]oxalamide	W.		
N-[2-[4-(Cycloheptylcarbonyl)-1-	_ \L_\_	1	
piperazinyl]-1,1-dimethylethyl]-N'-	Hy. O H <sub>2</sub> CCH <sub>3</sub>	526.2	503
[3-methoxy-4-(5-	0.2		
oxazolyl)phenyl]oxalamide	Ĉi,		
N-[3-Methoxy-4-(5-	· · ·		
oxazolyl)phenyl]-N'-]1,1-dimethyl-2-	Hr. O HCOH	496.1	504
[4-[(1H-pyrazol-4-yl)carbonyl]-1-	O. J. A. J.		
piperazinyl]ethyl]oxalamide	Çr*		
N-[2-[4-(Cyclopentylcarbonyl)-1-	1		
piperazinyl]-1,1-dimethylethyl]-N'-	H. O HECKS	498.1	505
[3-methoxy-4-(5-	0. / N N N		
oxazolyl)phenyl]oxalamide	\$1		
N-[3-Methoxy-4-(5-	3 2		
oxazolyl)phenyl]-N'-[1,1-Dimethyl-		509.1	506
2-[4-[(1-methyl-1H-pyrrol-2-		237.1	
yl)carbonyl]-1-	\$ ^ · '		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	9 N		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	n HCON,	514.1	507
	HIG. N. N. N.	314.1	307
[4-[(1,2,3-thiadiazol-4-yl)carbonyl]-	J		
1-piperazinyl]-ethyl]oxalamide	ry .		

N-[2-[4-(3-Fluorobenzoyl)-1-		:	i
piperazinyl]-1,1-dimethylethyl]-N'-		524.1	508
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	<u> </u>		
N-[2-[4-(4-Fluorobenzoyl)-1-	2.//		
piperazinyl]-1,1-dimethylethyl]-N'-	ME SHIPER CO	524.1	509
[3-methoxy-4-(5-			i
oxazolyl)phenyl]oxalamide			
N-[2-[4-(Cyclopropylcarbonyl)-1-	3		
piperazinyl]-1,1-dimethylethyl]-N'-	OMCCH	470.1	510
[3-methoxy-4-(5-	M. T. W. T. W.	470.1	310
oxazolyl)phenyl]oxalamide			
	~		
N-[2-[4-(2-Cyclohexylacetyl)-1-		F2.6.2	F11
piperazinyl]-1,1-dimethylethyl]-N'-		526.2	511
[3-methoxy-4-(5-	į į		
oxazolyl)phenyl]oxalamide	¥		
N-[3-Methoxy-4-(5-	4		
oxazolyl)phenyl]-N'-[2-[4-(3,3-		500.2	512
dimethylbutyryl)-1-piperazinyl]-1,1-			İ
dimethylethyl]oxalamide	<u></u>		
N-[2-[4-(3-Hydroxy-2,2-			
dimethylpropionyl)-1-piperazinyl]-	mind the second second second	502.1	513
1,1-dimethylethyl]-N'-[3-methoxy-4-			
(5-oxazolyl)phenyl]oxalamide	977		
N-[3-Methoxy-4-(5-	- ₹		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		510.1	514
[4-(3-methyl-2-furoyl)-1-	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	. >-		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		510.1	515
[4-(2-methyl-3-furoyl)-1-	HG T	310.1	
piperazinyl]ethyl]oxalamide		<del> </del>	
N-[3-Methoxy-4-(5-	HH2 0 H32H N N-H	F10.1	
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HAS OHIOW N	510.1	516
[4-[(5-methyl-1H-pyrazol-3-	(a) x x 0		
yl)carbonyl]-1-	M**		
piperazinyl]ethyl]oxalamide	5.		
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	3	511.1	517
[4-[(5-methyl-4-			
isoxazolyl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	La par		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	O MCCH N	511.1	518
[4-[(5-methyl-3-			
isoxazolyl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide	1		
piperazinjijemijijohalalilide	1	1	L

		,	
N-[2-[4-(4-Aminobenzoyl)-1-		į	
piperazinyl]-1,1-dimethylethyl]-N'-	Mil SHOW AND	521.1	519
[3-methoxy-4-(5-		1	
oxazolyl)phenyl]oxalamide	4.		
N-[2-[4-(2-Hydroxybenzoyl)-1-	Ž		
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	520
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	\		!
N-[2-[4-(4-Hydroxybenzoyl)-1-	\$		
piperazinyl]-1,1-dimethylethyl]-N'-	HS: OHCOS IN EXON	522.1	521
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	1. 1.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	1 HOP (5) The	524.1	522
[4-[(2,5-dimethyl-2H-pyrazol-3-	"A-ry		
yl)carbonyl]-1-	Ç:		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	2.05.94	526.1	523
[4-(3-methyl-2-thenoyl)-1-		021	020
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	£		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Hy. O H C CHS	526.1	524
[4-(4-methyl-2-thenoyl)-1-	No.	321	321
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	0 H29M	526.2	525
[4-[(2,2,3,3-tetramethyl-1-		320.2	323
cyclopropyl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Jane Dall	528.1	526
[4-[(4-methyl-1,2,3-thiadiazol-5-		320.1	320
yl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide		•	<u> </u>
N-[2-[4-(3-Cyanobenzoyl)-1-	7		<del> </del>
piperazinyl]-1,1-dimethylethyl]-N'-		531.1	527
[3-methoxy-4-(5-		331.1	321
oxazolyl)phenyl]oxalamide	( . · · · · · · · · · · · · · · · · · ·		
N-[2-[4-[(Bicyclo[4.2.0]octa-	3 /=\		+
N-[2-[4-[(Bicyclo[4.2.0]octa-   1(6),2,4-trien-7-yl)carbonyl]-1-		532.1	528
		352.1	320
piperazinyl]-1,1-dimethylethyl]-N'-			
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	<del>о</del> , он		<del> </del>
N-[2-[4-(3-Hydroxybenzoyl)-1-	W. O WE COT	522.1	520
piperazinyl]-1,1-dimethylethyl]-N'-	His Dudge and	522.1	529
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N-		<u> </u>

N-[2-[4-(2-Ethylbutyl)-1-	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		
piperazinyl]-1,1-dimethylethyl]-N'-	HC CHOOK TO	486.1	530
[3-methoxy-4-(5-	· · · · ·		İ
oxazolyl)phenyl]oxalamide	N:		
N-[3-Methoxy-4-(5-			:
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	*	506.2	531
[4-(2-phenylethyl)-1-			
piperazinyl]ethyl]oxalamide	1		!
N-[3-Methoxy-4-(5-	, ~s <sup>OH</sup> ,		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	н, носи	490.1	532
[4-[3-(methylthio)propyl]-1-			!
piperazinyl]ethyl]oxalamide	Nr.		į
N-[2-[4-(2,6-Difluorobenzyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	13 Y 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	528.1	533
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3-Furfuryl)-1-piperazinyl]-			
1,1-dimethylethyl]-N'-[3-methoxy-4-	H. 0 H, 10 / N = /	482.1	534
(5-oxazolyl)phenyl oxalamide	N -N	102.1	554
(3-0xazoryr)phenyrjoxalamide	N.		
N-[2-[4-[(2-Benzofuranyl)methyl]-	40 50		
1-piperazinyl]-1,1-dimethylethyl]-N'-	m pm o	532.1	535
[3-methoxy-4-(5-	0	002.1	
oxazolyl)phenyl)]oxalamide	Nº .		
N-[2-[4-(2-Cyanobenzyl)-1-	``		
piperazinyl]-1,1-dimethylethyl]-N'-		517.1	536
[3-methoxy-4-(5-		317.1	
oxazolyl)phenyl]oxalamide	100		!
N-[3-Methoxy-4-(5-	77,57		
oxazolyl)phenyl]-N'-[2-[4-(3,3-	40 O	486.2	537
dimethylbutyl)-1-piperazinyl]-1,1-		400.2	337
dimethylethyl]oxalamide			!
	N. C		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HOW THE THE	543.2	538
		343.2	330
[4-[(2-quinolinyl)methyl]-1-	The second secon		
piperazinyl]ethyl]oxalamide			
tert-Butyl 4-[2-[[[3-methoxy-4-(5-	OH; 1: √0 -4-OH; OH;	F 1 C	F20
oxazolyl)anilino]oxalyl]amino]-2-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	516	539
methylpropyl]-1-piperazineacetate	N CH		
4-[2-[[[3-Methoxy-4-(5-	A. J. of		<del> </del>
	5	460	540
oxazolyl)anilino]oxalyl]amino]-2-	1 0	400	340
methylpropyl]-1-piperazineacetic	- T		
acid trifluoroacetate (1:1)	*		
N-[2-[4-(Cyclopropylmethyl)-1-	Pr. Co. CH. C. N.	156	541
piperazinyl]-1,1-dimethylethyl]-N'-	, N 34,	456	541
[3-methoxy-4-(5-	N-		!
oxazolyl)phenyl]oxalamide			<u> </u>

tert-Butyl 4-[4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoate	NO NO NO NO NO NO NO NO NO NO NO NO NO N	578	651
4-[4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoic acid trifluoroacetate (1:1)	NO FILOH	522	652

In particular preferred compounds of formula (I) and formula (IX)  $\setminus$  are also those of the general formula

$$R^{10}$$
 $R^{9}$ 
 $R^{2}$ 
 $R^{23}$ 
 $R^{24}$ 
 $R^{24}$ 
 $R^{27}$ 
 $R^{27}$ 
 $R^{27}$ 
 $R^{27}$ 
 $R^{27}$ 
 $R^{27}$ 
 $R^{27}$ 
 $R^{29}$ 
 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>,R<sup>7</sup>,R<sup>9</sup>,R<sup>10</sup> and R<sup>13</sup> are defined as above, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup> and R<sup>26</sup> are H or lower alkyl,R<sup>27</sup> is alkyl, aryl or heterocyclyl, alkoxy, aryloxy, heterocyclyl oxy, especially aryl or aryloxy.

Particularly preferred compounds of formula (XVI) are those wherein R<sup>2</sup> is methoxy, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>13</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup> and R<sup>26</sup> are hydrogen.

Examples of such compounds are listed in table 1h below:

Name	Structure	ME(ES) (M+H)	Ex No
Phenyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl] carbamate	HC O N	487	415
N-[3-[(3-	он, о	489	
Fluorobenzamido)methyl]phenyl]-N'-	OH, O N O		416
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-[(3-	он, о		
Chlorobenzamido)methyl]phenyl]-N'-		505	417
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			

N-[3-[(3- Methoxybenzamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	501.2	418
N-[3-[(3,4- Dimethoxybenzamido)methyl]phenyl] -N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	531.2	419
N-[3-[(3- Cyanobenzamido)methyl]phenyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	496.1	420

In particular preferred compounds of formula (I) or formula (IX) are also those of the general formula

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>10</sup> are defined as above; R<sup>11</sup> and R<sup>13</sup> is H or lower alkyl and R<sup>12</sup> is heterocyclyl, aryl or lower cycloalkyl.

Particularly preferred compounds of formula (XVII) are those wherein  $R^2$  is methoxy,  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{13}$  are hydrogen and wherein  $R^{12}$  is phenyl or

10

Examples of such compounds are listed in table 1i below:

Name	Structure	$MS(ES)$ $(M+H)^{+}$	Ex No
N-[3-Methoxy-4-(4-oxazolyl) phenyl]-N'-[1,1-dimethyl -2-(4- phenyl-1-piperazinyl)ethyl] oxalamide		478	428

N-[2-(4-Benzyloxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide		500	429
N-[2-(4-Hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide	CH, CH, CH	410	43()
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	431
N-[3-Methoxy-4-(2-methyl-4-oxazolyl)-phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		522.4	432

The compounds of formula (IV) and (VIII) which are intermediates in the foregoing processes are novel and are also provided by the present invention.

5

10

With reference to Reaction Scheme A, the first step comprises the coupling of a compound of formula (II) with an activated oxalyl derivative, such as methyl chlorooxoacetate, to give a compound of formula (III). The reaction may be carried out in a conventional manner, suitably in an organic solvent which is inert under the reaction conditions and in the presence of an organic base at about 0°C to about room temperature. Suitable solvents include halogenated

hydrocarbons, e.g. dichloromethane. Pyridine and tri(lower alkyl)amines, e.g. triethylamine, can be mentioned as examples of suitable organic bases which can be used.

Subsequent hydrolysis of the compound of formula (III) to give the acid compound of formula (IV) may be carried out by treatment with a solution of an alkali metal hydroxide, such as sodium hydroxide, in a suitable solvent system, such as aqueous methanol.

Alternatively, a compound of formula (II) may be coupled with tert.butyl chlorooxoacetate, followed by treatment with acid to remove the tert.butyl group, to give a compound of formula (IV).

The compound of formula (IV) is then coupled with an amine compound of formula (V) using standard peptide coupling reagents, such as hydroxybenzotriazole in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, to give the oxamide compound of formula (I).

After this coupling step, the R groups of the resulting compound may be further modified by techniques known in the art, for example, functional groups may be altered, and/or connected to further groups

20

10

15

#### Reaction Scheme B

Referring to Reaction Scheme B, the first step comprises the coupling of a compound of formula (VI) with an activated oxalyl derivative, such as methyl chlorooxoacetate, to give a compound of formula (VII). The reaction is carried out in the manner described above for the formation of a compound of formula (III) from a compound of formula (II).

Subsequent hydrolysis of the compound of formula (VII) to give the acid compound of formula (VIII) is then carried out as described above for the hydrolysis of a compound of formula (III).

Alternatively, a compound of formula (VI) may be coupled with tert.butyl chlorooxoacetate, followed by treatment with acid to remove the tert.butyl group, to give a compound of formula (VIII).

10

20

25

The compound of formula (VIII) is then coupled with an amine compound of formula (V) to give the oxamide compound of formula (IX), under the conditions described above for the coupling of a compound of formula (IV) with a compound of formula (V).

After this coupling step, the R groups of the resulting compound may be further modified by techniques known in the art, for example, functional groups may be altered, and/or connected to further groups

#### Reaction Scheme C

$$R^{1}$$
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 
 $R^{5}$ 
 $R^{5}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{7$ 

Alternatively, compounds of formula (I) are made by the coupling of a compound of formula (II) with an oxalamic acid compound of formula (X), using standard peptide coupling reagents,

such as hydroxybenzotriazole in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, to give the oxamide compound of formula (I).

After this coupling step, the R groups of the resulting compound may be further modified by techniques known in the art, for example, functional groups may be altered, and/or connected to further groups

As mentioned above, the compounds of formula (I) and salts thereof are inhibitors of IMPDH enzyme both in vitro and in vivo, and can be used in the control or prevention of IMPDH mediated conditions or diseases.

IMPDH activity can be assayed using an adaptation of the method reported by Carr [S. Carr et al., J. Biol. Chem. 268, p.27286 (1993)], the disclosure of which is herein incorporated by reference. IMPDH activity was measured spectrophotometrically, by monitoring the increase in absorbance at 340nm due to the formation of NADH (ε340 is 6220 M-1 cm-1) from the reduction of NAD. The IMPDH reaction mixture contained 0.1M Tris pH8.0, 0.1M KCl, 1mM DTT, 3mM EDTA, 100mM IMP and 100mM NAD. The reaction was initiated by the addition of IMPDH (human type II) to a final concentration in the assay of between 1nM and 5nM with respect to the IMPDH tetramer. The initial rate is measured by following the linear increase in absorbance at 340nm at 37°C for 45 minutes. The reading was conducted using a Spectromax 190 (Molecular Devices) spectrophotometer in a 96 well plate format with a final reaction volume of 200μl.

20

25

3()

For inhibitor assay analysis, the compound is dissolved in DMSO to a final concentration of 10mM and added to the initial reaction mixture as 5µl to give final DMSO concentration of 2.5%. The enzyme reaction is initiated by the addition of IMPDH and the initial rates measured as above. IC<sub>50</sub> determinations are made by measuring the initial rates in the presence of 10 concentrations of inhibitor and fitting the data using the 4 parameter curve fit from the Softmax pro software (Molecular Devices).

Preferred compounds of the invention tested in the above assay have an IC<sub>50</sub> value up to 500nM i.e.  $0.5 \mu M$ .

Specific examples of  $IC_{50}$  values for preferred compounds of formula (I) are set out below in Table 2:

<u>Table 2</u>

Compound of Formula (I)		IC <sub>50</sub>
Compound of Formula (1)		$(\mu M)$
M STA	tert-Butyl [3-[[[3-methoxy-4-(5-	0.036
	oxazolyl) anilino]oxalyl]amino]benzyl]carbamate	
H,C H, C H, C H, C H, C H, C H, C H, C	N-tert-Butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	0.037
Steal Steal	[3-[[[3-Methoxy-4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamic acid tetrahydro-3(S)-furyl ester	0.044
	N-[3-(Benzamidomethyl)phenyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.013
	Isopropyl [3-[[[3-methoxy-4-(5- oxazolyl) anilino]oxalyl]amino]benzyl]carbamate	0.033
£, 0 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-(1-methyl-1-phenylethyl)oxalamide	0.03
H,C N N N CH,	N-(1,1-Dimethylpropyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.031
H <sub>3</sub> C H <sub>3</sub> C CH, O CH <sub>3</sub>	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-(1,1,3,3-tetramethyl-butyl)oxalamide	0.034
N OH,C CH,	N-(1,1-Dimethylpropargyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.048
, C C C C C C C C C C C C C C C C C C C	N-(2-Hydroxy-1,1-dimethylethyl)-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.072
N. J. J. S. S. S. S. S. S. S. S. S. S. S. S. S.	N-(1,1-Dimethyl-2-phenylethyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.015

		,
	Phenyl [3-[[[4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamate	0.011
, , , , , , , , , , , , , , , , , , , ,	)	0.025
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-[3-[(phenylcarbamoyl)methyl] phenyl]oxalamide	0.035
OH, OH; OH, OH, OH, OH, OH, OH, OH, OH, OH, OH,	tert-Butyl [2-[[[3-methoxy-4-(5- oxazolyl)anilino]oxalyl]amino]-2- methylpropyl]carbamate	0.075
o ho F	N-(2-Amino-1,1-dimethylethyl)-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)	0.097
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-[1,1-dimethyl-2-(4-nitrophenyl) ethyl]oxalamide	0.010
An a service of the s	N-[3-(Aminomethyl)phenyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide trifluoroacetate (1:1)	0.233
	Methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate	0.121
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-(3-pyridyl)oxalamide	0.277
	N-[3- [(Benzenesulfonamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	0.125
H <sub>2</sub> C · · · · · · · · · · · · · · · · · · ·	N-(2-Dimethylamino-1,1- dimethylethyl)-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide hydrochloride (1:1)	0.17
	N-[3-Methoxy-4-(5-oxazolyl)phenyl]- N'-[1-methyl-1- (methylcarbamoyl)ethyl]oxalamide	().199
H,C CI	N-tert-Butyl-N'-[3-chloro-4-(5- oxazolyl)phenyl]oxalamide	0.169
H <sub>3</sub> C N CH <sub>3</sub>	N-tert-Butyl-N'-[3-methoxy-4-(4- oxazolyl)phenyl]oxalamide	0.46

Compounds of formula (I) which are acidic can form pharmaceutically acceptable salts with bases such as alkali metal hydroxides, e.g. sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides, e.g. calcium hydroxide, barium hydroxide and magnesium hydroxide, and the like; with organic bases e.g. N-ethyl piperidine, dibenzylamine, and the like. Those compounds of formula (I) which are basic can form pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric acid and hydrobromic acid, sulphuric acid, nitric acid and phosphoric acid, and the like, and with organic acids, e.g. with acetic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malic acid, salicylic acid, citric acid, methanesulphonic acid and p-toluene sulphonic acid, and the like. The formation and isolation of such salts can be carried out according to methods known in the art.

The oxamide derivatives provided by the present invention (i.e. the compounds of formula (I) and their pharmaceutically acceptable salts, especially as depicted in all the formulae herein), can be used as medicaments, for example in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered enterally, such as orally, in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, or nasally, e.g. in the form of nasal sprays. They can also be administered rectally, e.g. in the form of suppositories, or parenterally, (e.g. intramuscularly, intravenously, or subcutaneously), for example, in the form of injection solutions.

20

25

30

10

For the manufacture of pharmaceutical preparations the oxamide derivatives can be formulated with therapeutically inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, generally required in the case of soft gelatine capsules. Suitable carriers for the manufacture of solutions and syrups are, for example, water, polyols, sucrose, saccharose, invert sugar, glucose and the like. Suitable carriers for the manufacture of injection solutions are, for example, water, saline, alcohols, polyols, glycerine, vegetable oils and the like. Natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like are suitable carriers for the manufacture of suppositories. The pharmaceutical preparations of the present invention may also be provided as sustained release formulations or other appropriate formulations.

The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colourants, flavourants, salts for adjustment of the osmotic pressure, buffers, masking agents or antioxidants. They may also contain other therapeutically active substances, such as an immunosuppressant, a chemotherapeutic agent, an anti-viral agent, an anti-binflammatory agent and/or an anti-vascular hyperproliferation agent. A preferred agent that may be used with the compounds of the present invention is interferon or derivatives thereof, such as conjugates with polyethylene glycol.

10

15

Accordingly part of this invention is a pharmaceutical composition comprising a compound of formula (I) or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, and, optionally, one or more additional therapeutically active substance(s). Such substances may be one or more immunosuppressants, chemotherapeutic agents, antivirals, antibiotic, antiparasitics, antifungals, antiinflammatories, or antivascular antiproliferation agents. Preferably the substance is interferon or an interferon derivative.

Medicaments containing compounds of formula (I) or salts thereof and a therapeutically acceptable carrier, as well as a process for the manufacture of such medicaments are also objects of the present invention. This process comprises bringing a compound of formula (I) or a pharmaceutically acceptable salt thereof into a galenical administration form together with a therapeutically inert carrier material and, if desired, one or more additional therapeutically active substances.

A further object of the invention comprises the use of the oxamide derivatives provided by the invention in the treatment of an immune mediated condition or disease, a viral disease, a bacterial disease, a parasitic disease, inflammation, an inflammatory disease, a hyperproliferative vascular disease, a tumour, or cancer. The dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case.

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day (preferably 0.5 - 75 mg/kg/day) in monotherapy and/or in combination therapy are preferred, administered from about 1 -5 times per day. The active ingredient may be combined with a carrier material.

A typical preparation will contain from about 5% - 95% active compound (w/w) (preferably

from about 20% - 80% active compound). The daily dosage can be administered as a single dosage or in divided dosages.

Accordingly this invention is also directed to a method for treating an immune mediated condition or disease, a viral, bacterial, parasitic, inflammatory ,hyperproliferative vascular disease, inflammation, a tumor, or cancer in a subject by administering to the subject a therapeutically effective amount of a compound of formula (I) or its pharmaceutically acceptable salts. In addition, this method includes concurrent or sequential administration of one or more therapeutically active substances taken from immunosuppresants, chemotherapeutics, antivirals, antibiotics, antiparasitics, antifungals, antiinflammatories, and anti-vascular hyperproliferation agents. Preferably the substance is interferon or an interferon derivative.

This invention is especially directed to a method for treating IMPDH mediated diseases.

The compounds and compositions of the present invention may be for use in monotherapy and/or combination therapy, i.e. the treatment may be in conjunction with the administration of one or more additional therapeutically active substance(s). When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the oxamide derivatives of the present invention. Thus, concurrent administration, as used herein, includes administration of the agents in conjunction or combination, together, or before or after each other.

It will be understood that references herein to treatment extend to prophylaxis as well as to treatment of existing conditions. Treatment of a disease or condition, as used herein, also includes preventing, inhibiting, regressing, reversing, alleviating or relieving the disease or condition, or the clinical symptoms thereof. The term "subject" as used herein refers to animals, including humans and other mammals.

30 The following Examples illustrate the present invention.

10

15

With regard to the starting materials that are known compounds some of these may be purchased from commercial suppliers. Other starting materials that are known and their analogues can be prepared by methods well known in the art. Examples of compounds available from commercial suppliers, and citations to the synthesis of other compounds and their analogues are provided in the following:

Compounds of formula (II) and the compounds of formula (VI) are obtained from commercial suppliers (e.g. 4-(5-oxazolyl)aniline, Maybridge catalogue number DFP 00120), or prepared by adaptation of the methods disclosed in published patent application WO 974002, or prepared by adaptation of the methods provided in Palacz et al., FEBS Lett., 1984, 176(2), 365-370.

10

The compounds of formula (V) are obtained from commercial suppliers (e.g. tert-butylamine, Aldrich catalogue number B8,920-5; Cumylamine, TCl-US catalogue number C1293), or prepared by adaptation of the methods provided in Kazuo Achiwa et al., Chem.Pharm.Bull., 1998, 46(4), 697-670.

15

The compounds of formula (X) are prepared by adaptation of the methods provided in Minisci et al., J. Org. Chem., 1995, 60(17), 5430-5433.

20

Examples of commercially available reagents include those used in Examples 7, 10 and 11, (2-methoxy-4-nitrobenzoic acid, Aldrich catalogue number 42,291-6; tert-butylacetic acid, Aldrich catalogue number B8,840-3; and p-tolualdehyde, Aldrich catalogue number T3,560-2, respectively).

25

30

Where indicated, the NMR spectra were recorded on a Bruker DRX 400 MHz spectrometer with the probe temperature set at 300 K.

Where indicated by "(M+;EI)", mass spectra were recorded under electron impact conditions (EI), on a THERMOQUEST MAT95 S with a source temperature of 200°C. Other mass spectra were recorded under electrospray ionisation spectra (ESI) conditions, on one of the following machines:

a) THERMOQUEST SSQ 7000 [Solvent 0.085% TFA in 90% Acetonitrile/water; flow rate 100 microliters/minute; capillary 250°C; spray voltage 5KV; sheath gas 80 psi], or

- b) LC-MS system (liquid chromatograph coupled to mass spectrum) THERMOQUEST TSQ 7000 ELECTROSPRAY or MICROMASS PLATFORM ELECTROSPRAY [Solvent 0.1% TFA in water or 0.085% TFA in 90% acetonitrile/ water or 0.085% TFA in acetonitrile].
- Unless otherwise indicated, the mass spectroscopy values recorded in the MS(ES) column refer to (M+H) values, apart from the ones shown as (M';EI).

#### Example 1

15

### N-Tert-butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

A solution of 26 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 15 mg (0.2 mmol) of tertiary butylamine, 28 mg (0.15 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 15 mg (0.11 mmol) of 1-hydroxy-7-azabenzotriazole in 1 ml of dimethylformamide was stirred at room temperature for 4 hours then diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate and water. The resulting solution was dried over magnesium sulphate and evaporated to dryness. The residue was triturated with diethyl ether/petrol (1:1) and collected by filtration to give 11 mg of

N-tert-butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 318.0  $[M+H]^{\dagger}$ .

The starting material was prepared as follows:

5

10

- 1) 5.7 g (30 mmol) of 3-methoxy-4-(5-oxazolyl)aniline and 3.33 g (33 mmol) of triethylamine were dissolved in 50 ml of dichloromethane and the solution was cooled to 0°C. A solution of 3.86 g (31.5 mmol) of methyl oxalyl chloride in 10 ml of dichloromethane was added dropwise and the resulting mixture was stirred for 1 hour then washed with 2M hydrochloric acid. The precipitated solid was collected by filtration and washed with dichloromethane and give 6.2 methyl N-[3-methoxy-4-(5water oxazolyl)phenyl]oxalamate as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>0</sub>) δ: 3.88 (3H,s), 3.94 (3H,s), 7.48 (1H,s), 7.58 (1H,dd), 7.65 (1H,d), 7.68 (1H,d)), 8.39 (1H,s), 10.92 (1H,s).
- 6.2 g (22.46 mmol) of methyl N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamate and 1.2 g 15 ii) (30 mmol) of sodium hydroxide were refluxed in 240 ml of methanol/water (1:1) for 2 hours then cooled, filtered and acidified with 2M hydrochloric acid. The precipitated solid was collected by filtration and washed with water, acetone and diethyl ether to give 5.1 g of N-[3methoxy-4-(5-oxazolyl)phenyl]oxalamic acid as a pale yellow solid. MS: m/e 262.9 [M+H]<sup>†</sup>.

20

3()

collected

by

Alternatively N-tert-butyl-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide can be prepared as follows:

A solution of 95 mg (0.5 mmol) of 3-methoxy-4-(5-oxazolyl)aniline, 73 mg (0.5 mmol) of Ntert-butyloxalamic acid, 134 mg (0.7 mmol)ethylcarbodiimide hydrochloride and 75 mg (0.55 mmol) of 1-hydroxy-7-azabenzotriazole in 4 ml of dichloromethane was stirred a room temperature for 18 hours. The resulting mixture was washed with 2M hydrochloric acid and saturated sodium bicarbonate, dried over magnesium sulphate and evaporated to dryness. The residue was triturated with petrol and

> 128 mg of N-tert-butyl-N'-[3-methoxy-4-(5filtration to give

of

1-(3-dimethylaminopropyl)-3-

## Example 2

# Tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl] amino]benzyl]carbamate

A mixture of 2.04 g (7.79 mmol) of N-(3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, prepared as described above in Example 1 above, 1.9 g (8.56 mmol) of tert-butyl (3-aminobenzyl)carbamate, 1.8 g (9.4 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1.3 g (9.6 mmol) of 1-hydroxy-7-azabenzotriazole in 30 ml of dimethylformamide was stirred for 20 hours at room temperature. The resulting precipitate was collected by filtration and washed with dichloromethane to give 1.8 g of tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate as a white solid. MS: m/e 466 M<sup>+</sup>.

15

## N-[3-(Aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate

.TFA

5

10

15 mg (0.032 mmol) of tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]-amino]benzyl]carbamate, prepared as described in Example 2 above, were dissolved in 1 ml of dichloromethane and 1 ml of trifluoroacetic acid at room temperature for 5 minutes. The solution was evaporated to dryness, the residue triturated with diethyl ether and collected by filtration to give 11 mg of N-[3-(aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate as a white solid. MS: m/e 408 [M+H+MeCN]<sup>†</sup>.

5

# N-[3-(Benzamidomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

$$\begin{array}{c} \text{NH}_2 \\ \text{NHOCCONH} \\ \text{NHOCCONH} \\ \end{array}$$

29 mg (0.21 mmol) of benzoyl chloride were added to a solution of 100 mg (0.21 mmol) of N-[3-(aminomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide trifluoroacetate, prepared as described in Example 3 above, and 46 mg (0.46 mmol) of triethylamine in a mixture of 2 ml of dimethylformamide and 5 ml of dichloromethane, and stirred at room temperature for 18 hours. The solution was washed with 2M hydrochloric acid and saturated sodium bicarbonate then dried over magnesium sulphate and evaporated to dryness. The residue was chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. After trituration with diethyl ether there was obtained 45 mg of N-[3-(benzamidomethyl)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 471.0 [M+H]<sup>+</sup>.

5

 $\frac{N-[3-[(Benzenesulphonamido)methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide}{phenyl]oxalamide}$ 

.TFA

In an analogous manner to that described in Example 4 but replacing benzoyl chloride with phenylsulphonyl chloride there was obtained N-[3-[(benzenesulphonamido)methyl]-phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 507  $[M+H]^{\dagger}$ .

# Example 6

10

# 15 Methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxazolyl]aminobenzyl]carbamate

In an analogous manner to that described in Example 4 but replacing benzoyl chloride with methyl chloroformate there was obtained methyl [3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate as a white solid. MS: m/e 425 [M+H]<sup>+</sup>.

## 5 Example 7

10

# N-Tert-butyl-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide

A mixture of 371 mg (1 mmol) of N-[4-(bromoacetyl)-3-methoxyphenyl]-N'-tert-butyloxalamide and 315 mg (5 mmol) of ammonium formate was refluxed in 10 ml of formic acid for 4 hours then cooled and evaporated to dryness. The residue was dissolved in ethyl

acetate, washed with 2M sodium hydroxide and dried over magnesium sulphate. The solution was evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (7:18) for the elution. There was obtained after trituration with diethyl ether/petrol (1:1) 65 mg of N-tert-butyl-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 318 [M+H]<sup>+</sup>.

### The starting material was prepared as follows:

- A mixture of 3.94 g (20 mmol) of 2-methoxy-4-nitrobenzoic acid, 3.9 g (40 mmol) of i) N,O-dimethylhydroxylamine hydrochloride, 5.73 g (29.92 mmol) of 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 3.37 g (22 mmol) of 1hydroxybenzotriazole hydrate and 5.06 g (44 mmol) of N-ethylmorpholine in 50 ml of dichloromethane was stirred at room temperature for 3 hours then washed with 2M hydrochloric acid and saturated bicarbonate. The resulting solution was dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether and collected by filtration to give 3.95 g of N,O-dimethyl 2-methoxy-4-nitrobenzohydroxamate as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 3.37 (3H,s), 3.48 (3H,s), 3.97 (3H,s), 7.45 (1H,d), 7.80 (1H,d), 7.91 (1H,dd).
- ii) A mixture of 1.2 g (5 mmol) of N,O-dimethyl 2-methoxy-4-nitrobenzohydroxamate and 4.75 g (25 mmol) of tin(II) chloride in 40 ml of ethanol was heated at 80°C for 30 minutes then cooled and evaporated to dryness. The residue was dissolved in dichloromethane, washed with 2M sodium hydroxide and the organic phase dried over magnesium sulphate and evaporated to dryness to give 960 mg of N,O-dimethyl 4-amino-2-methoxybenzohydroxamate as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 3.25 (3H,s), 3.62 (3H,s), 3.79 (3H,s), 6.22 (1H,d), 6.28 (1H,dd), 7.09 (1H,d).
  - iii) A mixture of 700 mg (3.33 mmol) of N,O-dimethyl 4-amino-2-methoxybenzohydroxamate, 483 mg (3.33 mmol) of N-tert-butyloxalamic acid, 600 mg (3.92 mmol) of 1-hydroxybenzotriazole hydrate and 960 mg (5.01 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 15 ml of dichloromethane was stirred at room temperature for 3 hours then washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate, evaporated to

dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (3:1) for the elution to give 960 mg of N,O-dimethyl 4-[[(tert-butylamino)oxalyl] amino]-2-methoxybenzohydroxamate as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.46 (9H,s), 3.25-3.4 (3H,br.s.), 3.45-3.65 (3H,br.s.), 3.89 (3H,s), 7.08 (1H,dd), 7.29 (1H,d), 7.44 (1H,s), 7.53 (1H,d), 9.40 (1H,s).

iv) 3.1 ml (4.34 mmol) of 1.4M methylmagnesium bromide in tetrahydrofuran were added in portions over 1 hour to a solution of 337 mg (1 mmol) of N,O-dimethyl 4-[[(tert-butylamino)oxalyl]amino]-2-methoxybenzohydroxamate in 10 ml of anhydrous tetrahydrofuran. The resulting solution was diluted with diethyl ether and washed with 2M hydrochloric acid. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (3:7) for the elution to give 255 mg of N-(4-acetyl-3-methoxyphenyl)-N'-tert-butyloxalamide as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.45 (9H,s), 2.61 (3H,s), 3.96 (3H,s), 7.03 (1H,dd), 7.43 (1H,s), 7.64 (1H,d), 7.82 (1H,d), 9.47 (1H,s).

10

15

20

25

v) 320 mg (0.85 mmol) of phenyltrimethylammonium tribromide were added in portions over 10 minutes to a stirred solution of 247 mg (0.85 mmol) of N-(4-acetyl-3-methoxyphenyl)-N'-tert-butyloxalamide in 5 ml of anhydrous tetrahydrofuran. After 15 minutes a further 100 mg (0.26 mmol) of phenyltrimethylammonium tribromide were added. The resulting suspension was diluted with diethyl ether, washed with water and the organic phase was dried over magnesium sulphate. Evaporation gave a gum which was chromatographed on silica gel using firstly 0.5% methanol in dichloromethane then 1% methanol in dichloromethane for the elution. The product was dissolved in diethyl ether/petrol (2:1) and the resulting crystals were collected by filtration to give 135 mg of N-[4-(bromoacetyl)-3-methoxyphenyl]-N'-tert-butyloxalamide as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &: 1.44 (9H,s), 3.99 (3H,s), 4.61 (2H,s), 7.06 (1H,dd), 7.42 (1H,s), 7.68 (1H,d), 7.93 (1H,d), 9.51 (1H,s).

## Examples 8-11

#### 5 <u>Example 8</u>

10

15

# Tert-butyl[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]carbamate

77mg (0.87 mmol) of tert-butyl (2-amino-2-methylpropyl)carbamate , 207 mg (1.05 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 166 mg (1.08 mmol) of 1-hydroxy-7-azabenzotriazole and 200 mg (0.76 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid were dissolved in 5 ml of dichloromethane and 5 ml of dimethylformamide and stirred for 16 hours at room temperature. The mixture was then diluted with 50 ml of dichloromethane and washed with a 10% solution of citric acid and brine. The organic layer was then dried with anhydrous magnesium sulphate, filtered and evaporated to dryness. The residue was chromatographed on silica gel using 30% ethyl acetate in hexane for the elution to give 165 mg of tert-butyl [2-[[[3-methoxy-4-(5-oxazolyl)-

anilino]oxalyl]amino]-2-methylpropyl]carbamate as a yellow solid, <sup>1</sup>H NMR (400MHz, d6 DMSO) δ: 1.35 (s, 6H), 1.45 (s, 9H), 3.25 (d, 2H), 3.95 (s, 3H), 7.25 (t, 1H), 7.55 (s,1H), 7.70 (m, 2H), 7.80 (s,1H), 8.25 (s, 1H), 8.50 (s, 1H), 10.8 (s, 1H).

## 5 Example 9

10

20

25

# N-(2-Amino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide trifluoroacetate (1:1)

26 mg (0.29 mmol) of tert-butyl [2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]carbamate was dissolved and stirred in 10 ml of a 1:1 mixture of 1,1,1-trifluoroacetic acid and dichloromethane. After 1 hour the solvent mixture was co-evaporated with toluene three times and dichloromethane twice. The resulting gum was then triturated with 40-60 petroleum ether to give 124 mg of N-(2-amino-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate (1:1) as a yellow solid,  $^1$ H NMR (400MHz, d6 DMSO)  $\delta$ : 1.40 (s,6H), 3.20 (m,2H), 3.90 (s, 3H), 7.50 (s,1H), 7.60-7.74 (m, 2H), 7.80 (s, 1H), 7.90 (s(br), 3H), 8.30 (s,1H), 8.40 (s,1H), 10.80(s,1H).

The previously described trifluoroacetic acid salt was partitioned between a saturated sodium hydrogencarbonate solution and ethyl acetate. The organic layer was then dried with magnesium sulphate, filtered and evaporated to give the free base used in Example 10.

#### Example 10

# N-(3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(3,3-dimethylbutyramido)-1,1-dimethylethyl]oxalamide

30 mg (0.09 mmol) of N-(2-amino-1,1-dimethyl-ethyl)-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide, 52 mg (0.45 mmol) of tert-butylacetic acid, 86 mg (0.45 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 69 mg of HOAt were dissolved and stirred in 2 ml of dimethylformamide. After stirring for 16 hours the mixture was diluted with 10 ml of dichloromethane and washed with 10% citric acid solution in water, saturated sodium hydrogen carbonate solution and brine. The organic solution was then dried with solid

magnesium sulphate, filtered and evaporated to give N-(3-methoxy-4-(5-oxazolyl)phenyl]-N'- [2-(3,3-dimethylbutyramido)-1,1-dimethylethyl]oxalamide as a pale yellow solid, MS: m/e 431.3 [M+H]+

### 5 Example 11

10

15

20

25

30

# N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(4-methylbenzylamino)-1,1-dimethylethyl]oxalamide

30 mg (0.09 mmol) of N-(2-amino-1,1-dimethyl-ethyl)-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide, 11.3 mg (0.095 mmol) of 4-methylbenzaldehyde and 30 mg (0.14 mmol) of sodium triacetoxyborohydride were dissolved in 2ml of a 5% acetic acid dichloromethane mixture for 16 hours. The reaction mixture was then diluted with 8 ml of dichloromethane and washed with water, saturated sodium hydrogen carbonate and brine. The resulting organic solution was then dried with magnesium sulphate, filtered and evaporated to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[2-(4-methylbenzylamino)-1,1-dimethylethyl]oxalamide as a yellow solid MS: m/e 437.3 [M+H]+.

#### Example 12

# 2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropionic acid

A mixture of 161 mg (0.446 mmol) of methyl 2-[[3-methoxy-4-(5-oxazolyl)anilinooxalyl]amino]-2-methylpropionate and 56 mg (1.33 mmol) of lithium hydroxide hydrate in 3 ml of methanol and 0.5 ml of water was heated at 50°C for 2 hours then diluted with water and washed with diethyl ether. The aqueous phase was acidified to pH2 with 2M hydrochloric acid and extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulphate and evaporated to dryness. The residue was

chromatographed on silica gel using dichloromethane/methanol/acetic acid/water (120:15:3:2) for the elution. After trituration with ether there was obtained 70 mg of 2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropionic acid as a white solid. MS: m/e 247.9 [M+H]<sup>†</sup>.

### Example 13

5

20

## N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1-methyl-1-(phenylcarbamoyl)ethyl]oxalamide

A solution of 30 mg (0.086 mmol) of 2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropionic acid, 16 mg (0.172 mmol) of aniline, 18 mg (0.132 mmol) of 1-hydroxy-7-azabenzotriazole and 25 mg (0.131 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 2 ml of dimethylformamide was stirred at room temperature for 18 hours then diluted with ethyl acetate and washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate and after evaporation the residue was triturated with diethyl ether and collected by filtration to give 20 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1-methyl-1-(phenylcarbamoyl)ethyl]oxalamide as a white solid. MS: m/e 423.0 [M+H]<sup>+</sup>.

5

10

15

# $\underline{N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1-methyl-1-(methylcarbamoyl)ethyl]oxalamide}$

of of Α mixture 30 mg (0.086 mmol)2-[[[3-methoxy-4-(5oxazolyl)anilino[oxalyl]amino]-2-methylpropionic acid, 12 mg (0.178 mmol) of methylamine hydrochloride, 18 mg (0.132 mmol) of 1-hydroxy-7-azabenzotriazole, 25 mg (0.131 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 22 mg (0.218 mmol) of triethylamine in 2 ml of dimethylformamide was stirred at room temperature for 18 hours then diluted with ethyl acetate and washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic solution was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/methanol (24:1) for the elution. After trituration with ether there was obtained 17 mg of N-[3-methoxy-4-(5oxazolyl)phenyl]-N'-[1-methyl-1-(methylcarbamoyl)ethyl]oxalamide as a white solid. MS:  $m/e 361.0 [M+H]^{+}$ .

## 2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid

740 mg of 2-[3-[[[3-methoxy-4-(5solution of (1.81 mmol)methyl oxazolyl)anilino]oxalyl]amino]phenyl]acetate and 152 mg (3.62 mmol) of lithium hydroxide hydrate in 10 ml of methanol, 10 ml of 1,4-dioxane and 5 ml of water was stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue dissolved in water. The aqueous solution was washed with diethyl ether and acidified with citric acid The solid which precipitated was collected by filtration and washed with water, solution. ethanol and diethyl ether give 414 mg of 2-[3-[[[3-methoxy-4-(5to oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid as a white solid. MS: m/e 396.0 [M+H]<sup>+</sup>.

5

5

10

15

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[3-[(phenylcarbamoyl)methyl] phenyl]oxalamide

(0.076 mmol) Α solution of 30 mg of 2-[3-[[[3-methoxy-4-(5oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid and 11 mg (0.096 mmol)ethylmorpholine in 1 ml of dimethylformamide was cooled to 0°C and a solution of 12 mg (0.088 mmol) of isobutyl chloroformate in 1 ml of dichloromethane was added. The resulting mixture was stirred for 30 minutes at 0°C then a solution of 7 mg (0.075 mmol) of aniline in 1 ml of dichloromethane was added and stirring was continued for a further hour at 0°C. After 18 hours at room temperature the mixture was evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/methanol (19:1) for the elution. There obtained 3 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[3was [(phenylcarbamoyl)methyl]phenyl]oxalamide as a white solid MS: m/e 471.0 [M+H]<sup>+</sup>.

5

1()

15

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[3-[(methylcarbamoyl)methyl] phenyl]oxalamide

NHOCCON

Α mixture of 30 mg (0.076 mmol)of 2-[3-[[[3-methoxy-4-(5oxazolyl)anilino]oxalyl]amino]phenyl]acetic acid, 22 mg (0.115 mmol)of 1 - (3 dimethylaminopropyl)-3-ethylacrbodiimide hydrochloride, 14 mg (0.092 mmol) hydroxybenzotriazole hydrate, 26 mg (0.385 mmol) of methylamine hydrochloride and 52 mg (0.452 mmol) of N-ethylmorpholine in 1 ml of dimethylformamide was stirred at room temperature for 18 hours. The solvent was removed by evaporation and the residue chromatographed on silica gel using dichloromethane/methanol (1:19) for the elution. There obtained 15 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[3-[(methyl was carbamoyl)methyl]phenyl]oxalamide as a white solid. MS: m/e 409 [M+H]<sup>+</sup>.

# N-(3-Aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate

20 mg (0.043 mmol) of tert-butyl [3-[[[3-methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]phenyl]carbamate were dissolved in a mixture of 1 ml of dichloromethane and 1 ml of trifluoroacetic acid at room temperature for 10 minutes. The solvent was removed by evaporation and the residue triturated with diethyl ether. The resulting solid was collected by filtration to give 18 mg of N-(3-aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate as a white solid. MS: m/e 394.0 [M+H+MeCN]<sup>+</sup>.

### 15 Example 19

5

## N-[3-(Benzamido)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

A mixture of 30 mg (0.064 mmol) of N-(3-aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate, 9 mg (0.074 mmol) of benzoic acid, 15 mg (0.078 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 15 mg (0.096 mmol) of 1-hydroxybenzotriazole hydrate and 22 mg (0.19 mmol) of N-ethylmorpholine in 0.5 ml of dimethylformamide was stirred at room temperature for 18 hours then diluted with ethyl acetate and washed with 10% citric acid solution, saturated sodium bicarbonate and water. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using dichloromethane/methanol (19:1) for the elution. There was obtained after trituration with diethyl ether/petrol (1:1). 12 mg of N-[3-(benzamidophenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 457.0 [M+H]<sup>+</sup>.

#### Example 20

10

15

20

25

N-[3-(Methanesulphonamido)phenyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide

12 mg (0.011 mmol) of methanesulphonyl chloride were added to a solution of 50 mg (0.011 mmol) of N-(3-aminophenyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate and 32 mg (0.317 mmol) of triethylamine in 0.5 ml of dimethylformamide. The resulting solution was left at room temperature for 18 hours then diluted with ethyl acetate and washed with 10% citric acid solution, saturated sodium bicarbonate and water. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 5 mg of N-[3-(methanesulphonamido)phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 431.0 [M+H]<sup>†</sup>.

5

# N-[2-(4-Aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide

A mixture of 44 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-nitrophenyl)ethyl]oxalamide and 90 mg (0.5 mmol) of tin(II) chloride were stirred and heated at 85°C in 2 ml of ethanol and 1 ml of 1,4-dioxane for 5 hours. The resulting solution was cooled, diluted with ethyl acetate and washed with 2M sodium hydroxide. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. After trituration with petrol there was obtained 31mg of N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide as a white solid. MS: m/e 409 [M+H]<sup>†</sup>.

5

N-[2-(4-Benzamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide

A mixture of 30 mg (0.074 mmol) of N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, 10 mg (0.082 mmol) of benzoic acid, 14 mg (0.092 mmol) of 1-hydroxybenzotriazole hydrate, 21 mg (0.11 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 18 mg (0.16 mmol) of N-ethylmorpholine in 2 ml of dichloromethane was stirred at room temperature for 18 hours then diluted with dichloromethane and washed with 2M hydrochloric acid and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 9 mg of N-[2-(4-benzamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a white solid. MS: m/e 513 [M+H]<sup>†</sup>.

20

5

N-[2-(4-Acetamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide

A mixture of 30 mg (0.074 mmol) of N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, 8 mg (0.078 mmol) of acetic anhydride and 17 mg (0.15 mmol) of N-ethylmorpholine in 1 ml of dichloromethane was stirred at room temperature for 2 hours. The solvent was removed by evaporation and the residue triturated with diethyl ether and collected by filtration to give 14 mg of N-[2-(4-acetamidophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide as a white solid. MS: m/e 451  $[M+H]^{+}$ .

#### Example 24

15

20

N2-[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]-N1,3-dimethyl-L-valinamide

290 mg (0.75 mmol) of N-[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]-3-methyl-L-valine methyl ester in 3 ml of methanol and 1 ml of 1M aqueous sodium hydroxide were warmed gently and the resulting solution left at room temperature for 18 hours. The mixture was diluted with water, washed with diethyl ether and the aqueous phase acidified with 2M hydrochloric acid. The solution was extracted with ethyl acetate and the organic phase dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/acetic acid (99:1) for the elution. After trituration with diethyl ether there was obtained 110 mg of N2-[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]-N1,3-dimethyl-L-valinamide as a white solid. MS: m/e 376.0 [M+H]<sup>†</sup>.

## Example 25

10

15

20

### Tert-butyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate

In an analogous manner to that described in Example 1 but replacing 3-methoxy-4-(5-oxazolyl)aniline with 4-(5-oxazolyl)aniline and N-tert-butyloxalamic acid with N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamic acid there was obtained tert-butyl [3-[[[4-(5-oxazolyl)anilino] oxalyl]amino]benzyl]carbamate as a white solid. <sup>1</sup>H NMR (400 MHz,

DMSO) δ: 1.4 (9H,s), 4.1 (2H,d), 7.02 (1H,d), 7.32 (1H,t), 7.40 (1H,t), 7.63 (1H,s), 7.69 (1H,d), 7.70-7.79 (3H,m, 7.97 (2H,d), 8.43 (1H,s), 10.82 (1H,s), 10.99 (1H,s).

The starting material was prepared as follows:

5

10

15

20

- 586 mg (4.78 mmol) of methyl oxalyl chloride were added to a solution of 1 g (4.5 mmol) of tert-butyl (3-aminobenzyl)carbamate and 508 mg (5.03 mmol) of triethylamine in 10 ml of dichloromethane. The resulting solution was stirred at room temperature for 30 minutes then washed with 5% citric acid solution and saturated sodium bicarbonate. The organic phase was dried over magnesium sulphate and the solvent removed by evaporation to give 1.5 g of methyl N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamate as a viscous gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 1.43 (9H,s), 3.96 (3H,s), 4.31 (2H,d) 4.9-5.0 (br.s, 1H), 7.11 (1H,d), 7.33 (1H,t), 7.51 (1H,s), 7.52 (1H,d), 8.86 (br.s. 1H).
- ii) A mixture of 1.232 g (4 mmol) of methyl N-[3-[(tert-butoxy formamido)methyl] phenyl]oxamate and 0.24 g (6 mmol) of sodium hydroxide in 15 ml of methanol/water (2:1) was stirred at room temperature for 2 hours. The solvent was removed by evaporation and the residue dissolved in water and diethyl ether. The aqueous layer was acidified with citric acid and washed twice with ethyl acetate. The combined organic solutions were dried over magnesium sulphate and the solvent removed by evaporation to give 670 mg of N-[3-[(tert-butoxyformamido)methyl] phenyl]oxamic acid as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO) δ: 1.48 (9H,s), 4.17 (2H,d), 7.09 (1H,d), 7.36 (1H,t), 7.49 (1H, t), 7.64 (1H,d), 7.74 (1H,s), 10.75 (1H,s).

### Tert-butyl [2-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate

In an analogous manner to that described in Example 25 but replacing N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamic acid with N-[2-[tert-butoxyformamido)-methyl]phenyl]oxamic acid there was obtained tert-butyl [2-[[[4-(5-oxazolyl)anilino]oxalyl]-amino]benzyl]carbamate as a white solid MS: m/e 437.0 [M+H]<sup>+</sup>.

# Example 27

5

10

15

20

### Tert-butyl [4-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate

In an analogous manner to that described in Example 25 but replacing N-[3-[(tert-butoxyformamido)methyl]phenyl]oxamic acid with N-[4-[tert-butoxyformamido)methyl]phenyl]oxamic acid there was obtained tert-butyl [4-[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate as a white solid. MS: m/e 436.6 [M] '.

## N-Tert-butyl-N'-[4-(5-oxazolyl)phenyl]oxalamide

In an analogous manner to that described in Example 1 but replacing 3-methoxy-4-(5-oxazolyl)aniline with 4-(5-oxazolyl)aniline there was obtained N-tert-butyl-N'-[4-(5-oxazolyl)phenyl]oxalamide as a pale yellow solid. MS: m/e 329.0 [M+H+MeCN] <sup>†</sup>.

#### Example 29

5

10

15

## N-[3-(Aminomethylphenyl]-N'-[4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate

In an analogous manner to that described in Example 3 but replacing tert-butyl [3-[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]benzyl]carbamate with tert-butyl [3-[[4-(5-oxazolyl)oxalyl]amino]benzyl]carbamate there was obtained N-[3-(aminomethylphenyl]-N'-[4-(5-oxazolyl)phenyl]oxalamide trifluoroacetate as a white solid. MS: m/e 336 [M] '.

# **Examples 30-193**

In a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid (prepared as described in Example 1, parts (i) and (ii)) and the appropriate amine the compounds shown in Table 3 were also prepared:

Table 3

Example	Structure	MS(ES)
30.		338.0
31.		362.9
32.		395.0
33.		352.0
34.	Xoln—Ontin	466 (M <sup>+</sup> ;EI)
35.		352.0
36.		330.0
37.		275.9

		<del>, 1</del>
38.		344.0
39.		352.9
40.		261.9
41.		358.9
42.		342.9
43.		341.9
44.		338.9
45.	N-N N N N N N N N N N N N N N N N N N N	327.9
46.		380.0
47.		332.0
48.	+ 1 N N N N N N N N N N N N N N N N N N	374.0
49.		362.0

50.		317.9
51.		332.0
52.		361.0
53.		389.9
54.		328.0
55.	The state of the s	346.0
56.		289.9
57.	N J N J N J	318.0
58.	N. J. N.	304.0
59.		333.9
60.	N S N N N N N N N N N N N N N N N N N N	394.0

	<del></del>	
61.		439 (M*-FL)
	2.0	(M';EI)
62.	N N N N N N N N N N N N N N N N N N N	386 (M <sup>+</sup> ;EI)
63.		304.0
64.		353.2
65.		360.2
66.		316.2
67.	O N N N N N N N N N N N N N N N N N N N	412.2
68.		345.8
69.		362.4
70.		334.2
71.	N O	348.0

72.		340.0
73.	0 N	345.8
74.		346.0
75.	0 S.	346.8
76.		395.8
77.	N N N N N N N N N N N N N N N N N N N	332.4
78.		332.4
79.	0,, N, T N N	316.2
80.		344.0
81.	0 . N . N	317.8
82.		328.2

83.	O N	332.4
84.		334.2
85.	0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0	334.2
86.	0 N N N N N N N N N N N N N N N N N N N	339.2
87.		344.8
88.		348.0
89.	O N N N N N N N N N N N N N N N N N N N	359.2
90.		358.2
91.		366.2
92.		389.4
93.		306.2

		<del>,</del>
94.	O N N N N N N N N N N N N N N N N N N N	319.8
95.		438.0
96.	0 N	504.2
97.		374.0
98.		299.8
99.	0	302.2
100.		316.2
101.		372.0
102.		319.8
103.	N N N N N N N N N N N N N N N N N N N	332.4
104.		332.4

105	.0	
105.	0 N N N N N N N N N N N N N N N N N N N	
	0 0	336.6
106.	N 9	
100.	0 N	
	0	342.0
	N-II	
107.	O. A. N. J. A. F	
		200 n
		308.0
108.	N	
100.	by a plant of the	
	ه نرځي ه	345.8
	N	
109.		
	9 1	
	• • • • • • • • • • • • • • • • • • •	402.0
	o c	
110	N	
110.		
		405.2
	'n-E	
111.	N L	2560
		356.0
	(N)	
112.	O N N N	
	<u> </u>	358.2
	N O	
113.		
	0 N N N N N N N N N N N N N N N N N N N	358.2
	0	
	N-di	
114.	0. A. N. J. S.	250.2
		359.2
	N T	
115.	i c	
	of white	
	Ö Ö	374.0
116	N- <sup>1</sup>	
116.	l long to the second se	372 ()
		372.0
	N-	

117.		389.2
118.		389.4
119.		276.0
120.	0. N F F F	394 (M <sup>+</sup> ;EI)
121.	O. N. N. N. N. N. N. N. N. N. N. N. N. N.	378.4
122.		428 (M <sup>+</sup> ;EI)
123.		435.2
124.	0 N J	357.2
125.		358.2
126.	0 N	358.2
127.		360.2
128.		378.4

129.		377.4
130.		378.4
131.		423
132.		389.4
133.		338.2
134.		363.4
135.	O N N N F	356
136.	P P P P P P P P P P P P P P P P P P P	370
137.		371.8
138.	O N CI	406.2
139.	N CI	402.2

140.	0 N	386.2
	N N CI	
141.	GI	406.2
	N N N CI	
142.		383.2
143.		384
144.		380.2
145.	N N F F	406.2
146.		366.2
147.		366.2
148.		368.2
149.	N N N N N N N N N N N N N N N N N N N	356
150.	O N N CO	371.8
151.		395

152.	383.2
153.	409.4
154.	380.8
155.	368.2
156.	424.2
157.	354.2
158.	380.2
159.	352.4
160.	377.4
161.	368.2
162.	395
163.	457.4

164.	396
165.	424
166.	434.2
167.	395
168.	416.4
169.	417.4
170.	378.4
171.	379.2
172.	405.2
173.	428.8
174.	396

175.	F F F	406.2
176.		406.2
177.		394.2
178.		407
179.	N N N N N N N N N N N N N N N N N N N	507.2
180.		473.2
181.		451.2
182.		405.2
183.		426
184.		459.2
185.		420.2

186.	409.4
187.	485.4
188.	471.6
189.	487.2
190.	437.2
191.	409.4
192.	445.2
193.	464

# Examples 194-214

In a manner analogous to that described in Example 4, starting with N-[3-(aminomethyl)phenyl]-N'-[3-methoxy-4-(5-(oxazolyl)phenyl]oxalamide trifluoroacetate (prepared as descibed in Example 3) and the appropriate carboxylic acid derivative the compounds shown in Table 5 also were prepared:

~	1 1		_
1.8	ıbl	e	-5

	1 able 5	1.10/50
Example	Structure	MS(ES)
194.	_N	
	0 0	409.1
	N	
	, Y , N	
195.	, N_, O_,	
	۰	453.0
196.	S. S.	
		445.0
	N N	
197.	\n\\\^\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
		481.0
	" N N N N N N C	
	Ö	
100	0~,"	
198.	de son son de la companya de la comp	435.1
	of the second of	455.1
	N N	
199.		
		449.1
200.		
		451.2
	ة الرياب ق	
201.	N	
۵01.		460.0
		400.0
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
202.		4.03
		461.1
203.	0	
	0	461.0
204.	N = N = N	
		461.0
	0	
	N-	l

205	· · · · · · · · · · · · · · · · · · ·	T
205.		465.1
206.	1 . N. 1 . N	472.1
207.	0 N N	472.0
208.		473.0
209.	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	477.0
210.	0 1 N N N N N N N N N N N N N N N N N N	477.0
211.		477.2
212.		477.2
213.	O. A. N. J. N. A. N. J.	485.1
214.		485.2

### Examples 215 - 301

In a manner analogous to that described in Example 10, starting with N-[2-amino-1,1-dimethylethyl)-N'-(3-methoxy-4-oxazol-5-ylphenyl)oxalamide (prepared as described in Example 9) and the appropriate carboxylic acid the compounds shown in table 4 were also prepared:

<u>Table 4</u>

Example	Structure	MS(ES)
215.	0 N N N N N N N N N N N N N N N N N N N	401.0
216.		415.0
217.	0 N	417.0
218.	N N N N N N N N N N N N N N N N N N N	426.0
219.		427.0
220.	NT N N N N N N N N N N N N N N N N N N	427.0
221.	N O O O O O O O O O O O O O O O O O O O	431.0
222.		438.0
223.	N N N N N N N N N N N N N N N N N N N	438.0
224.		439.0
225.	N S N N S N N N N N N N N N N N N N N N	443.0
226.		443.0

227.	,	443.1
228.	3 , N , N , N , O	443.1
229.	0	451.0
230.	0 N	451.0
231.		457.1
232.		462.0
233.		482.0
234.	0	428.0
235.	O N O N	429.1
236.		431.0
237.		440.0
238.	N N N N N N N N N N N N N N N N N N N	445.0

220		
239.	0	4550
	0 . · . N N · . ^ F	455.0
	0 0 0	
	Na market	
240.	ę c	
	C N. T. N.	455.0
	0 N E	
	N ···	
241.	0	
	0. · 0	<b>4</b> 57.1
	0 0	
	N	
242.	9 (* )	1
	0 , N	467.1
	0, 1, 2, 0	
2.12	N	
243.	0 N N N N N N N N N N N N N N N N N N N	
	) / N / N / N	471.0
	,o , · · · · · · · · · · · · · ·	
	N-	
244.	· ·	
	O N - N - SI	471.0
	0	
	1 1	
245.	0	
249.	0 N - N	471.0
	N N	4/1.0
	0 0	
		<u> </u>
246.		
	0 N N N N N N N N N N N N N N N N N N N	482.0
	0 0	
	Miles 1	
247.		
	by the state of th	487.1
	0 0	
	N=	
248.		
210.		476.1
	0 N - N O	1,0.1
	0	
	N°	
249.	0 0	
	C N - N	477.1
		1
		ļ
350	'N-Ú	<del>                                     </del>
250.	· · · · · · · · · · · · · · · · · · ·	1.50
	6	479.1
	0	
L	N-2	
	N-B	

251.		1
251.	• .	170.1
	0 ~ N ~ N ~ N	479.1
	,0_ · · · · · · · ·	į
	N	ļ
252.	N	
232.		480.1
		400.1
253.		
233.		480.1
	0 N	400.1
	N-7	
254.	O N N N N N N N N N N N N N N N N N N N	
		431.1
	0	
	N-mil	
255.	0 N N N N N N N N N N N N N N N N N N N	
	0 N - N - N N N N N N N N N N N N N N N	443.0
	0 .	
	N-	
256.	0	
250.	0 N N N N	444.0
	0 0	444.0
257	N O	
257.	N N N N N N N N N N N N N N N N N N N	4440
		444.0
	0	
	N-	
258.	N N C	
	0 N N	487.1
		107.1
250	N-	
259.		505.1
	0 N 7 N H	505.1
	] N	
	N-	
260.	N N	
	0 N N N N N N N N N N N N N N N N N N N	463.0
	N	
261	N .	
261.	· · · · · · · · · · · · · · · · · · ·	
	N N N N N N N N N N N N N N N N N N N	467.1
	o c	
		<u> </u>
262.		
	0 S N	472.0
	0 · ~ N · ~ N	1, 2.0
	,a × 0 0	
	\\\\-\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
	1	L

	· · · · · · · · · · · · · · · · · · ·	
263.	0	473.0
	0, - N N N N N N N N N N N N N N N N N N	
	,0	
	Ñ-	
264.		
	0	391.0
265.	Q Q	
205.	O. N. N. N. N. N. N. N. N. N. N. N. N. N.	401.0
	0 0	13113
	N-	
266.	N. I. N.	
		405.0
	. T	
267.	N O	
207.	O N N N N N N N N N N N N N N N N N N N	431.1
		131.1
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
268.	N. N. N. 10	
	N N N N N N N N N N N N N N N N N N N	433.0
		:
269.	N 0 0 -	
209.	O N N N N N N N N N N N N N N N N N N N	441.0
	0 0	111.0
	N	
270.	. 0 =	
	N N N N N N N N N N N N N N N N N N N	441.0
	N N	
271.	ρ , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		441.0
272	N N	
272.	0 N N N N	442.0
	0 0	112.0
	N-	
273.	1 N	
	The state of the s	442.0
	ه د د د د د د د د د د د د د د د د د د د	
	N-J	
274.	N. N. N.	1120
	O O	442.0
	N N	

	<del></del>	
275.	0 N N N N N N N N N N N N N N N N N N N	453.0
276.		453.0
277.		453.0
278.		453.0
279.		453.0
280.		454.()
281.		455.()
282.		455.()
283.		455.()
284.	N N N S	457.0
285.	S S S	457.0

	<del></del>	· · · · · ·
286.		457.1
	N-1	
287.	0 0 0 0 0	457.1
	<b>&gt;</b>	
288.		459.0
	N	
289.		527.2
290.		
		563.0
291.	^0	
	O COLOR	487.0
292.	N N N N N N N N N N N N N N N N N N N	494.1
293.		494.1
294.		497.1
295.	N N N N N N N N N N N N N N N N N N N	501.0
296.		502.1
L	· ··.	

297.	505.0
298.	505.0
299.	507.1
300.	462.0
301.	463.1

# Examples 302-315; 438-458 and 653-663

10

15

Typical methods used for the preparation of compounds of table 1c are described below:

### Example 440

# $\underline{N\text{-}[3\text{-}Methoxy\text{-}4\text{-}(5\text{-}oxazolyl)phenyl]\text{-}N'\text{-}[1,1\text{-}dimethyl\text{-}2\text{-}(1\text{-}oxido\text{-}4\text{-}pyridyl)ethyl]}oxalamide}$

30 mg (0.1 mmol) of 60% 3-chloroperoxybenzoic acid were added to a stirred solution of 20 mg (0.051 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-pyridyl)ethyl]oxalamide in 1 ml of dichloromethane. The mixture was stirred for 1 hour then diluted with ethyl acetate, washed with sodium bisulphite solution, sodium bicarbonate solution and brine. The organic solution was dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether to give 13 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-4-pyridyl)ethyl]oxalamide as an off-white solid. MS: m/e 411 [M+H]<sup>†</sup>.

#### The starting material was prepared as follows:

- i) A solution of 17.4 g (0.115 mol) of alpha, alpha-dimethyl-4-pyridineethanol in 115 ml of acetic acid was added dropwise to a mixture of 115 ml of acetic acid, 58 ml of concentrated sulphuric acid and 6.8 ml (0.126 mmol) of acetonitrile with cooling in an ice/salt bath. The resulting mixture was stirred for 2 hours at room temperature and the pH raised to 10 by the addition of 6M sodium hydroxide solution with ice cooling. The slurry was filtered, washed with ethyl acetate and the aqueous filtrate extracted twice with ethyl acetate. The combined organic extracts were dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/methanol (1:19), (1:9) and (3:17) for the gradient elution. There was obtained 1.87 g of N-[1,1-dimethyl-2-(4-pyridyl)ethyl]acetamide as an orange oil. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.29 (6H,s), 1.91 (3H,s), 3.11 (2H,s), 5.10 (1H,br.s.), 7.07 (2H,d), 8.50(2H,d).
- 15 ii) A solution of 1.8 g (9.3 mmol) of N-[1,1-dimethyl-2-(4-pyridyl)ethyl]acetamide, 2.66 g (9.3 mmol) of titanium (IV) isopropoxide and 2.56 g (14 mmol) of diphenylsilane in 10 ml of tetrahydrofuran was stirred at room temperature for 20 hours. The resulting mixture was chromatographed on silica gel using dichloromethane/methanol/acetic acid/water (60:18:2:3) for the elution. The product was dissolved in 20 ml of concentrated hydrochloric acid and 50 ml of methanol and evaporated to dryness. The residue was evaporated with toluene five times to give 620 mg of alpha, alpha-dimethyl-4-pyridineethylamine hydrochloride (1:1), as a pale brown solid. <sup>1</sup>H NMR (400 MHz DMSO) δ: 1.31 (6H,s), 3.26 (2H,s), 8.02 (2H,d), 8.4-8.6 (3H,br.s), 8.88 (2H,d).
- iii) A mixture of 100 mg (0.45 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine hydrochloride (1:1), 120 mg (0.45 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 105 mg (0.68 mmol) of 1-hydroxybenzotriazole hydrate, 105 mg (0.54 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 127 mg (1.1 mmol) of N-ethylmorpholine in 4 ml of dichloromethane was stirred for 20 hours at room temperature then diluted with ethyl acetate and washed with water and brine. The organic solution was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/methanol (19:1) for the elution. After trituration with diethyl ether there was obtained 32 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-

pyridyl)ethyl]oxalamide as a white solid. MS: m/e 395 [M+H].

10

15

20

25

# Example 455

2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid

A solution of 68 mg (0.12 mmol) of benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate in 10 ml of tetrahydrofuran was hydrogenated with 20 mg of 10% palladium on carbon for 4 hours. The resulting suspension was filtered , evaporated to dryness and the residue triturated with diethyl ether to give 41 mg of 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylic acid as a white solid. MS: m/e 477.9 [M+H] $^{\dagger}$ .

The starting material was prepared as follows:

A solution of 1.976 g (22.46 mmol) of isobutyric acid in 8 ml of anhydrous i) tetrahydrofuran was added to a stirred suspension of 1.078 g (26.95 mmol) of 60% sodium hydride and 2.268 g (22.46 mmol) of diisopropylamine in in 40 ml of anhydrous tetrahydrofuran under a nitrogen atmosphere and the mixture heated to reflux for 15 minutes. After cooling to 0°C a solution of 14.04 ml (22.46 mmol) of 1.6M butyllithium in hexanes was added maintaining the temperature at 0-5°C. After 5 minutes at 0°C the mixture was warmed to 30-35°C for 20 minutes, cooled to 0°C and a solution of 5.3 g (22.46 mmol) of 2-(bromomethyl)-5-benzofurancarbonitrile in 15 ml of anhydrous tetrahydrofuran was added maintaining the temperature at 0°C. The suspension was stirred for 5 minutes at 0°C then warmed to 30-35°C for 20 minutes before being cooled to 15°C and quenched by the careful addition of 50 ml of water and diluted with 50 ml of diethyl ether. The aqueous phase was separated, acidified with concentrated hydrochloric acid and extracted with diethyl ether. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 670 mg of 5-cyano-alpha, alpha-dimethyl-2-benzofuranpropionic acid as a white

solid.  $^{1}$ H NMR (400 MHz CDCl<sub>3</sub>)  $\delta$ : 1.23 (6H,s), 3.01 (2H,s), 6.46 (1H,s), 7.38 (1H,d), 7.42 (1H,d), 7.75 (1H,s).

ii) A mixture of 652 mg (2.68 mmol) of 5-cyano-alpha, alpha-dimethyl-2benzofuranpropionic acid, 732 mg (2.68 mmol) of diphenylphosphoryl azide and 269 mg (2.66 mmol) of triethylamine in 8 ml of tert-butanol was refluxed for 8 hours then evaporated to dryness and the residue dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:3) for the elution to give 225 mg of white solid which was suspended in 10 ml of 2M sodium hydroxide solution and stirred and refluxed for 20 hours. The resulting suspension was cooled, evaporated to dryness and 5 ml of ethylene glycol and 400 mg of potassium hydroxide were added. After heating at 190°C for 20 minutes 2 ml of water were added and after a further 20 minutes another 15 ml of water were added and heating continued for 20 minutes until a thick paste remained which was cooled and dissolved in 20 ml of water. Concentrated hydrochloric acid was added to bring the pH to 2 then 25 ml of dioxan, 3 g (21.74 mmol) of potassium carbonate and 1.5 g (6.88 mmol) of di-tert-butyl dicarbonate were added and the mixture stirred for 24 hours. The solvent was removed by evaporation and the residue dissolved in diethyl ether and water. The aqueous phase was separated, acidified with 2M hydrochloric acid and extracted with diethyl ether. The organic phase was dried over magnesium sulphate and evaporated to dryness to give 106 mg of 2-[2-(tert-butoxyformamido)-2-methylpropyl]-5benzofurancarboxylic acid as a colourless gum.

10

15

iii) A mixture of 105 mg (0.32 mmol) of 2-[2-(tert-butoxyformamido)-2-methylpropyl]5-benzofurancarboxylic acid, 80 mg (0.53 mmol) of benzyl bromide, and 200 mg (1.45 mmol) of potassium carbonate in 4 ml of dimethylformamide was stirred at room temperature for 1 hour then diluted with diethyl ether and water. The organic phase was washed twice with water, dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:5) for the elution. There was obtained 104 mg of benzyl 2-[2-(tert-butoxyformamido)-2-methylpropyl]-5-benzofurancarboxylate as a colourless gum. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.39 (6H,s), 1.50 (9H,s), 3.23 (2H,s), 4.49 (1H,s), 5.41 (2H,s), 6.52 (1H,s), 7.34-7.52 (6H,m), 8.02 (1H,d), 8.30 (1H,s).

iv) 103 mg (0.24 mmol) of benzyl 2-[2-(tert-butoxyformamido)-2-methylpropyl]-5-benzofurancarboxylate were dissolved in 5 ml of trifluoroacetic acid/dichloromethane (1:1) for 10 minutes then evaporated to dryness and the residue dissolved in 1 ml of dimethylformamide and added to a stirred solution of 66 mg (0.25 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 115 mg (1 mmol) of N-ethylmorpholine, 45 mg (0.29 mmol) of 1-hydroxybenzotriazole hydrate and 70 mg (0.37 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 2 ml of dimethylformamide and the resulting mixture stirred at room temperature for 18 hours. After dilution with ethyl acetate the organic solution was washed with 2M hydrochloric acid, saturated sodium bicarbonate solution and water, dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (45:55) for the elution. After trituration with diethyl ether there was obtained 81 mg of benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate as a white solid. MS m/e 568 [M+H]<sup>+</sup>.

#### Example 443

2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)]amino]-2-methylpropyl]phenoxy]acetic acid

A solution of 45 mg (0.081 mmol) of benzyl 2-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetate in 5 ml of ethanol/tetrahydrofuran (1:1) was hydrogenated with 4 mg of 10% palladium on carbon catalyst for 5 hours. The resulting suspension was filtered, evaporated to dryness and triturated with diethyl ether to give 29 mg of 2-[3-[2-[[[3-methoxy-4-(5-oxazolyl)amino]-2-methylpropyl]phenoxy]acetic acid as a white solid. MS: m/e 468 [M+H]<sup>+</sup>.

The starting material was prepared as follows:

10

15

20

30

i) 8 mg (0.2 mmol) of 60% sodium hydride were added to a stirred solution of 85 mg (0.2 mmol) of N-[2-(3-hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide in 1 ml of dimethylformamide. After 10 minutes 55 mg (0.24

mmol) of benzyl bromoacetate were added and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed twice with water, dried over magnesium sulphate and evaporated to dryness. The residue was chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 51 mg of benzyl 2-[3-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetate as a white solid. MS: m/e 558 [M+H]<sup>+</sup>.

In a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid, prepared as described in Example 1, parts (i) and (ii), and the appropriate amine, additional compounds shown in table 1c were also prepared.

table 1c

Name	Structure	MS(ES) $(M+H)^{\dagger}$	Ex No
N-[3-Methoxy-4-(5- oxazolyl)phenyl]-N'-[1,1-dimethyl- 2-(4- methylphenyl)ethyl]oxalamide	N - 10 0 N O-1, 0 OH,	408	302
N-[1,1-Dimethyl-2-(2- methylphenyl)ethyl]-N'-[3- methoxy-4-(5- oxazolyl)phenyl]oxalamide	N 1 C : CH, CH : Th	408	303
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-pyridyl)ethyl]oxalamide	N OHC CH	395	304
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methylphenyl)ethyl]oxalamide	N TO SHE	408	305
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(2-thienyl)ethyl]oxalamide	N 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	400	306
N-[2-(4-Benzyloxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	The state of the s	500	307
N-[2-(4-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	M. OHC OH	410	308

N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide	ν · · · · · · · · · · · · · · · · · · ·	424	309
N-[2-(2-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N O OH OH OH OH	410	310
N-(1,1-Dimethyl-2-phenyl- propyl)-N'-(3-methoxy-4-oxazol- 5-yl-phenyl)-oxalamide	N O H,	408	311
N-[2-(3-Hydroxy-phenyl)-1,1-dimethyl-ethyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N 3143	410	312
N-(3-Methoxy-4-oxazol-5-yl-phenyl)-N'-[2-(3-methoxy-phenyl)-1,1-dimethyl-ethyl]-oxalamide		424	313
N-[2-[4-(Cyanomethoxy)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N Service CHI	449	314
2-[4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	N	468	315
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid		468	438
2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenoxy]acetic acid	No.	468	439
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-4-pyridyl)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	411	440
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-3-pyridyl)ethyl]oxalamide	N O O OH NO	411	441
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-oxido-2-pyridyl)ethyl]oxalamide	N O S CH,	411	442

2-[3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)]amino]-2-methylpropyl]phenoxy]acetic acid	N 1 1 1 0 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1	468	443
N-[2-(2-Benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N	434	444
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(3-methyl-2-benzofuranyl)ethyl]oxalamide	N Proceedings	448	445
N-[2-(7-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N C C N HP.	464	446
N-[2-(5-Methoxy-2-benzofuranyl)- 1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	N W W	464	447
N-[2-(6-Methoxy-2-benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	No. 1 Constitution of the	464	448
Benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	N	528	449
4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	М	438	450
Benzyl 3-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoate	то почет о почет о то то то то то то то то то то то то	528	451
3-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]benzoic acid	N CONCOR	438	452
N-[2-(3-Benzofuranyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N N N N N N N N N N N N N N N N N N N	434	453
Benzyl 2-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzofurancarboxylate	Marian I grand	568	454

We at a	477.9	455
1,500 5,00H	421	456
N N N N N N N N N N N N N N N N N N N	437	457
100 mg	464	458
He a second of	423.22	653
N-O	439.3	654
	393	655
	409	656
	407	657
	421	658
	435	659
		421  437  464  439.3  409  407

N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1-[(1-oxido-4- pyridyl)methyl]-1- cyclohexyl]oxalamide		451	660
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-methyl-4-pyridyl)ethyl]oxalamide		409	661
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(2-methyl-1-oxido-4- pyridyl)ethyl]oxalamide		425	662
2-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-5-benzothiophenecarboxylic acid	N N N N S YOH	494	663

# Examples 316-330:

In a manner analogous to that described in Example 11 starting with N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, prepared as described in example 21, and the appropriate aldehyde compounds shown in table 1d were also prepared.

table 1d

Name	Structure	$MS(ES)$ $(M+H)^+$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(2- pyridinyl)methylamino]phenyl]ethyl]oxala mide		500.1	316
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-[(3- pyridyl)methylamino]phenyl]ethyl]oxalam ide	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	500.1	317
N-[2-[4-(2-Furfurylamino)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	CH	489.1	318
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-Dimethyl-2-[4-(2- thenylamino)phenyl]ethyl]oxalamide		505.1	319
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'- [1,1-dimethyl-2-[4-(2,2-dimethylpropylamino)phenyl]ethyl]oxalam	CHC SH CHCH	479.2	320

ide			1
N-[2-[4-[(1H-Imidazol-2-	NOT.		
yl)methylamino]phenyl]-1,1-	on one on	489.1	321
dimethylethyl]-N'-[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N-		i ·
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-	>> <sub>N</sub>		
[1,1-dimethyl-2-[4-[(4-	он о но эн	500.1	322
pyridyl)methylamino]phenyl]ethyl]oxalam	0. N _ 7.N X	200.1	322
ide	N-		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-	ş <u>-</u>		<del>!</del>
[1,1-dimethyl-2-[4-[(2-	3 H OI, 3 H N	506.1	323
thiazolyl)methylamino phenyl ethyl oxala	C. )	300.1	323
mide	C		
N-[2-[4-(3-Furfurylamino)phenyl]-1,1-			-
	3 No. 28 (1997)	489.1	324
dimethylethyl]-N'-[3-methoxy-4-(5-	0.	409.1	324
oxazolyl)phenyl]oxalamide	0. /		
N-[2-[4-[5-(Hydroxymethyl)-2-			
furfurylamino]phenyl]-1,1-dimethylethyl]-		519.1	325
N'-[3-methoxy-4-(5-	6.	317.1	323
oxazolyl)phenyl]oxalamide	·-		
N-[2-(4-Benzylaminophenyl)-1,1-	. 7 .		
dimethylethyl]-N'-[3-methoxy-4-(5-	THE PROPERTY OF STREET	499.1	326
oxazolyl)phenyl]oxalamide	On the second se	477.1	320
Oxazory 1/prieny 1 joxala mide	N-		
N-[2-[4-(2-Hydroxybenzylamino)phenyl]-			
1,1-dimethylethyl]-N'-[3-methoxy-4-(5-	THE STATE OF	515.1	327
oxazolyl)phenyl]oxalamide	0.		
	N-		
N-[2-[4-(3-Cyanobenzylamino)phenyl]-			
1,1-dimethylethyl]-N'-[3-methoxy-4-(5-		524.1	328
oxazolyl)phenyl]oxalamide	0 .		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-	1 1 1		
[1,1-dimethyl-2-[4-[4-(3-		576.2	329
pyridyl)benzylamino]phenyl]ethyl]oxalami		570.2	
de	51.7227		
N-[2-[4-(2-Fluorobenzylamino)phenyl]-			
1,1-dimethylethyl]-N'-[3-methoxy-4-(5-	H, 0H, 1M, 1	517.1	330
oxazolyl)phenyl]oxalamide	0 0 0	517.1	
Oxazoiyi)piiciiyijoxalaiiilde	N-		
	•		

# Examples 331-395 and 596-597:

In a manner analogous to that described in Example 22 starting from N-[2-(4-aminophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide, prepared as described in

example 21, and the appropriate carboxylic acid compounds shown in table 1e were also prepared.

Table 1e

Name	Structure	MS(ES) (M+H)	Ex No
N-[2-[4- (Cyclopropylcarboxamido)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	CH CH: H C	477.1	331
N-[2-[4-(Cyclobutylcarboxamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl oxalamide	CH CHC St.	491.1	332
N-{3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-(4- pivalamidophenyl)-1,1- dimethylethyl]oxalamide	CH 2H: 3- 1 M CH CH CH CH CH CH CH CH CH CH CH CH CH	493.1	333
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(1H-pyrrol- 2-yl)carboxamido]phenyl]ethyl] oxalamide	5 1 N 1 N 1 S 1 S 1 S 1 S 1 S 1 S 1 S 1 S	502.1	334
N-[2-[4-[(2-Furyl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	HG St. N. J.	503.1	335
N-[2-[4-[(3-Furyl) carboxamido]phenyl]-1,1- dimethylethyl]-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	on we on which	503.1	336
N-[2-[4-[(1H-Imidazol-4-yl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	Service Servic	503.1	337
N-[2-[4-[(Tetrahydro-2(RS)-furyl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		507.2	338
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4-[(2- pyridyl)carboxamido]phenyl]ethyl]ox alamide	91 M9 M	514.1	339
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-pyridyl) carboxamido]phenyl]ethyl]oxalamide		514.1	340

N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(2-thienyl) carboxamido]phenyl]ethyl]oxalamide	CH CHC CH	519.1	341
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[1,1-dimethyl-2-[4-[(3-thienyl) carboxamido]phenyl]ethyl]oxalamide		519.1	342
N-[2-[4-(2-Cyclopentylacetamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	On Opening No.	519.2	343
N-[3-Methoxy-4-(5-oxazolyl) phenyl] -N'-[1,1-dimethyl-2-[4-(2-methylbenzamido)phenyl]ethyl]oxala mide	Ox Hy 2x My 185	527.2	344
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-(4-methylbenzamido)phenyl]ethyl]oxala mide	01 19 2 19 2 19 2 19 2 19 2 19 2 19 2 19	527.2	345
N-[2-[4-(Cycloheptylcarboxamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	0 1 1 No 1 0	533.2	346
N-[2-[4-[(5-Isoxazolyl) carboxamido] phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	0H (M. ) (M. ) (M. )	504.1	347
N-[2-[4-(Cyclopentylcarboxamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		505.2	348
N-[2-{4-[(Tetrahydro-3(RS)-furyl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		507.1	349
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(1-methyl-1H-pyrrol-2-yl)carboxamido]phenyl] ethyl]oxalamide	CH. CH. CH. CH. CH.	516.1	350
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-(1,1-dimethyl-2-[4-[(1,2,3-thiadiazol-4-yl)carboxamido]phenyl] ethyl]oxalamide	N=N  C 1	521.1	351
N-[2-[4-(3-Fluorobenzamido)phenyl] -1,1-dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide		531.1	352

N-[2-[4-(4-Fluorobenzamido)phenyl]	/~ '		
-1,1-dimethylethyl]-N'-[3-methoxy-	0h, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	531.1	353
4-(5-oxazolyl)phenyl]oxalamide	,o		1
	N-		
N-[2-[4-(2-			
Methoxybenzamido)phenyl]-1,1-	N ON SON	543.2	354
dimethylethyl]-N'-[3-methoxy-4-(5-	,о., С		
oxazolyl)phenyl]oxalamide	Ň-		
N-[2-[4-(2-Chlorobenzamido)	` `		
phenyl]-1,1-dimethylethyl]-N'-[3-	H. CH 36 2NC 2. 2	547.1	355
methoxy-4-(5-oxazolyl)phenyl]	, , , , , , , , , , , , , , , , , , ,	2 1/11	
oxalamide	N-"		
N-[2-[4-(3-Chlorobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-	on one n	547.1	356
methoxy-4-(5-oxazolyl)phenyl]	ON SHAPE OF THE STATE OF THE ST	J-1/.1	2,20
	.o.		
oxalamide	,a		-
N-[2-[4-(4-Chlorobenzamido)	30 30 N	5 1 7 1	257
phenyl]-1,1-dimethylethyl]-N'-[3-	On No. Charles	547.1	357
methoxy-4-(5-oxazolyl)phenyl]	o.		
oxalamide			
N-[2-[4-[(1H-Indol-2-yl)			
carboxamido]phenyl]-1,1-	No. He record to the second se	552.1	358
dimethylethyl]-N'-[3-methoxy-4-(5-	]		
oxazolyl)phenyl]oxalamide	N-1		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	, a		
-N'-[1,1-dimethyl-2-[4-[4-	the state of the s	556.1	359
(dimethylamino)benzamido]phenyl]e	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		İ
thyl]oxalamide	1		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	0, N 1		
-N'-[1,1-dimethyl-2-[4-(3,3-	N N N N N N N N N N N N N N N N N N N	507.1	360
dimethylbutyramido)]phenyl]ethyl]o	No.		
xalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	THE SHOP HE SHOW IN THE SHOP		
-N'-[1,1-dimethyl-2-[4-[2-(1-	O	519.1	361
tetrazolyl)acetamido]phenyl]ethyl]ox	N-		
alamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	C Chiral		<u> </u>
-N'-[1,1-dimethyl-2-[4-[(5-oxo-2(S)-		520.1	362
pyrrolidinyl)carboxamido]phenyl]eth		220.1	50,2
yl]oxalamide	*~`		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	jr Chiral		
$-N'-(1,1-dimethyl-2-\{4-[(5-oxo-2(R)-1)]\}$		520.1	363
	a	J±0.1	1 303
pyrrolidinyl)carboxamido]phenyl]eth			
yl]oxalamide			ļ
N-[3-Methoxy-4-(5-oxazolyl)phenyl]	, , , , , , , , , , , , , , , , , , ,	562.1	2.54
-N'-[1,1-dimethyl-2-[4-[(2-	N 0	563.1	364
naphthyl)carboxamido]phenyl]ethyl]	o. 0		
oxalamide			

N-[2-{4-[(6-Cyano-3-pyridyl) carboxamido]phenyl}-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	ed one of	580.1 (M+H+ ACN)	365
N-[2-[4-(3-Methoxybenzamido) phenyl]-1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		543.1	366
N-[2-[4-(3,5-Difluorobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		549.1	367
N-[2-[4-[(1H-Indol-5-yl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		552.1	368
(E)-N-[2-[4-(2-Butenamido)phenyl]- 1,1-dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	CALL THE WAY TO SELECT	477.1	369
N-[2-[4-(2-Methoxyacetamido) phenyl]-1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	4, 2 N 2 N 1 N 1 1 3,000	481.2	370
N-[3-methoxy-4-(5-oxazolyl)phenyl]- N'-[1,1-dimethyl-2-[4-[(2-methyl-3-furyl)carboxamido]phenyl]ethyl]oxal amide	(10) (10)	517.1	371
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(5-methyl-4-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	372
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(3-methyl-4-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	373
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(5-methyl-3-isoxazolyl)carboxamido]phenyl]ethyl] oxalamide		518.1	374
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[1,1-dimethyl-2-[4-[(1-oxido-3-pyridyl)carboxamido]phenyl]ethyl]ox alamide		530.1	375
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(1-oxido-4-pyridyl)carboxamido]phenyl]ethyl]ox alamide		530.1	376

N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4,5-		531.1	377
dimethyl-2-furyl)carboxamido] phenyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(2,5-	On the state of th	531.1	378
dimethyl-2H-pyrazol-3-yl) carboxamido]phenyl]-1,1-			i i
dimethylethyl]oxalamide N-[3-Methoxy-4-(5-oxazolyl)phenyl]			
-N'-[1,1-dimethyl-2-[4-[(3-methyl-2-	N P P P P P P P P P P P P P P P P P P P	533.1	379
thienyl)carboxamido]phenyl]ethyl]ox alamide	4		
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[2-(3-	0.	533.1	380
thienyl)acetamido]phenyl]ethyl]oxala mide	٠		
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-2-		533.1	381
thienyl)carboxamido]phenyl]ethyl]ox	•	00011	
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-[(4-methyl-	S N N N N N N N N N N N N N N N N N N N	535	382
1,2,3-thiadiazol-5- yl)carboxamido]phenyl]ethyl]oxalami	0.		
de N-[2-[4-(4-Acetamidobenzamido)			
phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		570.1	383
N-[2-[4-(3,4-Dimethoxybenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide		573.1	384
N-[2-[4-(4-Chloro-2-methoxybenzamido)phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	ON LINE TO SOME	578.2	385
N-[2-[4-(2,6-Dichlorobenzamido) phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	N N N CO	581	386
N-[2-[4-[(Bicyclo[4.2.0]octa-1(6),2,4-triene-7(RS)-yl)carboxamido] phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	3. H. 3. 1 N O	539.1	387

N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N'-[1,1-dimethyl-2-[4-(2-oxo-2-phenylacetamido)phenyl]ethyl]oxala mide		541.1	388
N-[2-{4-[2-(2-Fluorophenyl) acetamido]phenyl}-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	III 3H II V CONST	545	389
N-[2-{4-[2-(4-Fluorophenyl) acetamido]phenyl}-1,1- dimethylethyl)-N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		545	39()
N-[3-Methoxy-4-(5-oxazolyl)phenyl] -N-[2-{4-[(4-methoxy-3-thienyl) carboxamido]phenyl}-1,1- dimethylethyl]oxalamide		549	391
N-[2-[4-(4-Acetylbenzamido) phenyl]-1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		555.1	392
N-[2-[4-[(1,3-Benzodioxol-5-yl) carboxamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		557.1	393
N-[2-[4-[2-(2-Chlorophenyl) acetamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	561.1	394
N-[2-[4-[2-(4-Chlorophenyl) acetamido]phenyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		561.1	395
tert-Butyl 4-[[4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]phenyl]carbamoyl)benz oate		613	596
4-[[4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropyl]phenyl]carbamoyl]benz oic acid		557	597

# Examples 396-406; 433-437; 542-595 and 635-650

Typical methods used for the preparation of the compounds of tables 1f<sup>4</sup>, 1f<sup>2</sup>and 1f<sup>3</sup> are described below:

#### Example 398.

## N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]oxalamide

- (i) A mixture of 0.5g (3.94 mmol) of 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and 0.5g (3.6 mmol) of 4-nitrophenol were heated at 180C under a nitrogen atmosphere for 6 hours. The resulting mixture was cooled and purified by chromatography on silica gel using ethyl acetate for the elution. There was obtained 524 mg of N-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]acetamide.
  - (ii) 693 mg (2.61 mmol) of N-[1,1-dimeyhyl-3-(4-nitrophenoxy)propyl]acetamide, 815 mg(2.87 mmol) of titanium isopropoxide and 719 mg (3.91mmol) of diphenylsilane were dissolved in 8 ml of tetrahydrofuran and left at room temperature for 18 hours. The resulting solution was dissolved in ethyl acetate and saturated sodium bicarbonate solution, filtered and the organic phase extracted twice with 2M hydrochloric acid. The combined acid extracts were basified with 2M sodium hydroxide solution, extracted with ethyl acetate and the organic extracts dried over magnesium sulphate, filtered and evaporated to dryness to give 266 mg of 1,1-dimethyl-3-(4-nitrophenoxy)propylamine. The 1,1-dimethyl-3-(4-nitrophenoxy)propylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]oxalamide as a pale yellow solid. MS: m/e 469 [M+H]<sup>+</sup>.

#### Example 433

25

10

15

20

## 4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid.

A solution of 650 mg (1.17 mmol) of benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate in 20 ml of tetrahydrofuran was hydrogenated with 65 mg of 10% palladium on charcoal catalyst for 48 hours, a further 65 mg of catalyst being added after 24 hours and again after 44 hours. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether to give 415 mg of 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid as a

white solid. MS: m/e 468  $[M+H]^+$ .

20

25

30

#### The starting material was prepared as follows:

- A mixture of 1.14 g (5 mmol) of benzyl 4-hydroxybenzoate and 800 mg (6.3 mmol) of 2,4,4-trimethyl-5,6-dihydro-1,3(4H)-oxazine was stirred and heated at 180°C for 3 hours. A further 600 mg (4.72 mmol) of oxazine were added and heating was continued for 21 hours. The resulting mixture was cooled and chromatographed on silica gel using ethyl acetate/petrol (3:1) for the elution. There was obtained 1.52 g of benzyl 4-(3-acetamido-3-methylbutoxy) benzoate as a white solid. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.43 (6H,s), 1.94 (3H,s), 2.26 (2H,t), 4.14 (2H,t), 5.36 (2H,s), 5.65 (1H,s), 6.91 (2H,d), 7.35-7.52 (5H,m), 8.05 (2H,d).
  - ii) A solution of 1.5 g (4.23 mmol) of benzyl 4-(3-acetamido-3-methylbutoxy) benzoate, 1.166 g (6.35 mmol) of diphenylsilane and 1.2 g (4.23 mmol) of titanium(IV) isopropoxide in 4 ml of tetrahydrofuran was stirred at room temperature for 6 hours. The resulting mixture was diluted with diethyl ether/2M sodium hydroxide solution, filtered and the organic phase extracted twice with 2M hydrochloric acid. The combined aqueous extracts were basified with 2M sodium hydroxide solution and extracted with ether. The organic extract was dried over magnesium sulphate and evaporated to dryness to give 1.16 g of benzyl 4-(3-amino-3-methylbutoxy) benzoate as a pale coloured gum. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.22 (6H,s), 1.92 (2H,t), 4.08 (2H,t), 5.36 (2H,s), 6.90 (2H,d), 7.33-7.48 (5H,m), 8.05 (2H,d).
  - iii) A solution of 873 mg (3.33 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 500 mg (3.27 mmol) of 1-hydroxybenzotriazole hydrate, 1.2 g (3.83 mmol) of benzyl 4-(3-amino-3-methylbutoxy) benzoate and 1 g (5.22 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 10 ml of dimethylformamide was stirred at room temperature for 24 hours. The resulting mixture was diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate solution and water then dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. After trituration with diethyl ether there was obtained 765 mg of benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate as a white solid. MS: m/e 558 [M+H]<sup>†</sup>.

#### Example 434

2-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid.

5

10

In an analogous manner to that described in Example 433 but replacing benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate with benzyl 2-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate there was obtained 2-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid as a white solid. MS: m/e 468 [M+H]<sup>+</sup>.

# The starting material was prepared as follows:

- i) A solution of 917 mg (3.5 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 650 mg (4.66 mmol) of 3-amino-3-methyl-1-butanol hydrochloride (1:1), 612 mg (4 mmol) of 1-hydroxybenzotriazole hydrate, 690 mg (6 mmol) of N-ethylmorpholine and 960 mg (5 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 10 ml of dimethylformamide was stirred at room temperature for 20 hrs. The resulting mixture was diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate solution and water then dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (3:1) for the elution. There was obtained 410 mg of N-(3-hydroxy-1,1-dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as a pale yellow solid. MS: m/e 348 [M+H]<sup>+</sup>.
- ii) A solution of 48 mg (0.276 mmol) of diethyl azodicarboxylate in 2 ml of tetrahydrofuran was added to a mixture of 72 mg (0.275 mmol) of triphenylphosphine, 57 mg (0.25 mmol) of benzyl salicylate and 87 mg (0.25 mmol) of N-(3-hydroxy-1,1-dimethylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide and left at room temperature for 1 hour. The resulting mixture was chromatographed twice on silica gel using first ethyl acetate/petrol (1:1) then methanol/dichloromethane (1:49) for the elutions. There was obtained 29 mg of benzyl 2-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate as a colourless gum. MS: m/e 558 [M+H]<sup>†</sup>.

#### Example 435

## 3-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid.

In an analogous manner to that described in Example 433 but replacing benzyl 4-hydroxybenzoate with benzyl 3-hydroxybenzoate there was obtained 3-[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid as a white solid. MS: m/e 468 [M+H]<sup>+</sup>.

Example 553

## 4-[2-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoic acid.

In an analogous manner to that described in Example 433 but replacing benzyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate with benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoate there was obtained 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoic acid as a white solid. MS: m/e 454 [M+H]<sup>+</sup>.

The starting material was prepared as follows:

5

10

15

20

25

- (i) A solution of 0.280 g (4 mmol) of 2,2-dimethylaziridine (Cairns, J. Am. Chem. Soc. 1941, <u>63</u>, 871) and 9 g (40 mmol) of benzyl 4-hydroxybenzoate in 30 ml of chloroform was heated under refluxed for 3 hr. The reaction mixture was allowed to cool and diluted with dichloromethane. The solution was washed with 2M sodium hydroxide solution, dried over anhydrous magnesium sulphate, and concentrated *in vacuo*. Column chromatography of the residue using(dichloromethane:methanol:acetic acid:water (240:12:3:2) afforded benzyl 4-(2-amino-2-methylpropoxy)benzoate (0.300g, 1 mmol, 25%).
  - (ii) The benzyl 4-(2-amino-2-methylpropoxy)benzoate was coupled to N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid in a manner analogous to that described for example 433,

part (iii) to give benzyl 4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropoxy]benzoate as a white solid.

Example 561 was prepared in a manner analogous to that described for example 433, parts (i) and (ii) where the benzyl 4-hydroxybenzoate was replaced with 3-cyanophenol.

Examples 585, 588 and 589 were prepared from the compounds of examples 583, 587 and 586 respectively, by reacting the nitrile substituent with trimethylsilyl azide and dibutyl tin oxide according to the method of S.J. Wittenberger and B.G.J. Donner, J. Org. Chem., 1993, <u>58</u>, 4139-4141.

For examples in table If containing unprotected hydroxyl or amino groups suitable protecting groups were used, such as benzyl for hydroxyl and benzyloxycarbonyl for amino or similar groups, hereinbefore mentioned and well known in the art.

15

table 1f

Name	Structure	MS(ES) (M+H)'	Ex No
N-[3-(4-Hydroxy-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	0 CH	440	396
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-(4- methoxyphenoxy)-1,1- dimethylpropyl]oxalamide		454	397
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- nitrophenoxy)propyl]oxalamide	N 2 3 1 15 15 15 15 15 15 15 15 15 15 15 15 1	469	398
N-[3-(2-Hydroxyphenoxy)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N O OH OH	440	399
N-[3-(4-Amino-phenoxy)-1,1-dimethyl-propyl]-N'-(3-methoxy-4-oxazol-5-yl-phenyl)-oxalamide	N CH, O CH,	439	400

N-[3-(4-Acetylamino-phenoxy)-			
1,1-dimethyl-propyl]-N'-(3-	NO CON	481	401
methoxy-4-oxazol-5-yl-phenyl)-			
oxalamide	• OH,		
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(3-	N O	425	402
pyridyloxy)propyl]oxalamide		423	402
pyriayioxy)propyrjoxaiamiae	, o		
N-[3-(3-Hydroxyphenoxy)-1,1-	N79 9		
dimethylpropyl]-N'-[3-methoxy-4-		440	403
(5-oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	.50 0		
phenyl]-N'-[3-(3-	N. A. O. O. O.	454	404
methoxyphenoxy)-1,1-	AN LIX COLD		
dimethylpropyl]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)   phenyl]-N'-[1,1-dimethyl-3-(3-	N O	469	405
nitrophenoxy)propyl]oxalamide	N N N N N N N N N N N N N N N N N N N	•02	105
	0		
N-[3-(3-Aminophenoxy)-1,1-		420	40.5
dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N N N N N N N N N N N N N N N N N N N	439	406
(3-0xazotyt)phenytjoxalamide			
4-[3-[[[3-Methoxy-4-(5-oxazolyl)	N TH		
anilino]oxalyl]amino]-3-		468	433
methylbutoxy]benzoic acid	Ö ÖH,		
2-[3-[[[3-Methoxy-4-(5-oxazolyl)	N C O CH,		
anilino]oxalyl]amino]-3-		468	434
methylbutoxy]benzoic acid	N Y CH3		
3-[3-[[[3-Methoxy-4-(5-oxazolyl)	N		
anilino]oxalyl]amino]-3-		468	435
methylbutoxy]benzoic acid	8 64		
2-[4-[3-[[[3-Methoxy-4-(5-	NO YOR		
oxazolyl)anilino]oxalyl]amino]-3-		498	436
methylbutoxy]phenoxy]acetic acid	I GH, LAONOH		
2-[2-[3-[[[3-Methoxy-4-(5-	»≈°		
oxazolyl)anilino]oxalyl]amino]-3-		498	437
methylbutoxy]phenoxy]acetic acid	6 5 1		
N [2 Mathoray 4 /5	.∞OH.		
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(1,1-dimethyl-	Nº O O'C	424	542
3-phenoxypropyl)oxalamide	N OH, O		2.12
	0 оң 🧼		

N-[3-Methoxy-4-(5-oxazolyl)	N T CH,		
phenyl -N'-[1,1-dimethyl-3-(1-	о он	441	543
oxido-3-pyridyloxy)propyl]	· N · O · O · O		
oxalamide	о он,		
			+
N-[3-(3,4-Dihydroxyphenoxy)-1,1-	k St. St.		
dimethylpropyl]-N'-[3-methoxy-4-	, , , , , , , , , , , , , , , , , , ,	456	544
(5-oxazolyl)phenyl]oxalamide	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
	>-		
N-[3-Methoxy-4-(5-oxazolyl)			
phenyl]-N'-[1,1-dimethyl-3-[4-		481	545
(methylcarbamoyl)phenoxy]propyl		101	313
	:D <sub>1</sub>		
]oxalamide			
N-[3-Methoxy-4-(5-oxazolyl)	No. 1		
phenyl]-N'-[3-(3,4-	N. O O	484	546
dimethoxyphenoxy)-1,1-	( 04		
dimethylpropyl]oxalamide	14,C H <sub>3</sub>		
N-[3-[4-[(2-Hydroxyethyl)	F. C. Top.		
carbamoyl]phenoxy]-1,1-dimethyl-	1 2 2	511	547
propyl]-N'-[3-methoxy-4-(5-		011	0 1,
oxazolyl)phenyl]oxalamide	!		
N-[3-(3-Chlorophenoxy)-1,1-	N 10 0 CH,	450	<b>540</b>
dimethylpropyl]-N'-[3-methoxy-4-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	458	548
(5-oxazolyl)phenyl]oxalamide	N H O		
N-[3-Methoxy-4-(5-oxazolyl)	04, 0 04, 5		
phenyl]-N'-[1,1-dimethyl-3-(3-	S. A.A. N. SH. G. V.N.	425	549
pyridyloxy)propyl]oxalamide	0		
	'4		
N-[3-Methoxy-4-(5-oxazolyl)	् ० ० ० ० ० ०		
phenyl]-N'-[1,1-dimethyl-3-(2-	N 0	425	550
pyridyloxy)propyl]oxalamide	[HC OL ]		
pyria/iox//propyrjoxaiamiae	CHC ON		
2-[4-[3-[[[3-Methoxy-4-(5-	Mary of the second		+
oxazolyl)anilino]oxalyl]amino]-3-	l a see o	482	551
	N. A. O. C. C. C. C. C. C. C. C. C. C. C. C. C.	402	100
methylbutoxy]phenyl]acetic acid	т түү түүлч тон		
2 [2 [[2 Mad] 4 /5			
2-[3-[3-[[[3-Methoxy-4-(5-	N	403	
oxazolyl)anilino]oxalyl]amino]-3-	HO, LO LON	482	552
methylbutoxy]phenyl]acetic acid	J.c. s.		
4-[2-[[[3-Methoxy-4-(5-oxazolyl)	0 1 N		
anilino]oxalyl]amino]-2-	O OH OH	454	553
methylpropoxy]benzoic acid			
./-[/,/,			
4-[3-[[[3-Methoxy-4-(5-oxazolyl)	N Sc. OS		
anilino]oxalyl]amino]-3-	·	482	554
methylbutoxy]-2-methylbenzoic	n on on	102	
, , , , , , , , , , , , , , , , , , , ,	CH OH		1
acid	- им		1

3-[3-[3-[[[3-Methoxy-4-(5-			
oxazolyl)anilino]oxalyl]amino]-3-		496	555
methylbutoxy]phenyl]propionic	2		; !
acid			
3-[4-[3-[[[3-Methoxy-4-	N. The		
(50xazolyl)anilino]oxalyl]amino]-		496	556
3-methylbutoxy]phenyl]propionic			330
acid			
3-[2-[3-[[[3-Methoxy-4-(5-	0.50		
oxazolyl)anilino]oxalyl]amino]-3-	" := ' o	496	557
methylbutoxy phenyl propionic	M (2)	120	337
acid			ļ
2-[3-[3-[[[3-Methoxy-4-(5-	N STATE OF S		
oxazolyl)anilino]oxalyl]amino]-3-	<b>N</b> 0	498	558
methylbutoxy]phenoxy]acetic acid	N O N O N ON ON	420	330
methyloutoxy phenoxy jacetic acid			
4-[3-[[[3-Methoxy-4-(5-oxazolyl)	NO STATE OF THE ST		
anilino]oxalyl]amino]-3-	No comments of the second	482	559
methylbutoxy]-3-methylbenzoic	N.	102	337
acid			
N-[3-(4-Cyano-2-		-	
methoxyphenoxy)-1,1-	On One on	479	560
dimethylpropyl]-N'-[3-methoxy-4-		4//	300
(5-oxazolyl)phenyl]oxalamide	ا الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء الساء		İ
N-[3-(3-Cyanophenoxy)-1,1-			
dimethylpropyl]-N'-[3-methoxy-4-	CH ON THE ST.	449.6	561
(5-oxazolyl)phenyl]oxalamide	3 )	447.0	301
(3-0xazotyr/phenyr)oxarannde	<b>~</b> ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		İ
N-[3-[4-(4-Acetyl-1-piperazinyl)	3		
phenoxy]-1,1-dimethylpropyl]-N'-		550.4	562
[3-methoxy-4-(5-oxazolyl)phenyl]	5-22-5	330.1	302
oxalamide			
N-[3-Methoxy-4-(5-	A		
oxazolyl)phenyl]-N'-[1,1-dimethyl-	OH, CHECH,	531.4	563
3-(2-morpholinophenoxy)propyl	O. T. Marie Committee Comm	$(M + Na)^+$	200
oxalamide	a series	(171   144)	<b>1</b>
N-[3-Methoxy-4-(5-oxazolyl)	(1)		
phenyl]-N'-[1,1-dimethyl-3-[3-	B A A A A A A A A A A A A A A A A A A A	489.6	564
(dimethylamino)phenoxy]	0 %	$(M + Na)^+$	J()-I
propyl]oxalamide	~	(111   114)	
N-[3-(1,3-Benzodioxol-5-yloxy)-			
1,1-dimethylpropyl]-N'-[3-		468.4	565
methoxy-4-(5-oxazolyl)phenyl]	) · · · · · · · · · · · · · · · · · · ·	7.00.4	303
oxalamide	Ň		
N-[3-Methoxy-4-(5-oxazolyl)	, "1		
	C. C. H. 124	514.4	566
phenyl]-N'-[3-(3,4,5-	1	314.4	200
trimethoxyphenoxy)-1,1-	1 · 2 · 3 · · · · · · · · · · · · · · · ·		
dimethylpropyl]oxalamide	<u> </u>		

N-[3-Methoxy-4-(5-oxazolyl)		50.5	
phenyl]-N'-[3-(3,5-	CH, CHP, OH,	506	567
dimethoxyphenoxy)-1,1-	\$ T	$(M + Na)^{\dagger}$	
dimethylpropyl]oxalamide	N -		
N-[3-(5,6,7,8-Tetrahydro-5-oxo-2-	ch oho oh		
naphthyloxy)-1,1-dimethylpropyl]-	CN	492.4	568
N'-[3-methoxy-4-(5-	o		
oxazolyl)phenyl]oxalamide	~		
N-[3-(2-Acetamido-5-	); ;		
methylphenoxy)-1,1-	5 m	517.6	569
dimethylpropyl]-N'-[3-methoxy-4-	· >	$  (M + Na)^{\dagger}  $	
(5-oxazolyl)phenyl]oxalamide			
N-[3-(3-Acetamidophenoxy)-1,1-	Cra H. H. 31,		
dimethylpropyl]-N'-[3-methoxy-4-		503.6	570
(5-oxazolyl)phenyl]oxalamide	N	$(M + Na)^{\dagger}$	
N-[3-(1H-Indol-4-yloxy)-1,1-	0. 0.00 ch.		
dimethylpropyl]-N'-[3-methoxy-4-	N N	485.2	571
(5-oxazolyl)phenyl]oxalamide	N	$(M + Na)^+$	
N-[3-(2-Fluoro-6-	OH, OH, CH, 5		
methoxyphenoxy)-1,1-		472.2	572
dimethylpropyl]-N'-[3-methoxy-4-	О СН,		
(5-oxazolyl)phenyl]oxalamide	, and the second		
N-[3-Methoxy-4-(5-oxazolyl)	OH,		
phenyl]-N'-[1,1-dimethyl-3-(2-	a	492.4	573
oxo-2H-1-benzopyran-7-	4-		
yloxy)propyl]oxalamide			
N-[3-(4-Acetyl-3-methylphenoxy)-	,		
1,1-dimethylpropyl]-N'-[3-	CH SHEDH STORES	480.2	574
methoxy-4-(5-oxazolyl)phenyl]	N N N N N N N N N N N N N N N N N N N		
oxalamide	N		
(E)-N-[3-Methoxy-4-(5-oxazolyl)	-H,		
phenyl]-N'-[1,1-dimethyl-3-[4-(3-	O COLONIA NO ST	492.4	575
oxo-1-butenyl)phenoxy]propyl]			
oxalamide	·		
N-[3-(3-Acetylphenoxy)-1,1-	Çrg rg rg		
dimethylpropyl]-N'-[3-methoxy-4-	Charles and the second	466.4	576
(5-oxazolyl)phenyl]oxalamide			
N-[3-(4-Acetylphenoxy)-1,1-	)- C		
dimethylpropyl]-N'-[3-methoxy-4-	Ch	466.2	577
(5-oxazolyl)phenyl]oxalamide	0_		
	ù-		
N-[3-(4-Acetamido-2-	CryH,y 34.		
chlorophenoxy)-1,1-	6	515.6	578
dimethylpropyl]-N'-[3-methoxy-4-	in in		
(5-oxazolyl)phenyl]oxalamide			
	·		

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-	NSO ON ON	425	579
3-(4-pyridyloxy)propyl]oxalamide	0 04 · · · · · · ·		
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(1-	√2.4. N EE 1	441	580
oxido-4-pyridyloxy)propyl]	0 04 × 1	441	380
oxalamide N-[3-Methoxy-4-(5-oxazolyl)	n ≎ - 4		
phenyl]-N'-[1,1-dimethyl-3-(2,6-	N	453	581
dimethyl-4-pyridyloxy)propyl] oxalamide	1 N N N N N N N N N N N N N N N N N N N		
N-[3-Methoxy-4-(5-oxazolyl)		<del></del>	
phenyl]-N'-[1,1-dimethyl-3-(2,6-dimethyl-1-oxido-4-pyridyloxy)	y =	469	582
propyl oxalamide	25		
N-[2-(4-Cyanophenoxy)-1,1-dimethylethyl]-N'-[3-methoxy-4-	CH, 0 3H, C N - 1 5 20	435	583
(5-oxazolyl)phenyl]oxalamide	N N	433	363
N-[3-Methoxy-4-(5-oxazolyl)			
phenyl]-N'-[3-(2-methoxy-4-	No. 20 May 10 Ma	455	584
pyridyloxy)-1,1-dimethylpropyl] oxalamide	145 ° 146 - 14		
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[4-	0 CH 0 CH 0 CH 0 CH 0 CH 0 CH 0 CH 0 CH	478	585
(1H-tetrazol-5-yl)phenoxy]ethyl]	N	470	303
oxalamide N-[3-(4-Cyanophenoxy)-1,1-	5m 15.5m		
dimethylpropyl]-N'-[3-methoxy-4-		449	586
(5-oxazolyl)phenyl]oxalamide	!		
N-[2-(3-Cyanophenoxy)-1,1-	CH	476	507
dimethylethyl]-N'-[3-methoxy-4- (5-oxazolyl)phenyl]oxalamide	o ca	476	587
N-[3-Methoxy-4-(5-oxazolyl)	OH 0 OH N. N.		
phenyl]-N'-[1,1-dimethyl-2-[3-	a. 6 a	478	588
(1H-tetrazol-5-yl)phenoxy]ethyl] oxalamide	N-		
N-[3-Methoxy-4-(5-oxazolyl)	24	462	700
phenyl]-N'-[1,1-dimethyl-3-[4- (1H-tetrazol-5-yl)phenoxy]propyl]		492	589
oxalamide	· ·		
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-		570.2	590
cyclobutyl]ethoxy]benzoate			
			<u>ئــــــــــــــــــــــــــــــــــــ</u>

Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoate		584.3	591
Benzyl 4-[2-[1-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoate		598.3	592
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopentyl]ethoxy]benzoic acid	SM, S, S, S, S, S, S, S, S, S, S, S, S, S,	494.2	593
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclohexyl]ethoxy]benzoic acid	St. Committee Co	508.2	594
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl)amino]-1-cyclobutyl]ethoxy]benzoic acid	The state of the s	480.2	595
Benzyl 2-methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoate		588	635
3-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 20 C C C C C C C C C C C C C C C C C C	502	636
2-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid		498	637
3-Methoxy-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 2	498	638
4-[2-[1-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-1-cyclopropyl]ethoxy]benzoic acid	N	466	639
2-Chloro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N 2	502	640
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid	1	519	641

(cis/trans)-4-[3-[[[3-Methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]-1-cyclohexanecarboxylic acid	NE O' NENT-O'CH	474	642
(cis/trans)-4-[2-[[[3-Methoxy-4- (5-oxazolyl)anilino]oxalyl]amino]- 2-methylpropoxy -1- cyclohexanecarboxylic acid	OF NEW TOH	460	643
3-Fluoro-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N O O O O O O O O O O O O O O O O O O O	486	644
3-Acetamido-4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-3-methylbutoxy]benzoic acid	N N N N N N N N N N N N N N N N N N N	525	645
3-(Methanesulfonamido)-4-[3- [[[3-methoxy-4-(5- oxazolyl)anilino]oxalyl]amino]-3- methylbutoxy]benzoic acid	N N N N N N N N N N N N N N N N N N N	561	646
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-3,5-dimethylbenzoic acid	N O O O O O O O O O O O O O O O O O O O	496	647
3-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-pyridinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	469	648
8-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-quinolinecarboxylic acid	N O O O O O O O O O O O O O O O O O O O	519	ń <b>4</b> 9
5-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutoxy]-2-indolecarboxylic acid	NO NO NO NO NO NO NO NO NO NO NO NO NO N	507	650

## Examples 615-631 and 664-670

## 5 <u>Example 615</u>

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl] oxalamide.

(i) A mixture of 2g (17.7 mmol) of 2,4,4-trimethyl-2-oxazoline and 1.95 g (17.7 mmol) of thiophenol were heated at 120C for 18 hours. After cooling the resulting solid was triturated

with diethyl ether/petrol (1:2) and filtered off to give 2.55 g of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide as a white solid.

10

15

20

(ii) A solution of 2.5 g (11.2 mmol) of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide, 3.18 g (11.2 mmol) of titanium isopropoxide and 3.09 g (16.8 mmol) of diphenylsilane in 12 ml of tetrahydrofuran were stirred at room temperature for 18 hours. The resulting mixture was chromatographed on silica gel using 3%, 6% and 10% methanol in dichloromethane for the elution. There was obtained 2 g of 1,1-dimethyl-2-(phenylthio)ethylamine as a pale orange oil. The 1,1-dimethyl-2-(phenylthio)ethylamine was then coupled to N-[3-methoxy-4-(5-oxazolyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide. MS: m/e 426 [M+H]<sup>+</sup>.

Example 616 was prepared by an analogous method to that described for example 615 but using 4-benzyloxythiophenol in place of the thiophenol and removing the protecting group using a mixture of hydrogen bromide in acetic acid.

The additional compounds in table 1f<sup>2</sup> were prepared in an analogous manner to that described for example 615 by reaction of the appropriate thiol with either 2,4,4-trimethyl-2-oxazoline or 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and, where necessary, removal of any protecting groups by conventional methods.

table 1f<sup>2</sup>

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N N N N N N N N N N N N N N N N N N N	426	615
N-[2-(4-Hydroxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		442	616
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N ○ 0 0H,  0 0H,  0 0H,  0 0H,  0 0H,  0 0H,	440	617

			_
N-[3-Methoxy-4-(5-oxazolyl)	ં ભ		
phenyl]-N'-[1,1-dimethyl-2-(2-	N o s N	427	618
pyridylthio)ethyl]oxalamide	~ N		
	€ Hit CHi		
N-[3-Methoxy-4-(5-oxazolyl)	N Ф ф <sup>98</sup> 5		
phenyl]-N'-[1,1-dimethyl-3-(2-		441	619
pyridylthio)propyl]oxalamide	N N S N		
F,,	C OH. N <sub>2</sub> ≥		
N-[3-Methoxy-4-(5-oxazolyl)	N O C ON		
phenyl]-N'-[1,1-dimethyl-3-(2-	1.1 0	446	620
thienylthio)propyl]oxalamide	, , , , , , , , , , , , , , , , , , ,		
	о сң		
N-[3-Methoxy-4-(5-oxazolyl)	N O OCH		
phenyl]-N'-[1,1-dimethyl-3-(2-	0 сн	442	621
pyrimidylthio)propyl]oxalamide	N - N S N		
	O OH, S. N		
N-[3-Methoxy-4-(5-oxazolyl)	N O O		
phenyl]-N'-[1,1-dimethyl-3-(4-	N CH, S	441	622
pyridylthio)propyl]oxalamide	N 5.		
N. [2 N. 4] 4 (5	9 0s , N		
N-[3-Methoxy-4-(5-oxazolyl)		4.47	(22
phenyl]-N'-[1,1-dimethyl-3-(2-	2 N O N OH S S	<b>44</b> 7	623
thiazolylthio)propyl]oxalamide	0 Сң		
N-[3-(4-Hydroxyphenylthio)-1,1-	N 0 0		
dimethylpropyl]-N'-[3-methoxy-4-	е сн	456	624
(5-oxazolyl)phenyl]oxalamide	0 (H ) OH		
			<del> </del>
N-[3-Methoxy-4-(5-oxazolyl)	N	163	£35
phenyl]-N'-[1,1-dimethyl-3-(5-	L. N. S. N.	462	625
methyl-1,3,4-thiadiazol-2-ylthio)	ુમાં છેત <b>ે</b> કે,		
propyl]oxalamide	. >/		
N-[3-(2-Benzooxazolylthio)-1,1-	N. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.		1
dimethylpropyl]-N'-[3-methoxy-4-		481	626
(5-oxazolyl)phenyl]oxalamide	ME SH GO		
NI [2 (2 Damath:1-14h:-) 1 1			
N-[3-(2-Benzothiazolylthio)-1,1-	N CONTROL OF	1/27	(27
dimethylpropyl]-N'-[3-methoxy-4-		497	627
(5-oxazolyl)phenyl]oxalamide	N. S. S. S. S. S. S. S. S. S. S. S. S. S.		
Methyl 4-[2-[[[3-methoxy-4-(5-	00, 00,		<del>                                     </del>
oxazolyl)anilino]oxalyl]amino]-2-		484	628
methylpropylthio]benzoate	- 24,		
tert-Butyl 6-[3-[[[3-methoxy-4-(5-	The state of the s		1
oxazolyl)anilino]oxalyl]amino]-3-	N	541	629
methylbutylthio]-3-	7 N 1 - 5 N N 1 - 5 N N 1 - 5 N N 1 - 5 N N 1 N N 1 N N N N N N N N N N N N N	J 11	
pyridinecarboxylate	(H € O+		
6-[3-[[[3-Methoxy-4-(5-oxazolyl)	( , , 24,		<del> </del>
	N 0 , 01	485	630
anilino]oxalyl]amino]-3-	N N S N	403	050
methylbutylthio]-3-	07° 07		
pyridinecarboxylic acid	,		
trifluoroacetate (1:1)			]

4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]benzoic acid	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	484	631
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N^O O N N N S N S N S N S N S N S N S N S	532	664
N-[2-(4-Benzyloxyphenylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	NºO O'NON NO SO	546	665
2-[3-[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-5-benzoxazolecarboxylic acid	N OHC OH CO	525	666
N-[3-(1H-Imidazol-2-ylthio)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		430	667
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-3-pyridinecarboxylic acid trifluoroacetate (1:1)	N N N N N N N N N N N N N N N N N N N	485	668
4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropylthio]benzoic acid		470	669
2-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylthio]-6-benzoxazolecarboxylic acid	Jung Con, San Jung	525	670

# Examples 632-634

The compounds in table 1f<sup>3</sup> were prepared in an analogous manner to that described for example 398 in table 1f<sup>4</sup> by replacing the 4-nitrophenol with the appropriate aniline and reaction with either 2,4,4-trimethyl-2-oxazoline or 2,4,4-trimethyl-5,6-dihydro-1,3(4H)oxazine and, where necessary, removal of any protecting groups by conventional methods.

table 1f3

Name	Structure	MS(ES) (M+H)	Ex No
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino) ethyl] oxalamide	O HC O HC O HC O HC O HC O HC O HC O CH	423	632
N-(3-Anilino-1,1-dimethylpropyl)- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide hydrochloride (1:1)	N C CH <sub>2</sub>	423	633
4-[3-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-3-methylbutylamino]benzoic acid	Process of the contract of the	467	634

## Examples 407-414; 459-541 and 651-652

Typical methods used for the preparation of the compounds of table 1g are described below: <u>Example 408.</u>

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl] oxalamide.

- 10
- (i) A stirred solution of 3.23 g (16.8 mmol) of 1-(4-methoxyphenyl)piperazine, 2.00 g (16.8 mmol) of 2-methyl-2-nitropropan-1-ol and 5.34 g (50.4 mmol) of sodium carbonate in 40ml of n-butanol was refluxed for 16h. The reaction mixture was allowed to cool and diluted with 100ml of dichloromethane. The solution was filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using petroleum ether/ethyl acetate (10:1) for the elution to afford 1.86 g (6.34 mmol, 38%) of 1-(4-methoxyphenyl)-4-(2-methyl-2nitropropyl)piperazine as a white solid.
- (ii) A solution of 1.86 g (6.34 mmol) of 1-(4-methoxyphenyl)-4-(2-methyl-2-nitropropyl)piperazine and 0.5 g of palladium on activated charcoal in 50 ml of ethanol was stirred at room temperature under an atmosphere of hydrogen for 48h. The reaction mixture was filtered and the filtrate concentrated in vacuo to afford 1.59 g (6.04 g mmol, 95%) of 2-[4-(4-methoxyphenyl)-piperazin-1-yl)-1,1-dimethylethylamine as a clear oil. The 2-[4-(4-methoxyphenyl)-piperazin-1-yl)-1,1-dimethylethylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to

afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide as a white solid. MS: m/e 508 [M+H]<sup>+</sup>.

Examples 407, 409, 410, 411, 412 and similar structures were prepared by an analogous procedure by replacing the 1-(4-methoxyphenyl)piperazine with the appropriately substituted piperazine.

Examples 413 and 414 were prepared by an analogous procedure by replacing the 1-(4-methoxyphenyl)piperazine with t-butyl-1-piperazinecarboxylate to give 4-(2-amino-2-methylpropyl)piperazine-1-carboxylic acid t-butyl ester which was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid. The resulting product could then be deprotected to give N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-piperazinyl)ethyl]oxalamide that could be used for the preparation of examples 413, 414 and a variety of additional N-acyl and N-sulfonyl derivatives, such as those shown in table 1g, by using the appropriate acylating or sulfonylating reagent.

## Example 489.

N-[2-[4-(Cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide.

20

30

10

15

A stirred solution of 48mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(1-piperazinyl)ethyl]oxalamide (1.2mmol) and 13mg of cyclohexanecarboxaldehyde (1.2mmol) in 1ml of a 5% acetic acid / dichloromethane mixture was treated with a solution of 38mg of sodium triacetoxyborohydride (1.8mmol) in 1ml of a 5% acetic acid / dichloromethane mixture. After stirring overnight at room temperature the reaction mixture was diluted with 10ml of dichloromethane and washed with 8ml of a sodium bicarbonate solution followed by 8ml of water. The organic layer was then evaporated and purified using flash chromatography on a silica gel column eluting with 5% methanol / dichloromethane to give after evaporation of the fractions 14.3mg (0.3 mmol, 25%) of N-[2-[4-(cyclohexylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide in the form of a white solid. MS: m/e 498.2 [M+H]<sup>†</sup>.

Additional N-alkylated compounds shown in table 1g were prepared by analogous methods.

. 1 '	1	•
tab.	le	Ιg
		- 27

table 1g			
Name	Structure	MS(ES) $(M+H)^{\dagger}$	Ex No
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide	OH, OH, N	478	407
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide	N S N S N S N S N S N S N S N S N S N S	508	408
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(3-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	409
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-phenyl-1-piperazinyl)propyl]oxalamide		492	410
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[2-[4-(2-methoxy-phenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		508	411
N-[2-(4-Benzyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		492	412
N-[2-[4-(Benzenesulfonyl)-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		452	413
N-[2-(4-Benzoyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		506	414
N-[2-[4-[4- (Trifluoromethyl)phenyl]-1- piperazinyl]-1,1-dimethylethyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide		546	459
N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]oxalamide		492	460

N-[2-[4-(2-Fluorophenyl)-1-		107	
piperazinyl]-1,1-dimethylethyl]-N'-	N	496	461
[3-methoxy-4-(5-	, ° , ° , ° , , , , , , , , , , , , , ,		ļ
oxazolyl)phenyl]oxalamide	; C		
N-[2-[4-(4-Fluorophenyl)-1-	~ ~ ~		İ
piperazinyl]-1,1-dimethylethyl]-N'-	34	496	462
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	" ≥ ₹		
N-[3-Methoxy-4-(5-	OH,		
oxazolyl)phenyl]-N'-[2-[4-(2-		508	463
methoxyphenyl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide			:
N-[3-Methoxy-4-(5-	CH. 0.10 X 1 4 4		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH. Bres sec. 18	548	464
[4-(2-thiophenesulfonyl)-1-	N. J. W.		
piperazinyl]ethyl]oxalamide	, J		
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		584.1	465
[4-(2,4,6-trimethylbenzenesulfonyl)-	S. J. J. W. J. J. J. J. J. J. J. J. J. J. J. J. J.	504.1	103
1-piperazinyl]ethyl]oxalamide			
N-[2-[4-(4-Fluorobenzenesulfonyl)-		560.1	166
1-piperazinyl]-1,1-dimethylethyl]-N'-	Carl Carl San San San San San San San San San San	560.1	466
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(Trifluoromethanesulfonyl)-			
1-piperazinyl]-1,1-dimethylethyl]-N'-	Company of the compan	534	467
[3-methoxy-4-(5-			
oxazolyl)phenyl)]oxalamide			
N-[2-[4-(Isopropylsulfonyl)-1-	SAL CHANGE AND STREET OF THE SALES OF THE SA		
piperazinyl]-1,1-dimethylethyl]-N'-	PAC CHY HE NO	508.1	468
[3-methoxy-4-(5-	c_		
oxazolyl)phenyl)]oxalamide	السائد المسائد		
(E)-N-[3-Methoxy-4-(5-	* )		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	On the state of	568.1	469
[4-(styrylsulfonyl)-1-			
piperazinyl]ethyl]oxalamide	· • J		
N-[2-[4-(Ethanesulfonyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	Line Control (1997)	494.1	470
[3-methoxy-4-(5-	0		
oxazolyl)phenyl]oxalamide	N-		
N-[3-Methoxy-4-(5-	.сн		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CHI CHI THE N C	508.1	471
	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	500.1	7/1
[4-(propanesulfonyl)-1-			
piperazinyl]ethyl]oxalamide	3		
N-[2-[4-(3-Chloropropanesulfonyl)-	FH; N NO	542.1	173
1-piperazinyl]-1,1-dimethylethyl]-N'-	O C C C C C C C C C C C C C C C C C C C	542.1	472
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			L

N-[3-Methoxy-4-(5-	^		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH UNC CH N S CH	556.1	473
[4-(o-toluenesulfonyl)-1-			
piperazinyl]ethyl]oxalamide	,		1
N-[2-[4-(2-Fluorobenzenesulfonyl)-	. , >		
1-piperazinyl]-1,1-dimethylethyl]-N'-	on one not	560.1	474
[3-methoxy-4-(5-	0 N N	200.1	., .
oxazolyl)phenyl]oxalamide	.27		
N-[2-[4-(2-Cyanobenzenesulfonyl)-			
1-piperazinyl]-1,1-dimethylethyl]-N'-		567.1	475
	87. 1. N. 2. 2. 1. N. 2. 1.	307.1	4/3
[3-methoxy-4-(5-	en che ne la la la la la la la la la la la la la		
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	C . *		
oxazolyl)phenyl]-N'-[2-[4-(3,5-	ত্র প্রত্তর ব <sup>া ম ম</sup> ুর ত্রু মুক্তর ম	561.1	476
dimethyl-4-isoxazolylsulfonyl)-1-			ĺ
piperazinyl]-1,1-dimethyl-	N <sup>-2</sup>		į
ethyl]oxalamide			
N-[2-[4-(5-Fluoro-2-			
methylbenzenesulfonyl)-1-		574.1	477
piperazinyl]-1,1-dimethylethyl]-N'-	a secolikies		
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2,5-	:		
Difluorobenzenesulfonyl)-1-	Jan grote	578.1	478
piperazinyl]-1,1-dimethylethyl]-N'-	3, 3, 4, 1, 2, 3	370.1	170
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	NA.		
N-[3-Methoxy-4-(5-	N-CH <sub>3</sub>	F 1 C 1	170
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	CH. CHECK THE ST.	546.1	479
[4-(1-methyl-1H-imidazole-4-			
sulfonyl)-1-	N		
piperazinyl]ethyl]oxalamide			
N-[2-[4-(2,6-			
Difluorobenzenesulfonyl)-1-	On A THIS HOLL IN	578.1	480
piperazinyl]-1,1-dimethylethyl]-N'-	The state of the s		
[3-methoxy-4-(5-	[ ·~!		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3,4-			
Difluorobenzenesulfonyl)-1-	C N T N N N N N N N N N N N N N N N N N	578.1	481
piperazinyl]-1,1-dimethylethyl]-N'-	c		
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			į
	2		-
N-[2-[4-	On Physical N	562.2	482
(Cyclohexylmethanesulfonyl)-1-	O. 10 M. 10	302.2	402
piperazinyl]-1,1-dimethylethyl]-N'-			
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			

N-[3-Methoxy-4-(5-	and and any any and any and any and any and any and any and any and any and any any any any any any any any any any		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	ભા ુમાદ્ભા	570.1	483
[4-(2-phenylethanesulfonyl)-1-	0.1.		
piperazinyl]ethyl]oxalamide	<b>,</b> ,		
N-[3-Methoxy-4-(5-	OR.	<u></u>	
oxazolyl)phenyl]-N'-[2-[4-(2,4-	7 ON C W	538	484
dimethoxyphenyl)-1-piperazinyl]-	40.		
1,1-dimethylethyl]oxalamide	N C		
N-[3-Methoxy-4-(5-	// √on.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		492	485
[4-(4-methylphenyl)-1-	Y N OL		
piperazinyl]ethyl]oxalamide	N .		
N-[3-Methoxy-4-(5-	; √a₁.		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	0 y 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	506	486
[4-(2,4-dimethylphenyl)-1-			į
piperazinyl]ethyl]oxalamide	N T		į
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[2-[4-(3,4-	25	538	487
dimethoxyphenyl)-1-piperazinyl]-			
1,1-dimethylethyl]oxalamide			
N-[2-(4-Cyclohexyl-1-piperazinyl)-	^ .		
1,1-dimethylethyl]-N'-[3-methoxy-4-	No. of the second second	484.4	488
(5-oxazolyl)phenyl]oxalamide	HC THE TANK THE NEW YORK		
(6 6.1	w·		
N-[2-[4-(Cyclohexylmethyl)-1-	H. OHEN, A		
piperazinyl]-1,1-dimethylethyl]-N'-	H. SHOOL N	498.2	489
[3-methoxy-4-(5-	3 . 1		
oxazolyl)phenyl]oxalamide	N=		
N-[2-[4-(2-Methoxybenzyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	490
[3-methoxy-4-(5-	J. J. J. J. J.		
oxazolyl)phenyl]oxalamide	•		]
N-[2-[4-(2-Hydroxybenzyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	1-3	508.1	491
[3-methoxy-4-(5-	ζ, , , , , , , , , , , , , , , , , , ,		
oxazolyl)phenyl]oxalamide	\_·		
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		506.1	492
[4-(2-methylbenzyl)-1-	2 - 1 - 1		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	5 4		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H, SHCON, N	498.1	493
[4-(2-thenyl)-1-	C		
piperazinyl]ethyl]oxalamide	N		ļ
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		520.2	494
[4-(2(RS)-phenylpropyl)-1-			
piperazinyl]ethyl]oxalamide			
	1,		<u> </u>

N-[3-methoxy-4-(5-	~ × ×		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	and the state of t	486.1	495
(4-pivaloyl-1-			
piperazinyl)ethyl]oxalamide	Ģi ,		
N-[2-[4-(2-Furoyl)-1-piperazinyl]-			
1,1-dimethylethyl]-N'-[3-methoxy-4-	5 MC 35	496.1	496
(5-oxazolyl)phenyl oxalamide	N N N	420.1	490
(3-0xazoiyi)phenyijoxalamide	o o		
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HAS DIRECTED IN THE DESCRIPTION OF THE DESCRIPTION	512.1	497
[4-(2-thenoyl)-1-	3., *,, ~ N	312.1	477
	o c		
piperazinyl]ethyl]oxalamide	·	·	
N-[3-Methoxy-4-(5-	~ N = 25	512	400
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	2 1 1 2 2 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2	512	498
[4-(3-thenoyl)-1-	3. <b>1</b>		
piperazinyl]ethyl]oxalamide	w <sup>†</sup>		
N-[2-[4-(2-Cyclopentylacetyl)-1-	"Y TELL		
piperazinyl]-1,1-dimethyl-ethyl]-N'-	2.00	512.1	499
[3-methoxy-4-(5-			
oxazolyl)phenyl)]oxalamide	Q.**		
N-[2-[4-(Cyclohexylcarbonyl)-1-	INS. N. OHE PASS		
piperazinyl]-1,1-dimethylethyl]-N'-	en o elche	512.1	500
[3-methoxy-4-(5-	0 N		0 0 0.
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	4;		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	(1,7=2)	520.1	501
	Howard Company	320.1	301
[4-(2-methylbenzoyl)-1-	°f .		
piperazinyl]ethyl]oxalamide	, O		
N-[3-Methoxy-4-(5-	ING - W W TW TW TW TW TW TW TW TW TW TW TW TW	520.1	502
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HIG - T'N - N - N - N - N - N - N - N - N - N -	520.1	502
[4-(4-methylbenzoyl)-1-	) · · · · · · · · · · · · · · · · · · ·		
piperazinyl]ethyl]oxalamide	N <sup>-2</sup>		
N-[2-[4-(Cycloheptylcarbonyl)-1-	\		
piperazinyl]-1,1-dimethylethyl]-N'-	mg . M. Districts	526.2	503
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	- N		
oxazolyl)phenyl]-N'-]1,1-dimethyl-2-	Hod OH; ≯ w ■N	496.1	504
[4-[(1H-pyrazol-4-yl)carbonyl]-1-	5		
piperazinyl]ethyl]oxalamide	~ f		ļ
N-[2-[4-(Cyclopentylcarbonyl)-1-	1 ~		
piperazinyl]-1,1-dimethylethyl]-N'-	HS OHESTS	498.1	505
[3-methoxy-4-(5-	0		
oxazolyl)phenyl]oxalamide	i i i i i i i i i i i i i i i i i i i		
N-[3-Methoxy-4-(5-	· 8.		
oxazolyl)phenyl]-N'-[1,1-Dimethyl-	The second of th	509.1	506
2-[4-[(1-methyl-1H-pyrrol-2-	The market has	303.1	300
	e ja ja ja ja ja ja ja ja ja ja ja ja ja		
yl)carbonyl]-1- piperazinyl]ethyl]oxalamide	اء ئىلارد ئىل		

N-[3-Methoxy-4-(5-	, L. N.		į
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HG - M LN	514.1	507
[4-[(1,2,3-thiadiazol-4-yl)carbonyl]-			
1-piperazinyl]-ethyl]oxalamide	J		
N-[2-[4-(3-Fluorobenzoyl)-1-	· · ·		
piperazinyl]-1,1-dimethylethyl]-N'-		524.1	508
[3-methoxy-4-(5-		V =	
oxazolyl)phenyl]oxalamide			
N-[2-[4-(4-Fluorobenzoyl)-1-	3 -	·····	
piperazinyl]-1,1-dimethylethyl]-N'-	OH OH	524.1	509
[3-methoxy-4-(5-	His company in the North Control of the North Contr	324.1	309
	o		
oxazolyl)phenyl]oxalamide	<b>™</b>		
N-[2-[4-(Cyclopropylcarbonyl)-1-	~~~	.=0.1	
piperazinyl]-1,1-dimethylethyl]-N'-	on on on	470.1	510
[3-methoxy-4-(5-	0.5		
oxazolyl)phenyl]oxalamide			
N-[2-[4-(2-Cyclohexylacetyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-	proge (	526.2	511
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[3-Methoxy-4-(5-	7 2		
oxazolyl)phenyl]-N'-[2-[4-(3,3-	HI SHEPH	500.2	512
dimethylbutyryl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide	J		
N-[2-[4-(3-Hydroxy-2,2-	нс е Д		
dimethylpropionyl)-1-piperazinyl]-	Q PA CHA	502.1	513
1,1-dimethylethyl]-N'-[3-methoxy-4-			
(5-oxazolyl)phenyl]oxalamide	OF CHI		
N-[3-Methoxy-4-(5-	<b>3</b> -		1
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	777	510.1	514
[4-(3-methyl-2-furoyl)-1-	**	310.1	314
	- <u>-</u>		
piperazinyl]ethyl]oxalamide	*		
N-[3-Methoxy-4-(5-	- Land of a	510 1	E15
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HU SHEAT )	510.1	515
[4-(2-methyl-3-furoyl)-1-			
piperazinyl]ethyl]oxalamide	N=1		
N-[3-Methoxy-4-(5-	1 = -ab		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	OH-CH N.	510.1	516
[4-[(5-methyl-1H-pyrazol-3-	0 0		
yl)carbonyl]-1-	السهنا		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	à. · c		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HC 0 H1 0 H1 0 H1 0 H1 0 H1 0 H1 0 H1 0	511.1	517
[4-[(5-methyl-4-	2).		
isoxazolyl)carbonyl]-1-	iJ		
piperazinyl]ethyl]oxalamide			
F - F	<u> </u>		

N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HC MCCH N	511.1	518
[4-[(5-methyl-3-	32 7 7		
isoxazolyl)carbonyl]-1-	فس		
piperazinyl]ethyl]oxalamide			
N-[2-[4-(4-Aminobenzoyl)-1-	- 1		
piperazinyl]-1,1-dimethylethyl]-N'-	HC OHCON	521.1	519
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	[ <del>-                                   </del>		
N-[2-[4-(2-Hydroxybenzoyl)-1-			
piperazinyl]-1,1-dimethylethyl]-N'-		522.1	520
[3-methoxy-4-(5-		522.1	
oxazolyl)phenyl]oxalamide	2		
N-[2-[4-(4-Hydroxybenzoyl)-1-	· · ·	-	
piperazinyl]-1,1-dimethylethyl]-N'-	O HE ON OH	522.1	521
[3-methoxy-4-(5-	H. O HOM N Y SON	322.1	321
oxazolyl)phenyl]oxalamide		1	
N-[3-Methoxy-4-(5-	-		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		524.1	522
[4-[(2,5-dimethyl-2H-pyrazol-3-	Harris Andrews	J-4.1	2-2
	a, i		
yl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-		5261	522
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	9 H O O O O O O O O O O O O O O O O O O	526.1	523
[4-(3-methyl-2-thenoyl)-1-	7		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	and you	<b></b>	
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	HC OHCON	526.1	524
[4-(4-methyl-2-thenoyl)-1-	0.		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	man har the hard the second of	526.2	525
[4-[(2,2,3,3-tetramethyl-1-			
cyclopropyl)carbonyl]-1-	النيا		
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-			
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-		528.1	526
[4-[(4-methyl-1,2,3-thiadiazol-5-			
yl)carbonyl]-1-			
piperazinyl]ethyl]oxalamide			
N-[2-[4-(3-Cyanobenzoyl)-1-	<b>1</b>		
piperazinyl]-1,1-dimethylethyl]-N'-	Ne j	531.1	527
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	, The state of the		
N-[2-[4-[(Bicyclo[4.2.0]octa-	₹ .Tx	1	
1(6),2,4-trien-7-yl)carbonyl]-1-	mi ya kata wa mara wa ma mara wa mara wa mara wa mara wa mara wa mara wa mara wa mara	532.1	528
piperazinyl]-1,1-dimethylethyl]-N'-		332.1	320
[3-methoxy-4-(5-	32		
oxazolyl)phenyl]oxalamide		L	<u> </u>

N-[2-[4-(3-Hydroxybenzoyl)-1-	S. a. or		
piperazinyl]-1,1-dimethylethyl]-N'-	н, онсон,	522.1	529
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N°		
N-[2-[4-(2-Ethylbutyl)-1-	он,		
piperazinyl]-1,1-dimethylethyl]-N'-	Hgs. O Hg (24) 1 2Hs	486.1	530
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide	N-		
N-[3-Methoxy-4-(5-	·		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	~. ***	506.2	531
[4-(2-phenylethyl)-1-	The same of the sa	300.2	331
piperazinyl]ethyl]oxalamide			
N-[3-Methoxy-4-(5-	~ <sub>3</sub> .ar,		
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	H. CH	490.1	532
[4-[3-(methylthio)propyl]-1-	The second secon	490.1	332
piperazinyl]ethyl]oxalamide			
			<del>                                     </del>
N-[2-[4-(2,6-Difluorobenzyl)-1-		520.1	F22
piperazinyl]-1,1-dimethylethyl]-N'-		528.1	533
[3-methoxy-4-(5-			
oxazolyl)phenyl]oxalamide			
N-[2-[4-(3-Furfuryl)-1-piperazinyl]-		400.1	504
1,1-dimethylethyl]-N'-[3-methoxy-4-	18. Out of w	482.1	534
(5-oxazolyl)phenyl]oxalamide	ا مریکی ا		
N-[2-[4-[(2-Benzofuranyl)methyl]-	N-1		<del>                                     </del>
1-piperazinyl]-1,1-dimethylethyl]-N'-	the Land Market N	532.1	535
[3-methoxy-4-(5-	The second of the second	332.1	333
oxazolyl)phenyl)]oxalamide	No.		
N-[2-[4-(2-Cyanobenzyl)-1-	3		
piperazinyl]-1,1-dimethylethyl]-N'-		517.1	536
		317.1	336
[3-methoxy-4-(5-	17		
oxazolyl)phenyl]oxalamide	50.00		
N-[3-Methoxy-4-(5-	70-	106.2	527
oxazolyl)phenyl]-N'-[2-[4-(3,3-		486.2	537
dimethylbutyl)-1-piperazinyl]-1,1-			
dimethylethyl]oxalamide	5-1		
N-[3-Methoxy-4-(5-	- 1 - 1	540.0	500
oxazolyl)phenyl]-N'-[1,1-dimethyl-2-	Me The Mark W	543.2	538
[4-[(2-quinolinyl)methyl]-1-	1		
piperazinyl]ethyl]oxalamide	N-2		
tert-Butyl 4-[2-[[[3-methoxy-4-(5-	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	_	
oxazolyl)anilino]oxalyl]amino]-2-	7 7 7 7 7	516	539
methylpropyl]-1-piperazineacetate	No. of the state o		
4 [2 [[[2 Most 4 /5	1 24		
4-[2-[[[3-Methoxy-4-(5-	3. 3. 3. 4.	460	F40
oxazolyl)anilino]oxalyl]amino]-2-		460	540
methylpropyl]-1-piperazineacetic			
acid trifluoroacetate (1:1)	<u> </u>		

N-[2-[4-(Cyclopropylmethyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	O, O, O, O, N	456	541
tert-Butyl 4-[4-[2-[[[3-methoxy-4-(5-oxazolyl)anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl] benzoate	NO NO NO NO NO NO NO NO NO NO NO NO NO N	578	651
4-[4-[2-[[[3-Methoxy-4-(5-oxazolyl) anilino]oxalyl]amino]-2-methylpropyl]-1-piperazinyl]benzoic acid trifluoroacetate (1:1)	N J N J N J N J F J CH	522	652

## Examples 415-420:

In a manner analogous to that described in Example 4 starting with N-[3-(aminomethylphenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide and the appropriate carboxylic acid chloride compounds shown in table 1h were prepared.

table 1h

Name	Structure	$ME(ES)$ $(M+H)^{+}$	Ex No
Phenyl [3-[[[4-(5-oxazolyl)anilino]oxalyl]amino]benzyl] carbamate	1 N 2 N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	487	415
N-[3-[(3- Fluorobenzamido)methyl]phenyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	CH C	489	416
N-[3-[(3- Chlorobenzamido)methyl]phenyl]-N'- [3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	ch ch ch ch ch ch ch ch ch ch ch ch ch c	505	417
N-[3-[(3- Methoxybenzamido)methyl]phenyl]- N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	on a second	501.2	418
N-[3-[(3,4- Dimethoxybenzamido)methyl]phenyl] -N'-[3-methoxy-4-(5- oxazolyl)phenyl]oxalamide	OH, O OH, O	531.2	419

N-[3-[(3- Cyanobenzamido)methyl]phenyl]-N'-		496.1	420
[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N-		

### Examples 421-427 and 598-614:

Typical methods used for the preparation of the compounds of table 1b are described below:

Examples 421 and 423 were prepared by reaction of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide with the appropriate acylating reagent.

Example 424 was prepared in a manner analogous to that described in Example 1, starting with N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid, prepared as described in Example 1, parts (i) and (ii), and the appropriate amine.

### Example 422

5

15

20

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl] oxalamide.

(i) A mixture of 2g (17.7 mmol) of 2,4,4-trimethyl-2-oxazoline and 1.95 g (17.7 mmol) of thiophenol were heated at 120C for 18 hours. After cooling the resulting solid was triturated with diethyl ether/petrol (1:2) and filtered off to give 2.55 g of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide as a white solid.

(ii) A solution of 2.5 g (11.2 mmol) of N-[1,1-dimethyl-2-(phenylthio)ethyl]acetamide, 3.18 g (11.2 mmol) of titanium isopropoxide and 3.09 g (16.8 mmol) of diphenylsilane in 12 ml of tetrahydrofuran were stirred at room temperature for 18 hours. The resulting mixture was chromatographed on silica gel using 3%, 6% and 10% methanol in dichloromethane for the elution. There was obtained 2 g of 1,1-dimethyl-2-(phenylthio)ethylamine as a pale orange oil. The 1,1-dimethyl-2-(phenylthio)ethylamine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid by a procedure analogous to that described in example 1 to afford N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(phenylthio)ethyl]oxalamide. MS: m/e 426 [M+H]<sup>+</sup>.

25

Example 427 was prepared by an analogous method to that described for example 422 but using 4-benzyloxythiophenol in place of the thiophenol and removing the protecting group using a mixture of hydrogen bromide in acetic acid.

5

Example 607 was prepared starting from benzofuran-3-acetic ethyl ester by alkylation iodomethane using potassium tertiary butoxide as base followed by alkaline hydrolysis, Curtius reaction, hydrolysis in ethylene glycol and water at 180°C. The resulting amine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid as described in Example 1.

10

Example 426 was prepared in a manner analogous to that described for example 408 in table lg using tetrahydro quinoline in place of 1-(4-methoxyphenyl)piperazine.

### Example 610

15

N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5oxazolyl)phenyl]oxalamide

14 mg (0.12 mmol) of methanesulphonyl chloride were added to a solution of 40 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl-N'-[1,1-dimethyl-2-(4-20 residue triturated with diethyl ether. There was obtained 23 mg of N-[2-[1-(methanesulfonyl)-

piperidinyl)ethyl]oxalamide in 1 ml of dichloromethane followed by 17 mg (0.15 mmol) of Nethylmorpholine and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed with 2M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate, evaporated to dryness and the

4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as an offwhite solid. MS m/e 479  $[M+H]^+$ .

The starting material was prepared as follows:

3()

A solution of 4.65 g (31 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine, 15.6 g i) (0.154 mol) of triethylamine and 13.5g (61.9 mmol) of di-tert-butyl dicarbonate in 100 ml of methanol was stirred at room temperature for 2 days then evaporated to dryness. The residue was dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 2.12 g of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate as a pale orange solid. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.29 (6H,s), 1.49 (9H,s), 3.04 (2H,s), 4.30 (1H, br.s), 7.10 (2H,d), 8.52 (2H,d).

- 2.1 g (8.4 mmol) of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate, in 20 ml of methanol were hydrogenated with 400 mg of 10% palladium on carbon catalyst at 70°C and 7 Bar for 6 days. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether/petrol (1:9) to give 1.2 g of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate as a white solid. <sup>1</sup>H NMR (400 MHz DMSO) δ: 1.18 (6H,s), 1.28-1.41 (2H,m), 1.37 (9H,s), 1.52-1.69 (3H,m), 1.75-1.83 (2H,d), 2.74-2.84 (2H,t), 3.12-3.21 (2H,d), 6.40-6.48 (1H,br.s), 8.60-8.95 (1H,br.s).
- iii) A solution of 1.2 g (4.68 mmol) of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate, 945 mg (9.36 mmol) of triethylamine and 2.33 g (9.36 mmol) of N-(benzyloxycarbonyloxy)succinimide in 20 ml of dichloromethane was stirred at room temperature for 18 hours then washed with 10% citric acid solution and saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 1.89 g of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.15-1.32 (2H,m), 1.29 (6H,s), 1.42 (9H,s), 1.49-1.78 (5H,m), 2.75-2.90 (2H,m), 4.05-4.16 (2H,m), 4.41 (1H,br.s), 5.12 (2H,s), 7.27-7.42 (5H,m).

25

30

iv) A solution of 1.79 g (4.6 mmol) of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate in 6 ml of trifluoroacetic acid/dichloromethane (1:1) was stirred at room temperature for 5 minutes then evaporated to dryness. The residue was dissolved in 20 ml of dichloromethane along with 1.2 g (4.58 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 1.1 g (5.74 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1.32g (11.5 mmol) of N-ethylmorpholine and 1.1 g (6.9mmol) of 1-hydroxy-7-azabenzotriazole. After stirring overnight the solution was diluted with ethyl acetate, washed with 10% citric acid solution and saturated sodium bicarbonate

- 165-

solution, dried over magnesium sulphate evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 1.14 g of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate as a white foam. MS: m/e 535 [M+H]<sup>†</sup>.

v) A solution of 1.1 g (2.05 mmol) of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate in 25 ml of methanol was hydrogenated with 100 mg of 10% palladium on carbon catalyst for 4 hours. The resulting suspension was filtered and evaporated to dryness to give 732 mg of N-[3-methylpropyl] and the state of the state

methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide as an offwhite solid. MS: m/e 401  $[M+H]^{\dagger}$ .

Example 616 was prepared starting from benzofuran-3-acetic ethyl ester by alkylation iodomethane using potassium tertiary butoxide as base followed by alkaline hydrolysis, Curtius reaction, hydrolysis in ethylene glycol and water at 180°C. The resulting amine was then coupled to N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid as described in Example 1

Example 619

5

10

15

25

 $\frac{N-[2-[1-(Methanesulfonyl)-4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide}{}$ 

14 mg (0.12 mmol) of methanesulphonyl chloride were added to a solution of 40 mg (0.1 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide in 1 ml of dichloromethane followed by 17 mg (0.15 mmol) of N-ethylmorpholine and the mixture stirred at room temperature for 4 hours. The resulting solution was diluted with ethyl acetate, washed with 2M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate, evaporated to dryness and the residue triturated with diethyl ether. There was obtained 23 mg of N-[2-[1-(methanesulfonyl)-1, principle and the problem of the p

4-piperidinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide as an off-white solid. MS m/e 479  $[M+H]^+$ .

The starting material was prepared as follows:

- i) A solution of 4.65 g (31 mmol) of alpha, alpha-dimethyl-4-pyridineethylamine, 15.6 g (0.154 mol) of triethylamine and 13.5g (61.9 mmol) of di-tert-butyl dicarbonate in 100 ml of methanol was stirred at room temperature for 2 days then evaporated to dryness. The residue was dissolved in ethyl acetate, washed with water, dried over magnesium sulphate, evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (2:1) for the elution. There was obtained 2.12 g of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate as a pale orange solid.  $^1$ H NMR (400 MHz CDCl<sub>3</sub>)  $\delta$ : 1.29 (6H,s), 1.49 (9H,s), 3.04 (2H,s), 4.30 (1H, br.s), 7.10 (2H,d), 8.52 (2H,d).
- ii) 2.1 g (8.4 mmol) of tert-butyl [1,1-dimethyl-2-(4-pyridyl)ethyl]carbamate, in 20 ml of methanol were hydrogenated with 400 mg of 10% palladium on carbon catalyst at 70°C and 7 Bar for 6 days. The resulting suspension was filtered, evaporated to dryness and the residue triturated with diethyl ether/petrol (1:9) to give 1.2 g of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate as a white solid. <sup>1</sup>H NMR (400 MHz DMSO) δ: 1.18 (6H,s), 1.28-1.41 (2H,m), 1.37 (9H,s), 1.52-1.69 (3H,m), 1.75-1.83 (2H,d), 2.74-2.84 (2H,t), 3.12-3.21 (2H,d), 6.40-6.48 (1H,br.s), 8.60-8.95 (1H,br.s).
  - iii) A solution of 1.2 g (4.68 mmol) of tert-butyl [1,1-dimethyl-2-(4-piperidinyl)ethyl]carbamate, 945 mg (9.36 mmol) of triethylamine and 2.33 g (9.36 mmol) of N-(benzyloxycarbonyloxy)succinimide in 20 ml of dichloromethane was stirred at room temperature for 18 hours then washed with 10% citric acid solution and saturated sodium bicarbonate solution. The organic phase was dried over magnesium sulphate, evaporated to dryness and the residue chromatographed on silica gel using ethyl acetate/petrol (1:2) for the elution. There was obtained 1.89 g of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate. <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>) δ: 1.15-1.32 (2H,m), 1.29 (6H,s), 1.42 (9H,s), 1.49-1.78 (5H,m), 2.75-2.90 (2H,m), 4.05-4.16 (2H,m), 4.41 (1H,br.s), 5.12 (2H,s), 7.27-7.42 (5H,m).
- iv) A solution of 1.79 g (4.6 mmol) of benzyl 4-[2-(tert-butoxyformamido)-2-methylpropyl]-1-piperidinecarboxylate in 6 ml of trifluoroacetic acid/dichloromethane (1:1) was stirred at room temperature for 5 minutes then evaporated to dryness. The residue was dissolved in 20 ml of dichloromethane along with 1.2 g (4.58 mmol) of N-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamic acid, 1.1 g (5.74 mmol) of 1-(3-dimethylaminopropyl)-3-

ethylcarbodiimide hydrochloride, 1.32g (11.5 mmol) of N-ethylmorpholine and 1.1 g (6.9mmol) of 1-hydroxy-7-azabenzotriazole. After stirring overnight the solution was diluted with ethyl acetate, washed with 10% citric acid solution and saturated sodium bicarbonate solution, dried over magnesium sulphate evaporated to dryness and chromatographed on silica gel using ethyl acetate/petrol (1:1) for the elution. There was obtained 1.14 g of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino}-2-methylpropyl}-1-piperidinecarboxylate as a white foam. MS: m/e 535 [M+H]<sup>†</sup>.

v) A solution of 1.1 g (2.05 mmol) of benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]amino]-2-methylpropyl}-1-piperidinecarboxylate in 25 ml of methanol was hydrogenated with 100 mg of 10% palladium on carbon catalyst for 4 hours. The resulting suspension was filtered and evaporated to dryness to give 732 mg of N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-piperidinyl)ethyl]oxalamide as an offwhite solid. MS: m/e 401 [M+H]<sup>+</sup>.

The remaining examples in table 1b were prepared by methods analogous to those described above, as appropriate to the structure, or by methods previously described for related structures.

20 table 1b

15

Name	Structure	MS(ES) $(M+H)^+$	Ex No
Benzyl 4-{2-[[[3-methoxy-4-(5-oxazolyl)phenylamino]oxalyl]a mino]-2-methylpropyl}-1-piperidinecarboxylate		535	421
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2- (phenylthio)ethyl]oxalamide	N O C CH,	426	422
N-[2-(1-Acetyl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	C H N N N N N N N N N N N N N N N N N N	443	423

N-(2-Cyclohexyl-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N' 0 0'CH	400	424
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-(N-methylanilino)ethyl]oxalamide	N	423	425
N-[2-(1,2,3,4-Tetrahydro-1-quinolyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		449	426
N-[2-(4-Hydroxyphenylthio)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		442	427
N-[3-(4-Hydroxyphenyl)-1,1-dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl] oxalamide	O H,C OH,	424	598
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-2-[(1-oxido-4-pyridyl)carboxamido] ethyl]oxalamide		454	599
N-[2-(4-Acetylbenzamido)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	2 × 0	479.1	600
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[3-[(4-methylbenzamido)methyl]pheny l]oxalamide	CH.	485.1	601
N-[3-[(2-Methoxybenzamido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		501.1	602
N-[3-[(4-Chlorobenzmido) methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide		505.1	603
N-[3-[[(1,3-Benzodioxol-5-yl)carboxamido]methyl]phenyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	(n, n, f, n, n, n, 1, 2)	515.2	604

N-[2-(2,3-Dihydro-1-indolyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide	0 H3	435	605
N-[2-(3,4-Dihydro-6-methyl- 2H-quinol-1-yl)-1,1- dimethylethyl]-N'-[3-methoxy- 4-(5-oxazolyl)phenyl]oxalamide	эн онс он (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	463	606
N-[1-(3-Benzofuranyl)-1-methylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]oxalamide	N OHC OH	420	607
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- phenoxypiperidino)propyl]oxala mide	Maria de la constantia del constantia de la constantia de la constantia della constantia della constantia de	507	608
N-[2-(1-Butyryl-4-piperidinyl)- 1,1-dimethylethyl]-N'-[3- methoxy-4-(5-oxazolyl)phenyl] oxalamide		471	609
N-[2-[1-(Methanesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	479	610
N-[2-[1-(Benzenesulfonyl)-4- piperidinyl]-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide		541	611
N-[2-(1-Isobutyryl-4- piperidinyl)-1,1-dimethylethyl]- N'-[3-methoxy-4-(5-oxazolyl) phenyl]oxalamide	M COM	471	612
tert-Butyl 4-[3-[[[3-methoxy-4-(5-oxazolyl)anilino] oxalyl] amino]-3-methylbutyl]-1-piperidinecarboxylate	245 CH 25	515	613
N-[3-Methoxy-4-(5-oxazolyl) phenyl]-N'-[1,1-dimethyl-3-(4- piperidinyl)propyl]oxalamide	OH, O OH, O	415	614
	·		

#### Examples 428-432:

15

Examples 428, 431 and 432 of table 1i were prepared in a manner analogues to that described for example 408 in table 1g but using N-[3-methoxy-4-(4-oxazoyl)phenyl oxalamic acid or N-[3-methoxy-4-(2-methyl-4-oxazoyl)phenyl oxalamic acid in place of N-[3-methoxy-4-(5-oxazoyl)phenyl oxalamic acid for the coupling step.

Examples 429 and 430 of table 1i were prepared by analogues procedures to those described for the preparation of the compounds of table 1f.

10 table 1i

Name	Structure	MS(ES) (M+H) <sup>+</sup>	Ex No
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[1,1-dimethyl-2-(4-phenyl-1-piperazinyl)ethyl]oxalamide		478	428
N-[2-(4-Benzyloxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide		500	429
N-[2-(4-Hydroxyphenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(4-oxazolyl)phenyl]oxalamide	CH, CH, CH,	410	430
N-[3-Methoxy-4-(4-oxazolyl)phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide	OH, OH, OH,	508	431
N-[3-Methoxy-4-(2-methyl-4-oxazolyl)-phenyl]-N'-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-1,1-dimethylethyl]oxalamide		522.4	432

The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.